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Preliminary findings suggest an increase in cervical cancer among sub-Sahara African 
women on highly active antiretroviral treatment (HAART). There has been a sharp rise in 
serious non-AIDS events among HAART recipients. This study explored the effect of co-
administering combined contraceptive hormones with antiretroviral drugs on promoting 
human cervical epithelial cancer cell proliferation, DNA mutation and cell transformation. 
Combinations of abacavir (ABC), zidovudine (ZDV), lamivudine (3TC), stavudine (d4T) 
and nevirapine (NVP) were co-administered with either ethinylestradiol or levonorgestrel. 
 
The combinations ZDV+3TC, ABC+ZDV+3TC, ZDV+3TC+NVP and d4T+3TC+NVP 
induced a time-dependent antiproliferative effect on HeLa cells. Co-treatment with 
levonorgestrel demonstrated antiproliferative effects on combination antiretroviral drug-
treated cells while co-administering 0.5µg/ml ethinylestradiol increases HeLa cell 
proliferation (P≤ 0.5). Single drugs (ABC, ZDV, 3TC, d4T and NVP) showed a time-
dependent DNA double strand breakage in both HeLa and Chinese hamster ovary cells. 
Both levonorgestrel and ethinylestradiol drastically increased apoptosis in ABC+3TC-, 
ZDV+3TC-, ABC+ZDV+3TC- and d4T+3TC+NVP-treated cells. Highly active 
antiretroviral treatment transformed pre-monocyte lymphoma (U937) cells to adherent 
cells with macrophage-like morphology and increased superoxide production.  
 
Increased HeLa cell death by apoptosis following co-administration of triple combination 
antiretroviral drugs with levonorgestrel suggests a protective effect against human cervical 
cancer cell proliferation among HAART users. Despite the drastic induction of apoptosis 
by 0.5µg/ml ethinylestradiol, ABC+3T-, ZDV+3TC-, ABC+ZDV+3TC- and 
ZDV+3TC+NVP-treated cells did not significantly differ from the untreated cells in their 
proliferation assayed by MTT (P≤0.05), thus suggesting a proliferative effect on the human 
cervical epithelial cancer cells. Transformation to macrophage-like morphology and 
increased superoxide anion production in U937 cells suggest precipitation of serious non-
AIDs events among HAART users. 
 
The antiproliferative effect of HAART on cervical cancer cells suggests a protective role 
against cell proliferation. The antiproliferative effect of levonorgestrel suggests its 
potential as a progestogen-only contraceptive alternative for women on HAART treatment. 
The present results also suggest the downside effect of HAART through precipitation of 
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GENERAL INTRODUCTION AND BACKGROUND 
1.0. Introduction 
Epidemiological studies show contradictory findings on whether or not initiation of highly 
active antiretroviral therapy (HAART) has an effect on cervical intraepithelial neoplasia 
(CIN) onset and progression. Some studies have suggested a positive correlation between 
initiation of HAART and development of CIN among HIV positive women (Dorrucci et 
al., 2001; Heard et al., 2006; Moodley et al., 2009). On the contrary, Minkoff et al. (2010) 
and Omar et al. (2011) maintain that HAART use seems to be associated with a significant 
reduction in squamous intraepithelial lesions (SILs). Sirera et al. (2008) and Shrestha 
(2010) concur that HAART treatment has no effect on initiating development of CIN but 
they both suggest the need to carry out related studies in larger populations to evaluate 
HAART‟s impact over longer periods of time. Due to the possibility of other predisposing 
factors linked to individual lifestyles, the cause-and-effect relationship is difficult to 
establish in most of these studies. There is limited information on whether or not co-
administration of HAART with hormonal contraceptives (HCs) affects cervical cancer 
progression. The present study seeks to elucidate the effect of ethinylestradiol (EE) and 
levonorgestrel (LNG) on antiretroviral drug-induced apoptosis in human cervical epithelial 
cancer cells. HeLa cells are cancerous cells which are important tools for studying the 
pathology of human cervical epithelium in vitro. They characteristically exhibit cellular 
morphology for the cancerous cervix, hence their choice in this study. 
 
1.1.0. The human immunodeficiency virus 
The human immunodeficiency virus (HIV) is a retrovirus that causes acquired 
immunodeficiency syndrome (AIDS) (Costin, 2007). It is predominantly transmitted 
through blood and other bodily fluids such as semen, pre-ejaculation or vaginal fluids 
(Waheed and Freed, 2010; Watts et al., 2009). HIV-1 is a potent spheroidal virus which 
belongs to the class of retroviruses. These retroviruses are particulate in structure with a 
diameter of 80-120 nm and they are encapsulated by a protein coat known as the viral 
envelope (Costin, 2007). In addition to AIDS, these single-stranded RNA retroviruses also 
cause cancer and other life-threatening diseases (Watts et al., 2009; Waheed and Freed, 















Fig 1.1: Cross-sectional structure of the HIV-1 virus. Structures represented by abbreviations 
are described by the full name in brackets just after the abbreviation as follows: NC 
(Nucleocapsid), CA (Capsid), RT (Reverse transcriptase), IN (Integrase), gp (glycoprotein) 












1.1.1. The HIV genome 
The genome of the HIV consists of two RNA molecules which resemble the eukaryotic 
messenger ribonucleic acid (mRNA) because they have a 5´-capped end and a poly A tail 
at the end 3'-end (Costin, 2007; Nisole and Saïb, 2004). Figure 1.2 outlines the structure of 
the HIV-1 genome. Four genes are necessary for HIV replication. Firstly, the gag gene 
encodes for viral core proteins. Secondly, the pro gene (not shown in the diagram) codes 
for a protease which cleaves the Gag and Pol proteins into functionally active forms 
(Costin, 2007). Thirdly, the pol gene encodes for the reverse transcriptase enzyme (RNA-
dependant DNA polymerase: Pol) responsible for DNA synthesis and formation of 
integrase, which is required for making a DNA copy of the genome. It also encodes the 
protease (PR) and integrase enzymes (Waheed and Freed, 2010). Finally, the env gene 
encodes for the HIV envelope (Env) structural proteins (Azevedo-Pereira et al., 2015; 
Costin, 2007). After synthesis, Env (gp160) is glycosylated, followed by proteolysis into 
surface glycoproteins (SU or gp120) and trans-membrane glycoproteins (TM or gp41) 
(Waheed and Freed, 2010). While gag, pol and env are structural genes, Vpu, Vpr, Vif and 
Nef comprise accessory genes which may be latent and are activated at the relevant stage 
of the replication cycle (Costin, 2007; Waheed and Freed, 2010). 
 
Fig1.2: Arrangement of the HIV-1 genome. The Gag polyprotein precursor for viral matrix 
(MA), capsid (CA) and nucleocapsid is encoded by the gag gene. The pol gene encodes the 
protease (PR), reverse transcriptase (RT) and integrase (IN). The env gene encodes the 
surface membrane glycoprotein (gp120) and the transmembrane glycoprotein (gp41). The 
starting point of the gene indicates the position of the (A) in the ATG start codon for a named 
gene. In the pol gene, the start implies the first T in the sequence TTTTTTAG (Adapted 




1.1.2. The HIV replication cycle  
The retroviral life cycle can be defined by two phases. The early stage refers to the 
sequential steps from attachment of the virus up to integration of the viral copy 
deoxyribonucleic acid (cDNA) into the host cell (Rӧling et al., 2015).   The late stage 
begins with the expression of the viral genome up to the release and maturation of the viral 
progeny (Nisole and Saïb, 2004). Figure 1.3 depicts the main stages of DNA replication. 
Briefly, in the presence of a T-lymphocyte, HIV attaches to the CD4-receptor through the 
gp120 glycoprotein (Rӧling et al., 2015; Nisole and Saïb, 2004). The hydrophobic gp40 
glycoprotein is then brought into proximity with the virion (Azevedo-Pereira et al., 2015). 
The attachment of the virus requires hydrophobic interactions between the viral envelope 
and the host cell membrane to allow fusion of the virion (Nisole and Saïb, 2004). The 
virion then releases its RNA and reverse transcriptase enzyme molecules into the host cell 
(Nisole and Saïb, 2004).  
 
While in the host cell, the reverse transcriptase synthesises complementary DNA from the 
viral RNA strand (Rӧling et al., 2015; Waheed and Freed, 2010). Integration is the process 
through which the newly synthesised double-strand DNA is transported into the nucleus of 
the host cell (Costin, 2007). This is aided by the enzyme integrase which binds the long 
terminal repeat (LTR) at each end of the viral DNA. The host DNA-dependent RNA-
polymerase transcribes the virion DNA (Waheed and Freed, 2010). Some of the 
transcribed viral mRNA molecules synthesise the viral proteins while others are 
incorporated into the virus particles as the genome (Nisole and Saïb, 2004; Waheed and 
Freed, 2010). At the surface of the cell, the structural proteins encapsulate the viral genome 
and the progeny buds out through the membrane. Viral protein precursors (Gag and Gag-
Pol) are then cleaved by proteases (Nisole and Saïb, 2004; Waheed and Freed, 2010). 
There are some cellular factors that interfere with the early stages of the viral reproduction 
cycle and these are perceived as defensive mechanisms against viral infections (Nisole and 
Saïb, 2004; Costin, 2007). The CEM 15 also known as the human apolipoprotein B 
mRNA-editing enzyme-catalytic polypeptide-like-3G (APOBEC3G) inhibits HIV 
replication. Ref1 and Lv1 block viral particles before reverse transcription, while Fv1 and 










Fig 1.3: Schematic representation of the HIV replication cycle. The diagram demonstrates the 
sequential stages of the virus replication from the time of fusion of the single virion up to 
release and maturation of the newly synthesised replicates. The surface membrane protein 
gp120 comes into contact with membrane receptors CCR5 and CXCR4 which serve as co-
receptors (Rӧling et al., 2015). Receptor-binding results in conformational changes that 
expose the transmembrane protein, leading to its insertion into the target CD4
+
 cell 
membrane. This results in fusion of the viral and CD4
+
 cell membranes. The viral core is then 
released into the host cell. The viral core uncoats and the RNA is transcribed by the reverse 
transcriptase (RT). The protein inhibitor complex (PIC) protects the newly synthesised DNA 
while it inserts into the host DNA. The enzyme integrase (IN) facilitates integration of viral 
DNA into the host chromosome. The viral DNA is then transcribed and transported to the 
cytoplasm. Env glycoproteins incorporate into the budding viral particles. The budding 
viruses attach to the membrane CD4
+
 receptors of the host cell and exude into circulatory 
system (Waheed  and Freed, 2010; Rӧling et al.., 2015).  Classes of drugs that inhibit each 
stage of the reproductive cycle are shown in orange. The abbreviations for inhibitor drugs 
depicted in the diagram are as follows: NtRTIs-nucleotide reverse transcriptase inhibitors, 
NRTIs-nucleoside reverse transcriptase inhibitors and NNRTIs-non-nucleoside reverse 
transcriptase inhibitors (Diagram adapted from Rӧling et al., 2015).  
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1.2.0. Antiretroviral therapy 
Antiretroviral (ARV) drugs treat infections caused by retroviruses, primarily HIV. Most 
have a research chemical name, generic name and brand name. It is common practice to 
use an abbreviation of the generic name. While combination antiretroviral therapy has its 
advantages, there are inherent undesired side effects associated with these drugs, thus 
limiting the number of useful combinations (Arts and Hazuda, 2012; Flepp et al., 2001). 
As described earlier, when antiretroviral drugs are taken in combinations of three or more, 
such an approach is known as highly active antiretroviral therapy (Arts and Hazuda, 2012).  
 
1.2.1. Classes of antiretroviral drugs 
Antiretroviral drugs are classified mainly dependent on their mechanism of action in 
interfering with viral replication. Each class of ARV interferes with the viral reproductive 
cycle differently. Major classes of antiretroviral drugs include entry inhibitors (EIs), 
nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), integrase inhibitors (IIs) and protease inhibitors (PIs) (AIDSinfo, 
2017; Flepp et al, 2001; Barry et al., 1999).  
 
1.2.2. Entry/Fusion inhibitors 
The genesis of viral infection is the attachment of the viral gp120 protein to the CD4
+
 
receptor on cell surfaces (Flepp et al., 2001). The process is facilitated by van der Waals 
forces and electrostatic forces between the positively charged CD4
+
 molecules and the 
negatively charged gp120 socket (Arts and Hazuda, 2012). Entry inhibitors interfere with 
the binding, fusion and entry of an HIV virion to a T-lymphocyte cell (Barry et al., 1999). 
These drugs are used in combinatorial HIV treatment. Examples of these drugs are 
enfvirtide (T-20) and muraviroc (MVC) (Flepp et al., 2001; Arts and Hazuda, 2012). 
 
1.2.3. Nucleoside reverse transcriptase inhibitors   
NRTIs inhibit reverse transcriptase, a DNA polymerase enzyme required for DNA 
synthesis. NRTIs act by competitive inhibition, hence acting as terminators by blocking 
natural substances needed for DNA replication (Flepp et al., 2001; Olivero et al., 2013). 
These drugs have been generally associated with host toxicity (Flepp et al., 2001). Some 
examples of NRTIs include abacavir (ABC), didanisine(ddi), emtricitabine (FTC), 
lamivudine (3TC),  stavudine (d4T), tenofovir (TDF), Zalcitabine (Ddc) and Zidovudine 
(AZT/ZDV) (Flepp et al., 2001; Barry et al., 1999). In this research, ABC, 3TC, d4T and 





Abacavir is a structural analogue of guanine that is commonly used in antiretroviral 
regimens (Fig 1.4). ABC metabolism is not affected by renal insufficiency, as shown by 
about 1% of the drug that is unchanged in urine (Akanbi et al., 2012; Jackson et al., 2012).  
The intracellular half-life of ABC ranges up to about 40 hours (Yuen et al., 2008; Jackson 
et al., 2012). While there are a number of recommended permutations, ABC+3TC 
(administered together with a protease inhibitor) and ABC+3TC+ZDV have found 
widespread use in HIV treatment (WHO, 2010). The triple combination ABC+3TC+ZDV 
does not constitute a HAART regimen since it consists of NRTIs only. Rather, it is known 
as triple NRTIs (WHO, 2010). In highly active antiretroviral combination approaches, 



















Stavudine is a thymidine analogue whose administration was approved in 1994 (Akanbi et 
al., 2012). There is no evidence of the effect of co-administration with food on stavudine 
metabolism. Due to its weak binding to proteins, d4T is distributed easily through the 
body, including the placenta (Akanbi et al., 2012; Rana and Dudley, 1997). It efficiently 
clears by both renal and non-renal processes (Rana and Dudley, 1997). Stavudine use has 
significantly reduced in developed countries due to its perceived cumulative toxicity 
(WHO, 2016). Although World Health Organisation guidelines of 2010 emphasised the 
need to eliminate the use of d4T gradually, it is still administered in some low-resource 





















Lamivudine is a cytidine analogue (Figure 1.6), which was approved in 1995. 3TC weakly 
binds to proteins, hence it distributes well in the body and between the maternal and foetal 
circulation. Its bioavailability is around 82-84% in adults (Yuen et al.,2004; Johnson et al., 
1999). Due to its prolonged half-life of up to 39 h, once or twice daily administration of 
3TC is desirable.  3TC is predominantly excreted through the kidneys, hence the need for 
dose adjustment during renal insufficiency (Else et al., 2012; Johnson et al., 1999; Yuen et 
al., 2004). 3TC is phosphorylated to lamivudine 5´-triphosphate (3TC-TP), which inhibits 






















ZDV is a thymidine analogue (Figure 1.7) and was the first ARV used for monotherapy in 
1987 (Akanbi et al., 2012). Due to its short half-life, in practise, daily multiple dosing is  
common  (Akanbi et al., 2012; Piliero, 2004). Glucoronidation in the liver, kidneys, and 
intestinal mucosa constitute the major pathway for its metabolism. ZDV binds weakly to 
proteins and its administration with food does not affect its plasma exposure. ZDV 
excretion is mainly renal (Piliero, 2004; Mu et al., 2016). In the host cell, ZDV/AZT is 
metabolised to AZT-5´-triphosphate (AZT-TP), which competitively inhibits the HIV 
reverse transcriptase (Mu et al., 2016). Compared to monotherapy, combination therapy 
has resulted in reduced adverse effects of ZDV. However, haematological toxicities have 



















1.2.8. Non-nucleoside reverse transcriptase inhibitors 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are allosteric inhibitors that bind 
directly to the reverse transcriptase (Röling et al 2015; Barry et al., 1999). This group 
comprises a number of drugs that differ structurally from each other. These drugs share the 
same characteristic and mechanism of action, through binding to a site on the reverse 
transcriptase, thereby causing a conformational change that blocks DNA polymerase 
activity (Arts and Hazuda, 2012; Flepp et. al., 2001). While nucleoside analogues require 
phosphorylation to be activated, NNRTIs do not require phosphorylation as they bind 
directly and noncompetitively to reverse transcriptase (Barry et al., 1999). Non-nucleoside 
reverse transcriptase induce some host cell toxicity (Arts and Hazuda, 2012; Flepp et al., 
2001). Examples of NNRTIs include delavirdine (DLV), efivarenz (EFV), Etravirine 
(ETR) and nevirapine (NVP) (AIDSinfo, 2017; Barry et al., 1999; Madigan et al., 2009). 
Figure 1.8 presents the structure of nevirapine, a non-nucleoside reverse transcriptase 















For some time, NVP was the NNRTI of choice in low-resource settings, where it is used in 
combination with other antiretroviral drugs to treat HIV-1 infected individuals (Chou et al., 
2010, Dong et al., 2012). It was also used in monotherapy to prevent mother-to-child 
infection (WHO, 2010). According to the British HIV Association (BHIVA) (2008) and 
Dong et al. (2012), while single-dose NVP has been associated with rash and/or 
hepatotoxicity, the aetiology of its toxicity remains obscure. Although single-dose NVP 
was previously used to prevent mother-to-child transmission, combinations with tinofovir 
(TDF) and emtricitabine (FTC) have been shown to reduce resistance mutations associated 
with NVP (Benaboud et al., 2011; WHO 2010). The combinations d4T+3TC+NVP and 
ZDV+3TC+NVP have found wide use for HIV-positive patients in low-resource settings 
although the current trend is to withdraw d4T gradually due to its reported toxicity (WHO, 
2010).  
 
1.2.9. Integrase inhibitors 
Integrase inhibitors block the action of integrase, an enzyme that facilitates insertion of 
viral genome into the host cell (Flepp et al., 2001; Barry et al., 1999). Blocking the 
integrase therefore stops further viral replication (Arts and Hazuda, 2012; Flepp et al., 
2001). In practice, integrase inhibitors are administered concurrently with other anti-HIV 
medication. Raltegravir (RGV) is an example of a widely-used integrase inhibitor (WHO, 
2010). 
 
1.2.10. Protease inhibitors 
Protease inhibitors act by competitively blocking the action of the protease enzyme, which 
is responsible for cleaving the HIV precursor proteins into smaller units that can be 
integrated into the HIV structure (Röling et al., 2015; Flepp et al., 2001; Arts and Hazuda, 
2012). Resultantly, protease inhibitors lead to the production of defective viral particles 
that cannot infect CD4
+
 cells, thus averting viral replication (Barry et al., 1999; Flepp et 
al., 2001). While protease inhibitors can be effective upon lone administration, prolonged 
use leads to viral resistance (Arts and Hazuda, 2012). In practice, protease inhibitors are 
administered concurrently with other anti-HIV medication (WHO, 2010). Examples of PIs 
include atazanavir (ATV), duranavir (DRV), fosamprenavir (FPV), indinavir (IDV), 
lopinavir + ritonavir (LPV/r), nelfinavir (NFV), ritonavir (RTV), saqunavir (SQV) and 





1.3.0. ARV combination therapy 
Combination therapy currently provides a promising approach in pharmacy with the aim of 
improving the efficacy of different drugs (Bulusu et al., 2016; Murugan et al., 2016). 
While synergistic effects of combination drugs may be beneficial, toxic effects may also 
result from the combination mixtures, as exemplified by carbamazepine toxicity if co-
administered with several drugs and inhibitors (Bulusu et al., 2016). Combination therapy 
has been shown to exhibit high therapeutic effects in other diseases such as cancer 
(Murugan et al., 2016). The large number of possible combinations and permutations 
makes combination research less feasible. This section discusses antiretroviral drug 
regimens that are widely used in low-resource settings. 
 
Combination antiretroviral drugs act by obstructing HIV replication, thereby keeping the 
number of the viral progeny very low (Schutz and Wendrow, 2001; Barry et al., 1999). 
Combination antiretroviral treatment ensures that, should resistance to one drug arise, 
continued suppression results from other drugs (Arts and Hazuda, 2012). Combinatorial 
antiretroviral treatment creates multiple obstacles to HIV replication to keep the number of 
budding offspring low and reduce the possibility of a superior mutation (Schutz and 
Wendrow 2001; Flepp et al., 2001). It has been shown that mono-antiretroviral therapy 
ultimately leads to superior mutations over time (Barry et al., 1999; Flepp et al., 2001; Arts 
and Hazuda, 2012), hence the combinatorial use of antiretroviral drugs ensures longer-
lasting effects (WHO, 2016; AIDSinfo, 2017). As a result, the standard of care is to use 
combinations of antiretroviral drugs (BHIVA, 2008; WHO, 2010). Table 1.1 and Table 1.2 
depict some of NRTIs based combination ARVs currently used in low-resource settings, 
although the trend is to exclude d4T gradually. 
Table 1.1: Some multiple class combination ARVs used in low-resource countries 
Combination Generic Name 
ZDV+3TC +EFV Zidovudine/Lamivudine/Efavirenz 
d4T +3TC +NVP Lamivudine/Stavudine/Nevirapine 
ZDV +3TC +NVP Lamivudine/Nevirapine/Zidovudine 
(After: Barry et al., 1999; Flepp et al., 2001)  
 
Table 1.2: Combined Nucleoside/Nucleotide analogues  
Combination Brand name 
ABC +3TC Epzicom (US) and Kivexa (Europe) 
ABC + ZDV +3TC Trizivir 
ZDV +3TC Combivir 
TDF +FTC Truvada 
(After: Barry et al., 1999; Flepp et al, 2001)  
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The present research investigates the effect of single nucleoside reverse transcriptase 
inhibitors and nevirapine on cervical epithelial cancer cell proliferation and apoptosis. This 
is coupled with an analysis of the effect of hormonal contraceptives on combination 
antiretroviral drug-induced apoptosis in human cervical epithelial cancer cells.  From 
Tables 1.1 and 1.2, the following combinations are of interest: d4T+3TC+NVP, 
ZDV+3TC+NVP, ABC+ZDV+3TC, ABC+3TC and ZDV+3TC. These regimens are 
reasonably accessible in low-resource settings. Of these, ZDV+3TC+NVP is a frequently 
used HAART regimen. The combination d4T+3TC+NVP still finds its use in sub-Saharan 
Africa, although the World Health Organisation is advocating for its gradual withdrawal 
due to long-term toxicity (WHO, 2010). Recent epidemiological contradictions of CIN 
development following initiation of HAART necessitate cell-culture experiments that 
would determine the role of HAART treatment and use of HCs as genotoxic agents. This 
serves to clarify the cause-and-effect relationship of exposure to highly active antiretroviral 
therapy in combination with levonorgestrel and ethinylestradiol. The British HIV 
Association and World Health Guidelines will be used to outline the clinical applications 
of these drug combinations. 
 
1.3.1. Abacavir + lamivudine (Kixeva) 
This drug is well tolerated but patients may experience hypersensitivity in the first six 
weeks, hence the need for counselling prior to initiating treatment (BHIVA, 2008). Kixeva 
is usually administered with a protease inhibitor. This regimen poses an increased risk of 
myocardial infarction in patients with a risk of cardiovascular events (CVD) (WHO, 2016; 
BHIVA, 2008). Due to higher virological failure rate associated with baseline viral loads 
higher than 100 000 copies/ml, the BHIVA Treatments Guidelines suggest that the use of 
Kixeva be reserved for first-line treatments in which Truvada has shown contraindications. 
It is therefore interesting to assess the in vitro association of this double combination with 
EE and LNG. 
 
1.3.2. Zidovudine + lamivudine (Combivir) 
Combivir is poorly tolerated, hence the BHIVA Treatments Guidelines (2008) recommend 
that this medicine be used in specific circumstances. Such circumstances include women 
with an intention to get pregnant and those travelling to low-resource settings where there 
are limited nucleotide backbone alternatives. There remains a paucity of information on 
whether the contraceptive hormones EE and LNG have an effect on human cervical 
epithelial cancer proliferation upon co-administration with Combivir. 
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1.3.3. Triple combinations 
AZT+3TC+NVP and d4T+3TC+NVP are HAART regimens that are administered as first-
line treatments in some countries. The WHO guidelines of 2016 recommend limited use or, 
if feasible complete withdrawal of d4T due to observed toxicities. The combination 
ABC+ZDV+3TC is triple NRTIs.  As is the case for3'-end double combinations described 
earlier, little is known about the effect of co-administration of hormonal contraceptives 
with triple antiretroviral combinations. 
 
1.3.4. Antiretroviral treatment and myocardial infarction 
While HAART has significantly increased the life expectancy among HIV-infected 
individuals, documentation of myocardial infarction (MI) has depicted major challenges 
with choices of ARVs. In a study involving thirteen antiretroviral drugs, indinavir, ABC 
lopinavir-retinovir and didanosine showed high risk of MI with cumulative use (Worm et 
al., 2010). However the research group was wary of confounding factors that could have 
influenced the results. In follow-up studies carried out in the UK, increased exposure to PIs 
was shown to be associated with MI. Interestingly, in the same study, no such evidence 
was found for NNRTIs-exposed patients although the sample size was smaller in this 
group (Worm et al., 2010). The NNRTI nevirapine in combination with NRTIs has 
therefore found widespread use in low-resource countries (WHO, 2010). Bedimo et al. 
(2011) did not observe an effect of current or cumulative use of ABC on MI. To this effect, 
the regimen Kixeva (ABC+3TC) is considered among first-line drugs that are administered 
with PIs (BHIVA, 2008).  
 
1.4.0. Human papillomavirus and cervical cancer 
It has since been suggested that classes of high risk papillomaviruses such as HPV16 and 
HPV18 are associated with development of high-grade cervical intraepithelial neoplasia 
and carcinoma (Mougin et al., 2001; Ponten and Guo, 1998). While most women are likely 
to be infected by HPV during their lifetime, only a small proportion has been shown to be 
at a risk of developing cancer (Mougin et al., 2001; Cox, 1995). This suggests the role of 
other factors in promoting genotoxic transformation in human cervical epithelial cancer 
cells. Oestrogen and progesterone have been implicated as cofactors (Webster et al., 2001). 
The long latency period between infection by HPV and cancer emergence suggests that 





Viral oncoproteins E6 and E7 are associated with malignant conversion of cervical cells. 
On their own, oncoproteins are not sufficient for conversion of cells to malignant 
phenotype (zur Hausen, 2009). The oncoproteins from high-risk HPV stimulate pleiotropic 
cell growth and at the same time induce mutations and aneuploidy in host DNA (Thierry, 
2009; zur Hausen, 1999). Interaction of E6 with p53 (a checkpoint protein for G1/S-phase 
transition) results in degradation of p53. This has been suggested to cause mutagenic 
events and aneuploidy karyotype formation (Fei and de Villiers, 2008; zur Hausen, 2009). 
E7 is also able to induce mutations in host DNA (Thierry, 2009). Expression of both E6 
and E7 proteins has been shown to be necessary for proliferation of cervical carcinoma 
cells. DeFillipis et al. (2003) demonstrated that repression of E7 proteins activates the Rb 
pathway and triggers senescence, while repression of E6 proteins activates the p53 
pathway, hence triggering both senescence and apoptosis. 
 
1.4.1. The HeLa cell                                                                                                                                                                                                           
HeLa cells were obtained from a tissue biopsy of Henrietta Lacks (hence the abbreviation 
HeLa) who died in 1951. Henrietta Lacks had developed a 2-3cm cervical tumour. HeLa 
cells provided the first successful culture growth of cells from adenocarcinoma of the 
cervix (Lucey et al., 2009). HeLa cells have since been shown to contain HPV18 and this 
has been associated with aggressive carcinoma (Peran et al., 2010; Mougin et al. 2001; 
Ponten and Guo, 1998). The HeLa cell is widely used as a model of a human cervical 
epithelial cancer cell line, hence the choice of this cell in the present study.  
 
1.5.0 Cytotoxicity and Genotoxicity 
Cytotoxicity refers to the degree to which any compound can be toxic to the cells. 
Cytotoxic compounds thus have the potential of inhibiting or preventing the normal 
physiological functions of the cell. These substances can induce necrosis by disrupting the 
cell membrane, hence leading to cell lysis. Alternatively cytotoxic substances can initiate a 
process of programmed cell death through apoptosis (Sadeghi-Aliabadi et al., 2010). 
Where some of these compounds result in non-pathophysiological rates of apoptosis, these 
can be candidates for treatment of cancer, since they can inhibit proliferation and growth of 
the cancer cell (Kang et al., 2012; Sadeghi-Aliabadi et al., 2010). On the contrary, apart 
from preventing normal physiological processes, cytotoxic substances may damage the 
DNA of a cell. The extent to which a substance damages DNA is known as genotoxicity 
(Moreno-Villanueva et al., 2011).  Human cells have well-developed DNA-repair 
mechanisms which deal with DNA alterations and damage. Alternatively, some damaged 
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cells are destroyed via apoptosis. When the genotoxicity of a substance is high, DNA 
damage-repair mechanisms are impaired, hence resulting in excessive apoptosis and 
possibly cancer (Christmann et al., 2003; Matt and Hofmann, 2016). 
 
There is limited information on the effect of hormonal contraception use on cancer cell 
proliferation and apoptosis upon co-administration with antiretroviral drugs. The present 
study seeks to investigate the proliferative activity of antiretroviral drugs (with and without 
contraceptive hormones) on HeLa cells and the genotoxic effect of each single 
antiretroviral drug on these cells.  
 
1.5.1. Apoptosis and cancer 
Apoptosis refers to programmed cell death. It is triggered by either exogenous stimuli, 
such as ultraviolet radiation, or endogenous stimuli such as genotoxic chemicals and 
intracellular oxidative stress (Elmore, 2007). Apoptosis and the genes that control it have 
an effect on malignancy. DNA damage activates and stabilises p53 in the nucleus and 
cytoplasm, thereby stimulating other proteins that stimulate apoptotic pathways (Lowe and 
Lin, 2000). Malfunctioning of apoptotic pathways may result in diseases such as cancer, 
neurodegenerative diseases and autoimmune disorders (Rastogi and Sinha, 2009). It is 
therefore intriguing to investigate whether exposure to levonorgestrel and ethinylestradiol 
simultaneously with highly active antiretroviral therapy affects apoptosis in cervical 
epithelial cancer cells. Caspases are enzymes that facilitate apoptosis by cleaving and 
inactivating PARP-1. This stops PARP-1 triggering repair of DNA which is being cut 
(Kang et al., 2012). The process leads to digestion of DNA and degradation of 
cytoskeleton (Matt and Hofmann, 2016; Kang et al., 2012). Morphological changes 
associated with apoptosis include membrane blebbing, cell shrinkage and condensation of 
nuclear chromatin, nuclear fragmentation and DNA cleavage (Matt and Hofmann, 2016; 
Lowe and Lin, 2000). While cells can trigger both apoptosis and necroptosis in response to 
DNA damage, apoptosis is perceived to be the prevalent form of cell death (Matt and 
Hofmann, 2016). The two major pathways of apoptosis are the extrinsic and intrinsic 
pathways as summarised in Figure 1.9. 
 
1.5.2. The extrinsic apoptosis pathway 
This pathway is signalled through proteins such as Fas and tumour necrotic factor (TNF) 
receptor via their intracellular domain (Kang et al., 2012). When TRAIL binds to death 
receptors DR4/and or DR5, this leads to trimerisation of the receptors and subsequent 
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recruitment of the Fas-associated death domain (FAAD) protein (Fulda et al., 2010). 
FAAD attracts initiator procaspases -8 or -10 which are then activated through proteolysis 
to respective caspases (Matt and Hofmann, 2016). Cellular FLICE-inhibitory protein (c-
FLIP) and ubiquitination of caspases-8 regulate procaspases activation (Matt and Hoffman, 
2016; Kang et al., 2012). Caspases -8 and/or -10 activate the executor caspases -3, -6 and -
7 thus up-regulating apoptosis. Alternatively, caspase-8 cleaves BID signalling expression 
of BAX/BAK, thereby playing a role in up-regulation of mitochondrial-dependent 
apoptosis (Kang et al., 2012; Fulda et al., 2010).  
 
1.5.3. The intrinsic apoptosis pathway 
The intrinsic pathway is activated by members of the BCL-2 family. Loss of growth factor 
signals and severe cellular stress activate this pathway (Kang et al., 2012). In the case of 
DNA damage, p53 is activated and it in turn activates PUMA and NOXA. Activated 
PUMA/NOXA stimulates BAX and BAK, thereby activating cytochrome c release from 
mitochondria (Matt and Hofmann, 2016; Fulda et al., 2010). Binding of cytochrome c to 
Apaf-1 leads to activation of caspase-9, which in turn, up-regulates the expression of 
caspases -3, -6 and -7, leading to apoptosis (Matt and Hofmann, 2016). Inhibitors of 
apoptosis are targeted by smac/DIABLO, which blocks their activity (Matt and Hofmann, 

























Fig 1.9: Schematic representation of the intrinsic and extrinsic apoptotic pathways. The 
extrinsic pathway is signalled through cell membrane receptors by death factors such as FAS 
and TNF receptors. The binding of TRAIL to death receptors results in a cascade leading to 
activation of caspases -3, -6 and -7, which are executors of apoptosis. In the intrinsic pathway 
for apoptosis, membrane receptors signal apoptosis via an intracellular domain that results in 
DNA digestion by caspases. The protein Apaf-1 is activated by cytochrome c, thus activating 
caspase-9 which in turn activates executioner caspases. Inhibitors of apoptosis are inactivated 









1.5.4. Apoptosis and compensatory proliferation 
Optimal apoptosis is beneficial for eliminating damaged and potentially cancerous cells 
(Matt and Hofmann, 2016).  Apoptosis that is too drastic may result in pathophysiology, 
leading to undesirable conditions such as neurodegenerative disease, tissue dysfunction 
and cancer (Ryoo and Bergmann, 2012; Matt and Hofmann, 2016). Studies in Drosophila 
wings have demonstrated evidence that some proapoptotic proteins, especially caspases, 
can induce proliferation in adjacent cells as a compensatory mechanism to replace lost 
cells (Ryoo et al., 2004). This phenomenon is referred to as compensatory proliferation 
(CP) or apoptosis-induced proliferation (Ryoo and Bergmann, 2012; Ryoo et al., 2004). 
One well-known mechanism in which CP occurs has been studied in Drosophila, in which 
apoptosis is initiated but the effector caspases are inhibited thereby maintaining the 
„undead cells‟. These cells emit mitogens which signal overgrowth (Fan and Bergmann, 
2008a; Ryoo and Bergmann, 2012). The second mechanism of CP observed in Drosophila 
eyes is dependent on effector caspases, which activate Hedgehog signalling for CP (Fan 
and Bergmann, 2008b). Ryoo and Bergmann (2012) maintain that such conditions of 
persistent mitogen signalling and overgrowth may contribute to certain kinds of cancer. 
 
1.5.5. Necroptosis and autophagy 
Although apoptosis is the predominant mechanism of programmed cell death, necroptosis 
and autophagy are other mechanisms of controlled cell death (Su et al., 2015). Necroptosis 
is a form of programmed necrosis. Morphological characteristics of the necroptic cell 
resemble those of a necrotic cell (Su et al., 2015; Matt and Hofmann, 2016). Necroptosis is 
characterised by lack of activation by caspases but instead receptor-interacting protein 
kinases -1 and -3 (RIPK1 and RIPK3) activate the process. Activation of necroptosis can 
be induced by death ligands such as TNFα and Apo2/TRAIL (Matt and Hofmann, 2016). 
Autophagy entails „self-death‟ in which intracellular membrane structures, such as Golgi 
apparatus, package protein complexes so as to degrade and renew these proteins. This is 
one mechanism that cells have evolved in order to survive under stressful conditions (Su et 
al., 2015).  
 
1.6.0. Haemopoietic cells and macrophages 
Blood is formed through the haemopoietic system, in which the pluripotential stem cell 
gives rise to separate cell lineages (Lim et al., 2013). Red blood cells carry oxygen while 
platelets prevent bleeding. Hematopoietic stem cells (HSC) differentiate into common 
myeloid progenitors (CMP) and common lymphoid progenitors (CLP) (Lim et al., 2013; 
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Shaikh and Bhartiya, 2012). The CMP mature into megakaryocyte-erythroid progenitor 
(MEP) and granulocyte monocyte progenitors (GMP). The GMP, in turn, commit to 
mature erythrocytes, megakaryocytes, platelets, monocytes, macrophages and granulocytes 
(Lim et al., 2013; Shaikh and Bhartiya, 2012; Domen et al., 2006). Fig 1.10 shows the 
pluripotent stem cell and the progeny cells that arise from the stem cell.  
 
Although monocytes and macrophages originate from a common progenitor, monocytes 
are short-lived, while macrophages have a longer lifespan (Shaikh and Bhartiya, 2012; 
Parihar et al., 2010). In the presence of differentiation factors, monocytes escape the 
apoptotic route and instead undergo differentiation into macrophages (Gordon and Taylor, 
2005; Parihar et al., 2010). While monocytes are vital for the defence system, their 
accumulation may lead to undesired medical conditions, such as atherosclerosis, multiple 
sclerosis and arthritis (Lim et al., 2013; Parihar et al., 2010).  The present research will 
also explore the potential of single and combination antiretroviral drugs to differentiate the 
U937 cells. These U937 cells are myeloid-derived cells that have found widespread use in 
evaluating the effect of various substances on their responses to different stimuli (Chanput 



























Fig 1.10: Diagrammatic representation of the differentiation of haematopoietic pluripotent 
stem cells. Pre-hematopoietic stem cells (Pre-HSC) mature into haematopoietic stem cells 
(HSCs). The HSC matures into a multipotent progenitor (MPP) which then further 
differentiates into common myeloid progenitor (CMP) and common lymphoid progenitor 
(CLP). CMP mature into megakaryocyte-erythroid progenitor (MEP) and granulocyte 
monocyte progenitors (GMP). The GMP in turn commits to mature erythrocytes, 
megakaryocytes, platelets, monocytes, macrophages and granulocytes. CLP differentiates 
into B cell, T cell and natural killer (NK) cell progenitors, followed by their differentiation 
into the corresponding mature cells. Each cell lineage may serve as a treatment tool for 
anaemia, thalassemia, leukocyte deficiencies and immune-deficiency related conditions. 
Macrophage differentiation may serve to clarify molecular mechanisms behind certain 









1.6.1. The U937 cell and differentiation studies 
In cases of chronic inflammatory diseases and in the tumour microenvironment, inhibition 
of apoptosis promotes monocyte survival and hence their conversion to macrophages (Lin 
et al., 2014; Parihar et al., 2010). The accumulation of macrophages and the continued 
expression of inflammatory milieux has since found widespread use for in vitro studies 
involving molecular mechanisms behind disorders such as cancer and atherosclerotic 
lesions (Lim et al., 2013; Heusinkveld and van der Burg, 2011). Two distinct states of 
macrophages have been categorised as polarisation of the classical type I (M1) 
macrophages and type II (M2) macrophages (Heusinkveld and van der Burg, 2011; 
Martinez and Gordon, 2014). M1 macrophages attract cells of the adaptive immunity in 
response to signals from bacteria and IFNγ (Heusinkveld and van der Burg, 2011). These 
cells are associated with expression of reactive oxygen species (ROS), inducible nitric 
oxide synthatase (iNOS) and activation of natural killer cells; hence these are associated 
with inflammatory response (Martinez and Gordon, 2014). M2 macrophages are associated 
with promotion of tumour growth and polarisation of T cells, hence dampening the 
immune response (Housinkveld and van der Burg, 2011; Martinez and Gordon, 2014). 
 
1.6.2. Reactive oxygen species and apoptosis 
Reactive oxygen species are metabolic end-products of oxygen metabolism. Ideally, in a 
balanced physiological process, the rate of formation of reactive oxygen species is 
balanced by the rate of their elimination (Elmore, 2007). Overproduction of reactive 
oxygen species results in intracellular oxidative stress (Elmore, 2007). This may result in 
an increase in endogenous stimulation of apoptosis. The U937, a histolytic lymphoma cell, 
has been widely used to evaluate the role of chemical stimuli in cellular transformation as 
well as ROS production (Matés and Sánchez-Jiménez, 2000; Meshkini et al., 2009). The 
present study also seeks to evaluate the effect of single and combination antiretroviral 
treatment on  morphological changes in U937 cells, including the potential to transform 
pre-monocyte U937 cells into adherent cells. It is also of interest to determine the amount 
of superoxide anion produced following treatment of U937 cells with antiretroviral drugs.  
 
1.7.0 Overview of the problem 
HAART entails combining two nucleoside reverse transcriptase inhibitors (NRTIs) with 
one non-nucleoside reverse transcriptase inhibitor (NNRTI), in the present study, 
nevirapine (NVP). Alternatively a combination of two NRTIs may be administered 
together with a protease inhibitor. The advent of HAART has resulted in increased survival 
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of HIV-infected individuals. However, acquired immunodeficiency syndrome-associated 
cancers present a challenge in modern day cancer epidemiology (Hsu et al., 2013; Engels 
et al., 2006). AIDS-defining malignancies include Kaposi‟s sarcoma, non-Hodgkin 
lymphoma and cervical cancer (Engels et al., 2006). HIV patients are also at an increased 
risk of non-AIDS-defining cancers (NADCs), such as anal, lung and liver cancer and 
Hodgkin lymphoma (Hsu et al., 2013; Engels et al., 2006).   
 
The introduction of HAART from the 1990s led to an improved life expectancy among 
HIV-positive patients (Shiels et al., 2011). Incidences of AIDS-defining malignancies such 
as Carposi‟s sarcoma and non-Hodgkin lymphoma have seen an up to four-fold decrease 
(Deeken et al., 2012; Shiels et al., 2011). While AIDS-defining cancers have been 
associated with chronic immune activation, the observed decrease in AIDS defining 
cancers with HAART has been attributed to the progress in CD4+  restoration, hence the 
efficiency of immune system (Hsu et al., 2013; Deeken et al., 2012). On the contrary, there 
has been a sharp rise in non-AIDS defining cancers, such as cancers of the lung, kidney, 
anus, skin, and Hodgkin‟s lymphoma by around three-fold (Deekeen et al., 2012; Shiels et 
al., 2011). There is limited information on whether HAART affects cervical cancer 
progression among users of hormonal contraceptives. Globally, hormonal contraceptive 
(HC) formulations with levonorgestrel and ethinylestradiol have since been most 
commonly used (Blackburn et al., 2000).  
 
1.7.1. HAART use and progression of cervical intraepithelial neoplasia 
A study in USA indicated that progression of neoplasia in high-risk human papillomavirus 
infected women was inversely proportional to CD4
+
 count. However the results suggested 
that, even in the era of HAART, some women developed high-grade cervical intraepithelial 
neoplasia (Lillo et al., 2001).  McKenzie et al. (2011) demonstrated that cervical squamous 
intraepithelial lesion (SIL) is more prevalent among women on non-nucleoside reverse 
transcriptase inhibitor (NNRTI) regimen than those not on this treatment. Similarly, a 
cross-sectional study among women in Cape Town (South Africa) linked high prevalence 
of abnormal Pap smears and high-risk human papillomavirus (HR-HPV) to HAART 
initiation (Moodley et al., 2009).  
 
1.7.2. HAART use and cervical intraepithelial neoplasia regression studies 
A seven-year cohort study carried out by Adler et al. (2012) in Soweto (South Africa) 
identified an increased likelihood of SIL regression among HAART users. A related study 
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carried out in Johannesburg (South Africa) concurs with these findings, as HAART use 
was associated with reduction of both incidence and progression to cervical neoplasia 
(Firnhaber et al., 2012). Omar et al. (2011) demonstrated higher rates of high-grade 
squamous intraepithelial lesion (HSIL) and low-grade squamous intraepithelial lesion 
(LSIL) among HIV-positive women from a cohort derived from Soweto. In this cohort, 
HAART was shown to reduce risk of progression. In their eight-year cohort study in 
Taiwan, Chen et al. (2014) found a four-times higher incidence of cervical neoplasia 
among HIV-positive women compared to HIV-negative women. The study, however 
demonstrated the protective effect of HAART against cervical neoplasia in HAART-
adherent women and they postulate that prolonged HAART use for more than three years 
may reduce the risk of cervical neoplasia. Minkoff et al. (2010) maintain that initiation of 
HAART is associated with reduction in HPV infection although the protective effect is 
reduced among non-adherent women.  
 
1.7.3. Studies demonstrating no effect of HAART on CIN 
In a study carried out in South Western Nigeria, Ezechi et al. (2014) demonstrated no 
effect of antiretroviral therapy against development of squamous intraepithelial lesion 
(SIL). However, their study was not clear on whether the participating women were on 
HAART (combination of three or more drugs), single or double drug combinations. It 
would appear the authors present observations on generalised antiretroviral treatment. 
According to Shrestha et al. (2010), HAART does not have an effect on HPV infection and 
neoplasia progression but they suggest the need for further research. Similarly, from their 
cohort study in Germany, Sirera et al. (2008) maintain that use of HAART presents a 
similar CIN incidence to women not on HAART.  
 
Such observed variations in CIN progression among different epidemiological studies 
necessitate in vitro studies in which confounding factors are precluded. Whether HAART 
affects cervical intraepithelial neoplasia risk progression into cervical cancer among users 
of hormonal contraceptives needs further elucidation. The present study thus seeks to 
evaluate the cause-and-effect relationship between exposure of human cervical epithelial 
cancer cells to antiretroviral treatments (both before and following exposure to 
levonorgestrel and ethinylestradiol that are common constituents of combined hormonal 
contraceptives) and apoptotic cellular transformations.  To this effect, HeLa cells are an 




1.8.0. Combined oral contraception and cervical cancer 
Hormonal contraception is widely used globally, including in sub-Saharan Africa, where 
apparently a high rate of HIV infection has been observed (Blackburn et al., 2000). The 
major benefit of combined oral contraceptives is prevention of unwanted pregnancies 
(Practice Committee of American Society for Reproductive Health, 2008; Messiou et al., 
2009). In addition, reduction in mortality, improved bone health and prevention of ovarian, 
endometrial and colorectal cancer have been associated with combined oral contraceptive 
(COC) use (Messiou et al., 2009). On the contrary, the Practice Committee of American 
Society for Reproductive Health (2008) concurs that combined oral contraceptives possibly 
act as co-factors for HPV-induced development of CIN. Such variation in observed results 
on cause-and-effect makes it necessary to investigate the effect of continued hormonal 
contraceptive (HC) use by HAART patients.  Whether or not HAART affects cervical 
cancer progression among hormonal contraceptive users is an area which needs further 
elucidation. It may thus be important to design in vitro experiments to evaluate the effect 
of exposure to levonorgestrel or ethinylestradiol and HAART on genotoxicity and 
apoptosis in human cervical epithelial cells. 
 
1.8.1. Constituents of combined oral contraceptives 
Progestins provide the dominant contraceptive benefits in combined oral contraceptives. 
These include suppression of follicle-stimulating hormone (FSH) and luteinising hormone 
(LH) associated with ovulation (Practice Committee of American Society for Reproductive 
Health, 2008). Progestins also increase cervical mucus secretion and result in decreased 
tubular motility, hence lowering sperm mobility (Blackburn et al., 2000). In addition to 
progestin, combined oral contraceptives contain oestrogens, which stabilise the 
endometrium, thereby minimising bleeding (Practice Committee of American Society for 
Reproductive Health, 2008). Monophasic COCs have consistent dosages of oestrogen, 
while multiphasic OCs have varying doses (Blackburn et al., 2000). 
 
The present study considered the oestrogen ethinylestradiol (EE) and the progestin ß-
levonorgestrel (LNG) because these are constituents of COCs predominantly used in sub-
Saharan Africa and other low-resource settings where the prevalence of HIV infection is 
high (Blackburn et al., 2000). EE is the most commonly used oestrogen in COCs. It is a 
semisynthetic female hormone derived from oestradiol with an ethinyl substitution at C17 
position (Figure 1.11A). EE is often present in low doses in combination with relatively 
higher doses of progestin (Practice Committee of American Society for Reproductive 
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Health, 2008). Levonorgestrel is a synthetic progestogen (Figure 1.11B). Whether or not 
hormonal contraceptives affect cell viability and apoptosis of human cervical cancer cells 
upon co-administration with antiretroviral drugs remains obscure, hence warranting the 












Fig 1.11: Chemical structures of ethinylestradiol and levonorgestrel. (A) Ethinylestradiol 
















1.8.2. Physiological concentrations of ethinylestradiol and levonorgestrel 
Different clinical studies have demonstrated plasma mean maximum concentrations 
(Cmax) for ethinylestradiol (EE) ranging from around 33pg/ml to about 85pg/ml. Steady-
state concentration of EE have been reported to be in the range 70±30pg/ml (mean±SD) 
(Stanczyk et al., 2013; Archer et al., 2012; Junior et al., 2011). Plasma Cmax for 
levonorgestrel (LNG) has been reported to be in the range around 2400±930pg/ml with 
steady-state concentrations of 1847±930pg/ml (Archer et al., 2012; Stanczyk et al., 2013).  
 
18.3. Physiological concentrations of antiretroviral drugs 
Related ranges of serum Cmax values have been reported for ZDV, 4T, 3TC, ABC and NVP 
(Donnerer et al., 2003, Donnerer et al., 2008 and van Praag et al., 2002) with absolute 
mean ranges of Cmax for these drugs as summarised as follows: 635ng/ml for zidovudine, 
930ng/ml for stavudine, 1195ng/ml for lamivudine, 1380ng/ml for abacavir and 6199ng/ml 
for nevirapine (Donnerer et al., 2003, Donnerer et al., 2008; van Praag et al., 2002). 
 
1.9.0. Philosophical basis of the research 
The present research utilises a deductive approach of initiating the research from what is 
generally known (assumed knowledge). Deduction is an aspect of positivism (Herbert and 
Higgs, 2004). In a positivist approach, experimental designs will be informed by the gaps 
in knowledge (Herbert and Higgs, 2004).  The knowledge gaps on the correlation between 
co-administration of antiretroviral drugs with contraceptive hormones and cervical cancer 
progression, inform the present experimental design. The observed scientific results will 
inform the knowledge gaps, hence making the last stage inductive.  
 
1.9.1. Research hypothesis and questions 
The present research seeks to establish whether interaction of antiretroviral drugs with 
levonorgestrel or ethinylestradiol have an effect on human cervical epithelial cancer cell 
proliferation and apoptosis. The underlying research hypothesis is thus: 
H0: Exposure to combined oral contraceptive hormones (ethinylestradiol and 
levonorgestrel) and antiretroviral drugs does not promote DNA mutation, cell 
transformation and human cervical epithelial cancer cell proliferation.  
H1: Exposure to combined oral contraceptive hormones (ethinylestradiol and 
levonorgestrel) and antiretroviral drugs promotes DNA mutation, cell transformation and 




The following research questions are therefore of interest: 
(a) Does exposure to antiretroviral drugs and levonorgestrel or ethinylestradiol alter the 
proliferation of human cervical epithelial cancer cells? 
(b) Do nucleoside reverse transcriptase inhibitors or nevirapine cause DNA double strand 
breaks in their supposed carcinogenic effect?  
(c) Does exposure to levonorgestrel or ethinylestradiol have an apoptotic effect on 
antiretroviral drug-induced apoptosis in human cervical epithelial cancer cells? 
(d) Do antiretroviral drugs have the potential of transforming U937 cells to adherent cells 
with macrophage-like characteristics? 
 
1.9.2. Specific objectives of research 
a. To evaluate the effect of single and combination antiretroviral treatment (with and 
without contraceptive hormones) on the viability of human cervical cancer cells. 
b. To determine the effect of antiretroviral drugs on inducing DNA double-strand 
breaks on Chinese hamster ovary (CHO) and human cervical epithelial cancer cells 
(HeLa). 
c. To evaluate the effect of contraceptive hormones (levonorgestrel and 
ethinylestradiol) on antiretroviral drug-induced apoptosis in human cervical 
epithelial cancer cells. 
d. To explore the effect of single and combination antiretroviral drugs on 
transformation of the U937 cells into „macrophage-like‟ adherent cells. 
e. To measure the amount of intracellular superoxide anion produced by transformed 
adherent cells following 72 h treatment of U937 cells with single and combination 
antiretroviral treatment.  
 
1.9.3. General approach to the problem 
The following section summarises the general approach and methodology used to explore 
the effect of ethinylestradiol and levonorgestrel on combination antiretroviral drug-induced 
apoptosis. In a bid to explore the precipitation of serious non-AIDS events (SNEs), the 
effect of highly active antiretroviral therapy on transforming premonocyte U937 cells to 
cells with macrophage-like characteristics is also outlined. 
 
1.9.3.a. Cell viability assay 
24 h effective concentrations (EC) were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay (MTT). Determination of antiretroviral drug 
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concentrations lying within EC15-25 was established, as these are the desired concentrations 
for toxicological assays because they do not induce toxicity that is too drastic. The MTT 
assay was then used to evaluate the effect of administering single and combination 
antiretroviral treatment on HeLa cell proliferation over 24, 48 and 72 h. The effect of 
ethinylestradiol and levonorgestrel co-administration on Hela cell proliferation was also 
evaluated using the MTT assay over a period of 72 h. 
 
1.9.3.b. Fluorimetric analysis of DNA unwinding 
Using the fluorimetric analysis of DNA unwinding (FADU), concentrations of 50µg/ml of 
each antiretroviral drug were then assayed for their potential to cause double strand breaks 
in CHO and HeLa cells. The efficiency of reparing DNA strand breaks was evaluated by 
treating  HeLa  cells with  each antretroviral drug for 72 h followed by continued culture in 
drug-free medium under microscopic observation over a period of two weeks.  
 
1.9.3.c. Determination of apoptosis 
Annexin-V/PI staining  quantified normal, early apoptotic, late apoptotic and necrotic cells, 
following treatment of HeLa cells with either single or combination antiretroviral drugs 
over a period of 48 h. 
 
1.9.3.d. Transformation of U937 cells 
U937 cells were seeded in 24-well plates and treated with single and combination 
antiretroviral drugs. The cells were then incubated for 72 h and the number of adherent and 
non-adherent cells counted. Morphological transformation was assessed using an EVOS 
inverted microscope. Concurrently, the superoxide anion production potential of these 
transformed cells was evaluated cognisant of the association betweem MI macrophages 
and superoxide anion production (Matés and Sánchez-Jiménez, 2000; Meshkini et al., 
2009).  
 
1.10. Dissemination of research findings and ideas  
Open Access (OA) publication has been shown to accelerate the timely dissemination of 
information, especially in low-resource settings (Eysenbach, 2006). This is mainly due to 
limited financial resources to access some subscription based databases (Eysenbach, 2006). 
The Southern African Regional Universities Association (SARUA) supports the notion of 
OA publication in order to encourage visibility in these mostly low and medium countries. 
During the taught phase of my doctoral programe (first and second year) prior to the 
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research phase, I was fascinated by writing skills, evidence-based practice and health 
policy studies courses delivered. Consequently we wrote a short opinion article with Dr 
Hilda Matarira of  the University of Zimbabwe (Chemical Pathology Department) on 
hormonal contraception and HIV from a Zimbabwean perspective and disserminated it in 
the OA Journal of Public Health in Africa. The vision in this short review also informed 
some introductory concepts to this thesis. During the research phase, I presented ordinary 
and electronic posters at a number of international conferences. Cognisant of some 
unanswered questions in the present research, feeedback from these conferences lead to 
introspection into future directions as discussed in Chapter 6. The following is a summary 
of dissemination articles: 
 
1.10.1 Short communication/opinion article 
 Mafuva, C., and Marima-Matarira, H.T., 2013. Hormonal Contraception and 
HIV/AIDS Transmission: Challenges for Zimbabwe‟s Reproductive Health Service 
Providers in Promoting Informed Contraceptive Choices. Journal of Public Health 
in Africa. 2013; 4(e16):73-75. Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345434/  
1.10.2 Conference proceedings 
 Mafuva, C., and Morgan, W.A., 2016. Transformation of monocytes to adherent  
cells by combination antiretroviral treatment. Proceedings of the British 
‘Pharmacology 2016’ annual conference, 13-15 December 2016, Queen Elizabeth 
II Hotel, London, United Kingdom. Available from: 
http://roar.uel.ac.uk/6457/1/Pharmacology%202016%20abstract-
%20Christopher%20Mafuva%20Winston%20Morgan%202.pdf  
 Mafuva, C., and Morgan, W.A., 2017. Effect of contraceptive hormones on a 
nevirapine based antiretroviral combination induced apoptosis in human cervical 
epithelial cancer cells. Proceedings of the 32nd Annual Conference on Genes and 
Cancer, 11-13 April 2017; pp72, Robinson College, University of Cambridge, 
United Kingdom.  
 Mafuva, C., Pula, G., and Morgan, W.A., 2017. Role of contraceptive hormones on 
combination antiretroviral treatment induced apoptosis in human cervical cancer 
cells. Proceedings of the 13
th
 World Congress on Inflammation;  8-2 July 2017, 






EFFECT OF ANTIRETROVIRAL DRUG CO-ADMINISTRATION WITH 
CONTRACEPTIVE HORMONES ON HUMAN CERVICAL CANCER CELL 
VIABILITY 
2.1.0. Introduction 
Ethinylestradiol and levonorgestrel elicit their effect through interaction with hormone 
receptors. Different responses to oestrogen exposure are elicited through binding to 
estrogen receptor-α (ERα) and estrogen receptor-β (ERβ). The receptors have different 
subtypes and several isoforms (Yu et al., 2010; Mazzucco et al., 2006). Oestrogen 
modulation of gene transcription is termed genomic action (Felty and Roy, 2005). In 
addition to the genomic pathway, there is evidence that a non-genomic signalling pathway 
via ERs contributes to cell proliferation (Mosli et al., 2013; Mazzucco et al., 2006). It has 
since been established that 17β-oestradiol (E2)-dependent cellular proliferation is mediated 
through ERα control of gene transcription and kinase activation (Pesiri et al., 2015; Scaling 
et al., 2014; Atawia et al., (2013). Leucine (L
429
) and alanine (A
430
) are located within the 
ERα ligand-binding domain and contribute to E2-induced proliferation although the 
mechanism of their action has not been fully elucidated (Pesiri et al., 2015). 
 
Mosli et al. (2013) demonstrated that in vitro exposure of non-transformed benign prostatic 
hyperplasia (BPH-1) epithelial cells to catechol oestrogens (CEs) have a neoplastic effect. 
They further demonstrated that the CE 4-hydroxyestradiol (4-OHE2) showed more 
carcinogenicity, relative to the parent hormone 17β-oestradiol (E2). It has also been shown 
that oestrogen has proliferative effects in normal and MCF-7 breast cancer cells (Scaling et 
al., 2014; Pesiri et al., 2015). G protein-coupled estrogen receptor (GPER), previously 
known as GPR30, modulates breast cancer proliferation downwards. In MC7 10A cells, 
stimulation by oestrogen, in the presence of GPER-selective agonist G-1, was shown to 
increase the mitogenic index (Scaling et al., 2014). Mazzucco et al. (2006) demonstrated 
that dual activation of ERα and ERβ showed reduced cell proliferation thus suggesting that 
ERα and ERβ modulate each other‟s activity. This research explores the effect of 
ethinylestradiol (EE), a derivative of 17β-oestradiol, on antiretroviral drug-induced 
proliferative effect in human cervical epithelial cancer cells. It utilises the HeLa cell as the 
cancer cell model. The cells have continued to have widespread use as a model for human 
cervical cancer research. 
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Two isoforms of progesterone receptor (PR), namely progesterone receptor-A (PRA) and 
progesterone receptor-B (PRB), are associated with endometrial differentiation (Vereide et 
al., 2006). Deregulation of either of the genes has been associated with carcinogenesis of 
the endometrium and failure of progestin therapy (Gunderson et al., 2014; Kudesia et al., 
2014, Vereide et al., 2006). Levonorgestrel inhibits human endometrial stromal cell 
(HESC) and human endometrial glandular cell (HEGC) proliferation, while inducing 
apoptosis in both cell lines (Zhao et al., 2015). This is attenuated through an increase in 
permeability of gap junctions and upregulation of Cx43 (Zhao et al., 2015). The 
levonorgestrel intra-uterine system (LNG-IUS) has since been shown to induce regression 
of complex endometrial hyperplasia (Wildemeersch et al., 2015; Haoula et al., 2011; Zhao 
et al., 2015). LNG-IUS down-regulates expression of PRA, PRB, ER-α and ER-β (Gomes 
et al., 2009. Vereide et al., 2014). Complex atypical hyperplasia (CAH) was also shown to 
decrease after progestin therapy (Gunderson et al., 2014; Kudesia et al., 2014). Women 
with CAH and endometrial carcinoma were shown to have an overall response of about 
65% upon receiving progestin-only treatment (Gunderson et al., 2014). Progestin-based 
treatment of CAH and endometrial cancer was shown to be effective and associated with 
an increase in desired pregnancy rates (Kudesia et al., 2014). Here, the effect of co-
administration of levonorgestrel (a synthetic progestogen) with ARVs on HeLa cell 
proliferation is investigated. 
 
While androgens and oestrogen have a pathological role in benign prostatic hyperplasia 
(BPH), Atawia et al. (2013) demonstrated the protective effect of silymarin in preventing 
testosterone-induced BPH in rats by protection against decline in caspase-3 activity. Baker 
and Bauer (2015) also demonstrated that epigallocatechin gallate (EGCG) modifies 
oestrogenic activity in MFC-7 breast cancer cells, hence making it a suitable chemo-
preventive agent. Wang et al. (2004) demonstrated the antiapoptotic effect of oestrogen in 
normal cervical and human epithelial cancer cells (HT3 and CaSki), where baseline 
apoptosis was mediated by P2X7-receptor-induced activation of the pathway. It was shown 
that the antiapoptotic effect was dependent on attenuation of caspase-3 and caspase-9. 
Interestingly, oestradiol did not affect apoptosis in SiHa and HeLa cells (Wang et al., 
2004). This demonstrates that some cells acquire apoptosis-eversion characteristics hence 
enabling growth and proliferation of the tumour. As outlined in the previous chapter, HPV 
alone does not necessarily induce cervical cancer (zur Hausen 2009; Thiery, 2008). While 
HPV-6, E2 and E7 proteins are required for neoplastic transformation of normal human 
cervical cancer cells, it has since been shown that oestrogen and progesterone upregulate 
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the level of HPV-E2 and E7 protein-induced apoptosis in HeLa cells (Webster et al., 2001; 
Wang, 2004). To date there is paucity of information regarding the effect of co-
administration of either LNG or EE with HAART on human cervical epithelial cancer cell 
proliferation.  
 
While HAART reduces HIV-1 transmission, a Burkina Faso follow-up study isolated 
genital HIV-1 in patients on HAART (Low et al., 2014). NVP (nevirapine: a first-
generation non-nucleoside reverse transcriptase) and ZDV (zidovudine: a nucleoside 
reverse transcriptase inhibitor) regimens were shown to exhibit higher rates of 
cervacovaginal shedding relative to d4T (stavudine: a first-generation nucleotide reverse 
transcriptase inhibitor) and efavirenz (EFV)-based regimens (Low et al., 2014). McGuigan 
et al. (2013) evaluated the anticancer activity of the phosphorodiamidate phosphate 
prodrugs for nucleoside analogues (NAs), among which were ABC (abacavir), 3TC 
(lamivudine) and d4T. These studies were devoid of co-administration of contraceptive 
hormones. Stavudine did not show proliferative activity against HeLa cells, while its 
phosphorodiamidates showed anticancer activity. This could be due to the greater 
concentration of active metabolites achieved. In the same study, d4T showed cytostatic 
activity against murine L1210 cells. 3TC also displayed cytostatic activity for HeLa cells, 
while its prodrug displayed some antiproliferative activity. ABC and its prodrugs did not 
exhibit proliferative activity. It is interesting to speculate whether or not co-administration 
with either levonorgestrel and/or ethinylestradiol affects the observed proliferative trend. 
 
There is paucity of information regarding whether pre-exposure to combined oral 
contraceptives followed by co-administration with HAART has an effect on cervical 
intraepithelial neoplastic progression. Using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, this section seeks to evaluate the effect of pre-
exposure to contraceptive hormones (levonorgestrel and ethinylestradiol) on proliferation 
of human cervical epithelial cancer cells. The effect of subsequent co-administration of 
antiretroviral drugs is also investigated. In this section, proliferative assays were performed 
using low effective concentrations (EC15-25) of each antiretroviral drug estimated from the 
24 h proliferation assay. Drug sensitivity is usually defined as IC50 which is that 
concentration resulting in 50% growth inhibition (Sadegh-Aliabadi et al., 2010; Trivedi et 
al., 1990). The half-maximum effective concentration (EC50) is that concentration of a 
drug eliciting half its maximum effect after a specific exposure time. Most toxicological 
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studies use minimal stimulating concentrations, resulting in relative decreases in 
absorbance while IC50 or EC50 equivalents may be used as high-dose exposures.  
 
In the present section, the proliferative effect of single and combination antiretroviral 
treatment (with or without contraceptive hormones) on HeLa cells over a treatment period 
of 72 h is  elucidated. Moodley et al (2009) and Sirera et al (2008) agree that there is need 
to evaluate the role of other factors, such as use of hormonal contraceptives and smoking 
on the onset of CIN among women on highly active antiretroviral therapy (HAART). In 
the past two decades, most single-drug treatments have since been substituted with 
HAART, due to their observed toxicities (BHIVA, 2008; WHO, 2010). Presently, HAART 
is the predominant intervention, although other double and triple combinations have been 
recommended (WHO, 2016). The effect of single drugs on HeLa cell proliferation is 
explored concurrently with antiretroviral drug combinations used in low-resource settings. 
 
Phenol red (Phr)-containing medium used in most cell culture experiments ensures 
monitoring the sterility of the medium, cell culture environment and the aseptic technique. 
However, it has since been suggested that Phr has weak oestrogenic properties in 
concentrations used in most tissue culture medium and Phr was shown to stimulate 
proliferation of MCF-7 cancer cells (Hofland et al., 1987). Ortmann et al. (1990) 
demonstrated that Phr and oestradiol have a synergistic  stimulatory effect on 
gonadotrophin-releasing hormone (GnRH) secretion by pituitary cells. To this effect, 
phenol red free medium is preferred for hormone-based assays (Webster et al., 2001; 
Wang et al., 2004). 
2.1.1. Objectives of the chapter 
a. To evaluate the effect of single and combination antiretroviral treatment (with and 
without contraceptive hormones) on the viability of human cervical epithelial 
cancer cells over a 72 h treatment. 
b. To evaluate the morphological changes on the cervical epithelial cancer cells after 
24 h treatment with single antiretroviral drugs and contraceptive hormones at 
varying concentrations. 
The mechanistic effect of single drugs on HeLa cell proliferation is explored concurrently 
with antiretroviral drug combinations used in low-resource settings. The nucleotide reverse 
transcriptase inhibitors abacavir, zidovudine, lamivudine and stavudine simultaneously 
with nevirapine (a first-generation widely used non-nucleotide reverse transcriptase 
inhibitor) are considered. These constitute the backbone of the most widely used 
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nucleotide plus non-nucleotide antiretroviral drug combinations namely; abacavir and 
lamivudine (ABC+3TC), zidovudine and lamivudine (ZDV+3TC), zidovudine, abacavir 
and lamivudine (ZDV+ABC+3TC) zidovudine, lamivudine and nevirapine 
(ZDV+3TC+NVP) and zidovudine, stavudine and nevirapine (ZDV+d4T+NVP). 
 
2.2. Materials and Methods 
2.2.1 Materials 
Cell culture media, Dulbecco‟s Modified Eagle Medium (DMEM) with and without phenol 
red were purchased from Life Technologies (United Kingdom). Antiretroviral drugs 
(abacavir, lamivudine, nevirapine, stavudine and zidovudine), penicillin-streptomycin, 
sodium pyruvate, dimethylsulfoxide (DMSO), non-essential amino acids, glutamine, 
charcoal-treated foetal bovine serum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT),  were obtained from Sigma (United Kingdom). 96-
well plates were purchased from Nunc Denmark. The HeLa cell line was obtained courtesy 
of the University of East London tissue culture research laboratory. Trypsin/ 
ethylenediaminetetraacetic acid (EDTA) was purchased from Life Technologies (UK). 
 
2.2.2 HeLa cell culture and maintenance  
HeLa cells were maintained in 75cm
2
 flasks. The cells were grown in DMEM with phenol 
red supplemented with 10% FBS 1% non-essential amino-acid solution, 1% sodium 
pyruvate, 2mM glutamine and 1% (v/v) penicillin/streptomycin [10,000 U/ml penicillin, 
10,000 µg/ml streptomycin]. The cells were incubated at 37
o
C and 5% atmospheric CO2. 
The cells were split every 3 to 4 days at approximately 75% confluence. For hormone 
assays, HeLa cells were sub-cultured in DMEM devoid of phenol red supplemented with 
charcoal-treated FBS under similar conditions.   
 
2.2.3 Cryopreservation of HeLa cells 
Cells were grown to about 75% confluence in T75 culture flasks. The cell medium was 
aspirated from the culture flask with growing cells, the cells washed with 5ml PBS and the 
PBS aspirated. 2ml of trypsin/EDTA was added to cover the surface of the flask and the 
flask returned to the incubator for about a minute. Trypsin was quenched by adding 8 ml of 
medium to the flask followed by gently pipetting up and down about 4 times while 
washing the sides and middle part of the flask in order to harvest the highest number of 
cells. The cells were transferred to a 15ml centrifuge tube and spun at 1000rpm for about 5 
minutes. The supernatant was removed, cells re-suspended in 1ml of fresh freezing 
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medium (with 10% DMSO and 20% FBS) and transferred to a cryotube.  The cells were 
placed at -80
o
C overnight and then transferred to liquid nitrogen the next day. Upon 
resuscitation, up to 15 passages were used for experimental assays. 
 
2.2.4 Standard curves for MTT assay 
The MTT cell proliferation assay measures the cell proliferation rate and, conversely, when 
metabolic events lead to apoptosis or necrosis, the reduction in viability (Sieuwerts et al., 
1995).  Metabolic reduction of the yellow tetrazolium salt (MTT) results in a purple 
formazan whose concentration is directly proportional to viable cells. This resultant purple 
complex is quantifiable by spectroscopy (Sieuwerts et al., 1995, Sylvester, 2011; van 
Meerloo et al., 2011). For drug-sensitivity measurements, the absorbance value of 
untreated wells are compared to wells exposed to the drug and the result expressed as a 
percentage: [Absorbance of treated well/Absorbance of the control well] x 100. The 
decrease in cell absorbance is directly proportional to decrease in cell viability and is 
indicative of cell growth inhibition.  
The optical cell count was adapted as outlined in the American Type Culture Collection 
(ATCC) MTT cell proliferation assay instruction guide and from Trivedi et al. (1990). 
Briefly, cells were released from the T75 flask by trypsin (Life Technologies). 1.0 x 10
6 
cells per ml were re-suspended. The cells were serially diluted in cell culture medium from 
1.0 x 10
6
 to about 1.0 x10
3
 cells per ml. The culture medium contained 10% charcoal 
treated FBS, 2mM glutamate, 1% (v/v) penicillin/streptomycin [10,000 U/ml penicillin, 
10,000 µg/ml streptomycin]  and 1% essential amino acids. At short exposure time up to 
24 h, 100µl of medium were deemed sufficient as nutrients will still be present in the 
medium at the end of the incubation period. As the incubation period is increased to 72 h, a 
higher volume of medium (200µl) was used to ensure continuous supply of nutrients and 
limiting the accumulation of metabolic end products.   
 
For preliminary 24 h assays, 100µl of serially diluted cells were seeded in quadruplicates 
onto 96-well plates. Four control wells with medium only constituted the reagent blank for 
absorbance readings. The cells were left overnight (24 h at 37
o
C and 5% atmospheric CO2) 
to adhere and recover from handling. The medium was aspirated, fresh medium was added 
and the cells incubated under same conditions for a further 24 h. 10µl of 5µg/ml MTT 
reagent were added to each well and the well plates further incubated for 1 h. The 
medium/MTT solution was removed from the wells and 100µl DMSO added. The plates 
were left in the dark for 2 h and the absorbance read on a microplate reader at 540nm. 
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Average values from the quadruplicate readings were determined and the average value for 
the blank subtracted. Three independent experiments were considered. Ideally, the seeding 
cell density should lie within the straight line of the curve (Sieuwerts et al., 1995; van 
Meerloo et al., 2011). Seeding densities for hormone treatment were estimated using 
200µml of the medium over 24 h, 48 h and 72 h post adherence of cells. The procedure 
was repeated as described above but this time using 200µl of medium and 20µl MTT 
solution.  
          
2.2.5 Preliminary 24-hour MTT assay for NRTIs 
100μl of 5.0 x 10
4
cells/ml were seeded in 96-well plates. The plates were incubated at 
37
o
C and 5% CO2 for 24 h. After the 24 h incubation period, working stock solutions of 
1000μg/ml of the water-soluble nucleotide reverse transcriptase inhibitors ABC, ZDV, 
3TC and d4T were freshly prepared in sterile medium consisting of 1% (v/v) 
penicillin/streptomycin [10,000 U/ml penicillin, 10,000 µg/ml streptomycin], 10% 
charcoal-treated FBS, 2mM glutamate  and 1% essential amino acids. The working 
solutions were then adjusted to final concentrations of 50µg/ml, 100µg/ml, 150µg/ml, 
200µg/ml, 250µg/ml and 300μg/ml of each drug by diluting with the complete medium to 
a final volume of 1ml. The control solution consisted of medium only (0µg/ml). The 
vehicle control and all treatment medium were adjusted to a final concentration of 0.25% 
(v/v) DMSO. The medium was replaced with 100µl of the freshly prepared medium with 
varying drug concentrations for a further 24 h. Each concentration was administered in 
quadruplicates and the average absorbance taken. For every given drug concentration, each 
experiment was repeated three times. Morphological changes were observed using an 
EVOS
®
 inverted microscope.  
 
2.2.6 Preliminary 24-hour MTT assay for nevirapine  
The preliminary 24 h MTT assay was carried out in order to determine the concentrations 
of NVP ideal for toxicity and apoptosis assays in HeLa cells. Nevirapine is a non-
nucleoside reverse transcriptase inhibitor that is sparingly soluble in water. Its solubility in 
DMSO is ≥22mg/ml. In in vitro assays, it has since been established that DMSO 
concentrations of 1% and below do not affect the toxicity in HeLa cells (Trivedi et al., 
1990). 10mg of nevirapine were dissolved in 0.5 ml of DMSO, thus giving a stock solution 
of 20mg/ml. This solution was diluted in DMEM (consisting 10% charcoal-treated FBS, 
2mM glutamate, 1% (v/v) penicillin/streptomycin [10,000 U/ml penicillin, 10,000 µg/ml 
streptomycin] and 1% essential amino-acids to give solutions of 40µg/ml, 80µg/ml, 
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120µg/ml, 160 µg/ml and 200μg/ml. The maximum concentration of 200μg/ml ensured the 
limit of 1% DMSO in solution. The vehicle control and all treatment media were adjusted 
to a final concentration of 1% DMSO. HeLa cells were then treated in quadruplicate in 96-
well plates with each of the concentrations to determine single-drug viability effect as 
previously described for NRTIs. The experiment was repeated three times (n=3). 
 
2.2.7. Preliminary 24-hour MTT assay for ethinylestradiol and levonorgestrel  
The preliminary 24-h MTT assay was carried out in order to determine the concentrations 
of EE and LNG ideal for toxicity and apoptosis assays in HeLa cells. Briefly, 
approximately 0.5 x10
4
 HeLa cells per well were seeded in flat bottom 96-well plates. The 
cells were seeded in a suspension DMEM without phenol red, supplemented with 10% 
FBS 10ml/L minimum essential amino-acids and 1% (v/v) penicillin/streptomycin [10,000 
U/ml penicillin, 10,000 µg/ml streptomycin]. The cells were then incubated overnight (24 
h) at 37
o
C and 5% CO2 to allow them to attach. Following cell attachment, the medium 
was aspirated and replaced with 4µg/ml, 8µg/ml, 12µg/ml, 16µg/ml and 20µg/ml of EE 
and LNG in DMEM with its constituent supplements. The cells were then incubated for a 
further 24 h, viewed on an inverted EVOS® microscope and photographs captured with 
great caution since the culture medium was colourless, hence giving a grey background. 
 
2.2.8.   72-Hour viability assay for antiretroviral drug treated cells 
About 3.0 x 10
4
 cells/ml were suspended in DMEM without phenol red supplemented with 
10% charcoal-stripped FBS, 10ml/L minimum essential amino-acids and 1% (v/v) 
penicillin/streptomycin [10,000 U/ml penicillin, 10,000 µg/ml streptomycin]. 200µl of cell 
suspension (6.0 x 10
3
 cell per well) were seeded in flat bottom 96-well plates. A 
quadruplicate of wells with 200μl of medium only constituted the reagent blank. The plates 
were incubated at 37
o
C and 5% atmospheric carbon dioxide for 24 h. The medium was 
replaced with 200μl quadruplicates of the freshly prepared single and combination 
antiretroviral drugs at final concentrations of 50μg/ml of each drug. The vehicle control 
and all treatment medium were adjusted to a final concentration of 0.25% DMSO. The 
control cells were treated with the vehicle medium without antiretroviral drugs. Blank 
wells constituted of the medium only with no cells.  For each concentration, the set of 
quadruplicates was commensurate with the number of single drug and HAART 
combinations under investigation. The cells were then incubated for 72 h and the 
morphology of the cells captured by an EVOS
®




2.2.9. 72-Hour viability assay for ARV co-treatment with contraceptive hormones 
Approximately 6.0 x10
3
 cells per well were seeded in flat-bottom 96-well plates. A 
quadruplicate of wells had 200µl of medium without cells and this constituted the reagent 
blank. The plates were incubated at 37
o
C and 5% atmospheric carbon dioxide. After 24 h 
of initial incubation, the working stock solutions of ethinylestradiol and levonorgestrel 
were adjusted to final concentrations of 0.5µg/ml, 1.0µg/ml and 2.0µg/ml or 1.0µg/ml, 
2.0µg/ml and 4.0µg/ml, by diluting with DMEM. The medium was replaced with 
quadruplicates of 200µl hormone solutions. Control wells were treated with 200µl of 
vehicle medium only. Blank wells constituted of the medium only with no cells. The wells 
were incubated for 24 h. A mixture of antiretroviral drugs at final concentration of 50µg/ml 
for each drug was freshly prepared and supplemented with hormones maintained at 
original concentrations. The medium was then aspirated and replaced with 200µl of the 
antiretroviral drug/hormone mixtures and incubated for a further 48 h. After the total 
exposure time (72 h), cell proliferation was assessed by MTT.  The set of quadruplicates 
constituted of 50µg/ml of single drugs (ABC, ZDV, 3TC, d4T and NVP) or antiretroviral 
drug combinations (ABC+3TC, ZDV+3TC, ABC+ZDV+3TC, ZDV+3TC+NVP and 
d4T+3TC+NVP). At each stage, the cells were viewed on an inverted EVOS
®
 microscope 
and photographs captured. Each set of experiments was repeated three times. The 
procedure of the proliferation assay is summarised in Figure 2.1. 
 
2.2.10 Data Analysis 
For preliminary proliferation assays, differences in proliferation rates among groups were 
compared by one-way ANOVA followed by Dunnett‟s multiple comparison. Three 




















Fig 2.1: Outline of the experimental design for the effect of antiretroviral drug co-
administration with contraceptive hormones on human cervical epithelial cancer cell 
proliferation. HeLa cells were treated with either single drugs or the combination ARVs at a 
final concentration of 50µg/ml of each drug. The rate of proliferation for ARV-only treated 
cells was compared to the untreated control after 24 h, 48 h and 72 h using the MTT assay. 
Simultaneously, 0.5µg/ml, 1.0µg/ml and 2.0µg/ml ethinylestradiol (EE) or 1.0µg/ml, 2.0µg/ml 
and 4.0µg/ml of levonorgestrel (LNG) were administered for 24 h followed by co-
administration with single and combination drugs and cell proliferation evaluated against the 













The results for the effect of contraceptive hormones on HeLa cell proliferation upon co-
administration with both single and combination antiretroviral drugs are presented in this 
section. 
 
2.3.1 MTT Standard curves 
Figure 2.2 and Figure 2.3 show the standard curves for 24 h and 72 h MTT assays 
respectively.  
 
                                 
Fig. 2.2: Linearity between absorbance and HeLa cell numbers over a range of densities in 48 
h. To each well was added 100µl of the given cell concentration and cells left for 24 h to allow 
for adherence. The medium was changed and the cells further incubated for 24 h. 10µl of 
MTT (5µg/ml) was added to each well and cells incubated in the dark for 2 h after which the 
suspension medium was discarded. The formazan (i.e. the intensely absorbent product of 
cellular metabolic activity in the MTT assay) in each well was extracted with 100µl of DMSO. 
The linearity of the MTT reduction for each cell concentration was determined using the 
Multiskan Spectrum® ELISA plate reader. 100µl of 5.0 x 10
4
 cells per ml (5.0 x 10
3
 cells per 
well) was preferred for further experiments as it fell within the linear portion of the plot and 
extrapolates to an absorbance of 0.840 on (GraphPad Prism 7.0). 
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Fig. 2.3:  Linearity between absorbance and HeLa cell numbers over a range of densities in 
96 h. To each well was added 200µl of the given cell concentration and cells left for 24 h. The 
medium was changed and the cells further incubated for 24, 48 and 72 h. 20µl of MTT dye 
(5µg/ml) was added to each well and cells incubated in the dark for 2 h after which the 
suspension medium was discarded. The formazan in each well was extracted with 200µl of 
DMSO. The linearity of the MTT reduction for each cell concentration was determined using 
the Multiskan Spectrum® ELISA plate reader. 200µl of 3 x 10
4
 cells per ml (6.0 x 10
3
 cells per 
well) was preferred for further experiments as it fell within the linear portions of the plots for 






2.3.2. 24-Hour antiproliferative effect of NRTIs and NVP on HeLa cells  
The proliferative effect for each drug at given concentrations was expressed as a 
percentage absorbance relative to that of the untreated cells. Figure 2.4 summarises the 
proliferative assay results for NRTIs. With increasing antiretroviral drug concentration 
from 50µg/ml to 300µg/ml, the mean percentage absorbance for ABC and ZDV decreased 
in a concentration-dependent manner, from 82% to 37% and 84% to 47%, respectively. 
The absorbance for 3TC fell from an average of 80% following administration of 50µg/ml 
to 64% at 300µg/ml. This 3TC decrease depicts a linear concentration-dependent decrease 
up to 150µg/ml after which an almost static trend is observed. The trend is inconsistent for 
d4T-treated cells, whose  absorbance decreases from 76% at 50µg/ml to 67% at 300µg/ml 
but in a non-linear trend.  Figures 2.5(a) and 2.5(b) depict the MTT proliferation results 
and dose-response curves for NVP-treated HeLa cells, respectively. The computed mean 
relative absorbance value for formazan produced by the NVP-treated cells fell in a 
concentration-dependent manner, from 82% with 50µg/ml to 58% at 200µg/ml. The use of 
DMSO as a vehicle was shown to have no effect on HeLa cell rate of proliferation 





















     
     
  
Fig 2.4: Viability of HeLa cells exposed to different concentrations of NRTIs for 24 h. Cell 
proliferation was determined by MTT assay. Data are expressed as the comparison of 
absolute absorbance values of treated cells compared to the absolute absorbance values for 
the untreated control whose cell survival is set to 100% (mean ± SEM, n=3 independent 
experiments). Data were analysed using one-way ANOVA followed by Dunnett’s multi-
comparison test (P≤0.05). Asterisks (*) indicate data that are significantly different compared 
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Fig 2.5:  (a) Viability of HeLa treated with varying concentrations of nevirapine for 24 h. Cell 
proliferation was determined by MTT assay. Data are expressed as the comparison of 
absolute absorbance values of treated cells compared to the absolute absorbance values for 
the untreated control whose cell survival is set to 100% (mean ± SEM, n=3 independent 
experiments). Data were analysed using one-way ANOVA followed by Dunnett’s multi-
comparison test (P≤0.05). Asterisks (*) indicate data that are significantly different compared 
to the untreated control while ns denotes no significant difference. (b) Dose response curve 
for NVP.  Drug concentration was plotted against the relative percentage of absorbance 
(mean ± SEM, n =3 independent experiments). The equation of this line was used to estimate 
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2.3.3 Determination of percentage viability at 50µg/ml drug treatment  
Table 2.1 depicts percentage of absorbance relative to the control (vehicle-treated cells), 
following treatment with 50µg/ml of ABC, ZDV, 3TC and d4T. The relative absorbance 
(Abs) value for 50µg/ml NVP (
a
) was estimated from the equation of the line of best fit by 
calculating the value of x when y=50 (Figure 2.5b).  
 
Table 2.1: Minimum exposure concentration data from 24-hour proliferation assays. 
Treatment ABC ZDV 3TC d4T NVP 
%Abs of 
50µg/ml 
 82.4±1.5 84.0±2.1 80.8±0.6 76.4±1.5 82.0
a
 
The table summarises the percentage of absorbance of cells treated with 50µg/ml of each 
antiretroviral drug relative to untreated control cells (% Abs of 50µg/ml ± SEM, n=3 
independent experiments). (
a
) Indicates a value estimated from linear interpolation. 
 
2.3.4 Morphological observation of HeLa cells after 24-hour ARV treatment 
Photographs were captured using an EVOS
®
 inverted microscope. Detailed microscopic 
pictures and change of cellular morphology with treatment at different concentrations of 
antiretroviral drugs is shown in Appendix 1.  The major morphological changes observed 
with varying antiretroviral combinations are summarised in this section. 
 
For ABC-treated cells, as the concentration increases to 50µg/ml and 100µg/ml, there is no 
obvious morphological change compared to untreated cells. At these concentrations, there 
are some dividing cells as evidenced by large nuclei. As the concentration increases to 
200µg/ml and 300µg/ml,  the cells become spindle- and star-shaped, respectively, while 
there is a decrease in cell density with increasing concentration. At 300µg/ml, some cells 
with protruded membrane and apoptotic bodies are observed.  Cells treated with 50µg/ml 
and 100µg/ml of ZDV still exhibit the generic HeLa morphological characteristics. 
Increasing the concentration to 200µg/ml and 300µg/ml results in cells that are 
heterogenous in morphology. There is a gradual decrease in cell density with increasing 
ZDV concentration. Following treatment with 50µg/ml and 100µg/ml 3TC, the typical 
HeLa morphology is mantained. With 200ug/ml and 300µg/ml 3TC treatment, the cells are 
still viable and actively dividing with no obvious morphological changes although the cells 
appear less dense. With 300µg/ml 3TC treatment, some large nuclei of dividing cells are 
still apparent. Treatment with up to 200µg/ml d4T does not elicit obvious morphological 
differences relative to untreated cells regarding the nuclear/cytoplasmic ratio. Large nuclei 
of dividing cells are still apparent. Cells treated with 300µg/ml dT4 have large dividing 
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nuclei, although there seems to be a mixture of some anvil, spindle- and normal-shaped 
cells. At this concentration, some cells with protruded membrane and apoptotic bodies are 
observed. Most nevirapine-treated cells exhibit nomal morphological features up to 
80µg/ml. However, from 120µg/ml to 200µg/ml the cells are increasingly becoming 
spindle-shaped and less dense.  
 
HeLa cells remained able to  accomplish cell division and growth. Concentrations of 
50µg/ml of each antiretroviral drug were thus considered  for  further proliferation, 
apoptosis and toxicity experiments. In this 24 h treatment, all the antiretroviral drug 
treatments result in reduction of viability by within 20-25% compared to the untreated 
control. Such reduction in viability have been recommended as low-dose concentrations 
for toxicological assays. Although d4T significantly altered the proliferation rate in 
medium with phenol red, the inhibitory effect was within the 20-25% range in Phr-free 
medium which was used for later assays. While  50µg/ml was chosen for further assays 
involving all drugs, it is important to note the different molarities of each drug as shown in 
Table 2.2 below. 
Table 2.2. Concentration of antiretroviral drugs used for further assays 
Drug MW Conc. (µg/mL) µmol/L 
Abacavir (ABC) 286.33 50 175 









Nevirapine (NVP) 266.30 50 188 
 
2.3.5. Twenty-four hour viability effect of contraceptive hormones on HeLa cells 
Figure 2.6 depicts the MTT assay results for treating HeLa cells with varying 
concentrations of hormones for 24 h. There is a concentration-dependent decrease in 












Fig 2.6: Effect of levonorgestrel (LNG) and ethinylestradiol (EE) on HeLa cell 
viability over 24 h.  Cell viability was determined by MTT assay. Data are expressed 
as the percentage of absolute absorbance values of treated cells compared to the 
absolute absorbance values for the untreated control whose cell survival is set to 
100%  (mean ± SEM, n=3 independent experiments). Data were analysed using one-
way ANOVA followed by Dunnett’s multi-comparison test. The relative absorbance 
of drug-treated cells was compared to the untreated control, where a, b and c 







































2.3.6 Morphology of cells treated with ethinylestradiol and levonorgestrel 
Figure 2.7 and Figure 2.8 depict the appearance of HeLa cells following 24 h treatment 
with EE and LNG, respectively. As shown in Figure 2.7, treatment with 4.0µg/ml EE 
results in some cells becoming apoptotic. Further exposure to 4.0µg/ml EE for 24 h results 
in most of these treated cells becoming shrunk and characterised by membrane blebbing 
thus depicting grossly apoptotic cells (Figure 2.9). Microscopic observation of the 
morphology in 2.0 EE treated cells over 48 h did not show any obvious morphological 
transformation (Figure 2.9). Concentrations of 0.5µg/ml, 1.0µg/ml and 2.0 µg/ml EE were 
therefore preferably used in succeeding assays on the role of contraceptive hormones upon 
co-administration with antiretroviral drugs. Figure 3.7 shows no apparent morphological 
changes with 4.0µg/ml LNG, although further increases in concentration depict varying 
morphological changes. No morphological changes were observed with 4.0µg/ml LNG 
over 48 h of treatment hence concentrations of 1.0µg/ml, 2.0µg/ml and 4.0µg/ml LNG 
were used for later assays. Phenol red-free medium was preferred for these assays because 
other experiments involved treatment of cells in the presence of  hormones 
(ethinylestradiol and levonorgestrol). The common practice to use phenol red-free medium, 
coupled with charcoal-treated foetal bovine serum in hormone-based assays, ensures 
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Fig 2.7: Microscopic appearance of cells after single drug treatment with ethinylestradiol 
(EE). At 12µg/ml, most cells have lost their polygonal structure and have an increased 
nuclear / cytoplasmic ratio. At 16µg/ml and 20µg/ml as cells are dying, there is increased 
cellular debris and most cells become detached from the cell plates.  White arrows illustrate 
changes in cellular morphology, as typified by a spherical shape, while black arrows depict 




















                                                                                                      
           
        
Fig 2.8: Microscopic appearance of cells after single drug treatment with levonorgestrel.  At 
12µg/m and 16µg/ml most cells have lost their polygonal structure and characterised by an 
increased nuclear cytoplasmic ratio. Although at 12µg/ml and 16µg/ml, there is increased 
cellular debris, there is a mixture of detached cells and some cells that are still attached to the 
cell plate. At 16µg/ml and 20µg/ml, most cells are dying, there is increased cellular debris and 
most cells become detached from the cell plates. White arrows illustrate changes in cellular 
morphology as the polyhedral shape is lost typified by a spherical morphology, while black 
arrows depict cells that have grossly lost their normal morphology and are dying. The scale 




















   
   
Fig 2.9: Morphological assay of 48 h hormone treatment for HeLa cells. 0.5 x 10
4
 cells 
per well were seeded in 96-well plates and incubated overnight at 37
o
C and 5% CO2 
for cells to adhere. The medium was removed and replaced with 100µl of untreated 
(control) medium (a), 4.0µg/ml ethinylestradiol (b), 2.0µg/ml ethinylestradiol (c), or 
4.0µg/ml levonorgestrel (d). The cells were incubated at 37
o
C and 5% CO2. The plates 
were left for 48 h and morphological appearance captured by an EVOS
®
 inverted 
microscope. Cells in a, c and d maintain their polygonal elongated morphology, while 
those in b showed a drastic change in morphology with most of them being spherical 










2.3.7. Effect of antiretroviral drug treatment on HeLa cell viability 
Figure 2.10 depicts the results from MTT viability assay for single drug treatment over 72 
h. Most cells depict normal morphology for ABC-, 3TC- and d4T-treated cells, with very 
few cells however showing altered morphology as depicted by loss of the typical polygonal 
structure and membrane blebbing after 72 h of treatment. After 72 h, ZDV- and NVP-
treated cells had predominantly normal morphology, although a higher proportion of 
atypical cells were noted compared to those treated with ABC, 3TC and d4T. Figure 2.11 
shows the viability of combination antiretroviral-treated cells over 72 h. Combination 
antiretroviral-treated cells were predominantly polygonal although there was a general 

































Fig 2.10: Effect of single antiretroviral treatment on HeLa cell proliferation. HeLa cells were 
seeded in phenol red-free DMEM for 24 h to allow attachment. The cells were treated with 
single antiretroviral drugs at final concentrations of 50µg/ml for 24, 48 and 72 h. Untreated 
cells served as the control. Significant differences among the treatments were determined by 
one-way ANOVA followed by Dunnett’s multiple comparison test. Data are expressed as the 
comparison of absolute absorbance values of treated cells compared to the absolute 
absorbance values for the untreated control whose cell survival is set to 100%  (mean ± SEM, 















































Fig 2.11: Effect of combination antiretroviral treatment on HeLa cell proliferation. HeLa 
cells were seeded in phenol-red free DMEM for 24 h to allow attachment. The cells were then 
treated for 24, 48 and 72 h with combination antiretroviral drugs at final concentrations of 
50µg/ml of each drug. Untreated cells served as a control. Following each exposure time the 
treated cells were compared to untreated cells using one-way ANOVA followed by Dunnett’s 
multiple-comparison test. Data are expressed as the percentage of absolute absorbance values 
of treated cells compared to the absolute absorbance values for the untreated control whose 
cell survival is set to 100% (mean ± SEM, n=3 independent experiments). Asterisks (*) 











































2.3.8 Effect of antiretroviral drug co-treatment with levonorgestrel on HeLa cell 
viability 
 Figure 2.12 depicts the viability of HeLa cells following co-administration of single 
antiretroviral drugs with levonorgestrel (LNG). Untreated cells (control) and those treated 
with 1.0µg/ml, 2.0µg/ml and 4.0µg/ml grew well with typical polygonal morphology, 
colour and loose chromatin over the whole 72 h treatment time. Co-treatment of ABC, 
ZDV and NVP with 1.0µg/ml, 2.0µg/ml and 4.0µg/ml LNG appeared normal. Co-
treatment of ABC with 4.0µg/ml over 72 h results in normal morphology but darker than 
the control and dense at the plate periphery. ABC-, ZDV- and NVP-treated cells appeared 
less dense compared to the control. 3TC and d4T showed increased numbers of spherical 
clumped morphology upon co-administration with 4.0µg/ml LNG. Figure 2.13 
demonstrates the effect of co-administering LNG with combination antiretroviral drugs on 
HeLa cell proliferation.  While treatment with 1.0µg/ml, 2.0µg/ml and 4.0µg/ml depicted 






























Fig 2.12: Effect of single antiretroviral drug co-treatment with levonorgestrel (LNG) on HeLa 
cell proliferation. HeLa cells were seeded in phenol red-free DMEM for 24 h to allow 
attachment. The medium was replaced with solutions of 1.0µg/ml, 2.0µg/ml and 4.0µg/ml 
levonorgestrel which were then incubated for 24 h. The medium was then replaced with each 
single drug at a final concentration of 50µg/ml co-administered with 1.0µg/ml, 2.0µg/ml and 
4.0µg/ml levonorgestrel. The cells were incubated for a further 48 h. After the total exposure 
time (72 h), the viability of drug-treated cells with each hormone concentration co-treatment 
were compared to untreated cells using one-way ANOVA followed by Dunnett’s multi-
comparison test. Data are expressed as the percentage of absolute absorbance values of 
treated cells compared with the absolute absorbance values for the untreated control whose 
cell survival is set to 100% (mean ± SEM, n=3 independent experiments).  Asterisks (*) 
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Fig 2.13:  Effect of combination antiretroviral co-treatment with levonorgestrel (LNG) on 
HeLa cell proliferation. HeLa cells were seeded in phenol red-free DMEM for 24 h to allow 
attachment. The cells were pre-treated with levonorgestrel at concentrations of 1.0µg/ml, 
2.0µg/ml and 4.0µg/ml for 24 h. The cells were then co-treated with combination 
antiretroviral drugs for a further 48 h, thus making the total exposure time 72 h. For each 
concentration of levonorgestrel, the relative absorbance for drug-treated cells was compared 
to untreated cells by one-way ANOVA followed by Dunnett’s multiple comparison test. Data 
are expressed as the percentage of absolute absorbance values of treated cells compared to 
the absolute absorbance values for the untreated control  whose cell survival is set to 100% 
(mean ± SEM, n=3 independent experiments). Asterisk (*) indicate significant difference 










































2.3.9 Effect of antiretroviral co-treatment with ethinylestradiol on HeLa cell viability 
The effect of single antiretroviral co-treatment with ethinylestradiol on the viability of 
HeLa cells over a 72 h treatment period is shown in Figure 2.14. All single drugs co-
treatments with 0.5µg/ml EE showed normal morphology. With increasing EE 
concentration, the cell density appears to be decreasing for 3TC, ZDV and NVP. Figure 
2.15 depicts the effect of combination antiretroviral co-treatment with ethinylestradiol on 
HeLa cell viability over a 72 h treatment period. 0.5µg/ml EE co-treatment with 
























Fig 2.14: Effect of single antiretroviral co-treatment with ethinylestradiol (EE) on HeLa cell 
proliferation. HeLa cells were seeded in phenol red-free DMEM for 24hrs to allow 
attachment. The medium was replaced with 0.5µg/ml, 1.0µg/ml and 2.0µg/ml medium 
prepared ethinylestradiol for 24 h. The cells were then co-treated with combination 
antiretroviral drugs for a further 48 h. After the total exposure time (72 h), proliferation for 
each hormone concentration co-treatment was compared to untreated cells using one-way 
ANOVA followed by Dunnett’s multi-comparison test. Data are expressed as the percentage 
of absolute absorbance values of treated cells compared to the absolute absorbance values for 
the untreated control whose cell survival is set to 100% (mean ± SEM, n=3 independent 












































Fig 2.15: Effect of combination antiretroviral co-treatment with ethinylestradiol (EE) on 
HeLa cell proliferation. HeLa cells were seeded in phenol red-free DMEM for 24 h to allow 
attachment. The cells were pre-treated with ethinylestradiol at concentrations of 0.5µg/ml, 
1.0µg/ml and 2.0µg/ml for 24 h. The cells were then co-treated with combination 
antiretroviral drugs for a further 48 h, thus making the total exposure time 72 h. For each 
concentration of ethinylestradiol, the relative absorbance for drug treated cells was compared 
to untreated cells by one-way ANOVA followed by Dunnett’s multiple comparison tests. Data 
are expressed as the percentage of absolute absorbance values of treated cells compared to 
the absolute absorbance values for the untreated control whose cell survival is set to 100% 
(mean ± SEM, n=3 independent experiments). Asterisks (*) indicate data significantly 



































The HeLa cell is a cancerous cell line that can be used as a model of the human cervical 
epithelial cancer cell line. Effective therapy entails a reduction in the proliferative rate of 
the cancer cell.  As such, it is interesting to enquire into whether or not antiretroviral drug 
therapy has an effect on the proliferation of the cancer cell. Furthermore, this section seeks 
to discuss whether or not co-administration of contraceptive hormones with highly active 
antiretroviral therapy  affects the viability of the human cervical cell line. 
Combination treatments provide a promising approach towards combating multifactorial or 
complex disorders (Bulusu et al., 2016). The multiplicity of possible combinations and 
variations in individual drug concentration implies that exhaustive experimental testing is 
not feasible (Bulusu et al., 2016., Pauzi et al., 2016). The organisation of toxicity and 
proliferation assays, therefore, rests on the ability to predict the behaviour of drugs if 
administered singly, prior to examining the combinatorial effect (Pauzi et al., 2016; 
Doudican et al., 2015; Murugan et al., 2016). In the present research, 50µg/ml of each 
nucloeside reverse trancriptase inhibitor (abacavir, zidovudine, lamivudine and stavudine) 
and nevirapine (a first-generation non-nucleoside reverse transcriptase inhibitor) did not 
impact drastically on the morphology of human cervical epithelial cancer cells during 24 h 
exposure, although these concentrations were cytotoxic.  
The preliminary 24 h MTT proliferation assay carried out for varying concentrations was 
to deduce the concentrations of drugs which do not induce a drastic antiproliferative effects 
over 24 h. These concentrations which do not present drastic morphological 
transformations are ideal for toxicological and apoptosis studies (Muthusamy et al., 2016; 
Yu et al., 2013). Following 24 h treatment, overall there is a concentration-dependent 
decrease in HeLa cell proliferation, although a static relationship was seen for cells treated 
with concentrations above 150µg/ml of d4T and 3TC. The results therefore show a 
concentration-dependent decrease in cell proliferation for ABC, ZDV and NVP-treated 
HeLa cells. The observed concentration-dependent decrease on treating HeLa cells with 
d4T and 3TC up to 150µg/ml is thus suggesting the cytostatic activity at higher 
concentrations. 
After 24 h treatment with 50µg/ml of each antiretroviral drug in medium containing phenol 
red (Phr), there was no significant difference between the untreated cells and all single 
treatments except for 3TC. On the contrary, the 24 h treatment in Phr-devoid medium 
showed no significant differences for all single drug treatments characterised by relative 
concentrations within the EC15-22 range for all individual treatments. This suggests the ideal 
64 
 
use of 50µg/ml of each drug for toxicity and apoptosis assays, since they show no drastic 
morphological change. The comparative differences for means observed in 24 h treatments 
between Phr-containing and Phr-free medium, especially with 3TC treatment, could be 
partially due to the oestrogenic effect of phenol red. Phr has been shown to exhibit weak 
oestrogenic effects in MCF-7 (Węsierska-Gądek et al., 2007; Welshons et al., 1988) and 
T47D breast cancer-derived cells (Welshons et al., 1988). Ernst et al. (1989) further 
demonstrated that Phr exerts oestrogen-like effects in vivo by stimulating bone cells in 
mice. Such observations suggest that Phr is likely to interfere with experimental designs 
exploring hormone effects in vitro. To this end, therefore Phr-free medium is of choice in 
hormone-based assays (Webster et al., 2001; Wang et al., 2004). 
In the absence of hormonal contraceptive co-administration, it has been suggested that the 
cytostatic activity of first-generation non-nucleoside reverse transcriptase inhibitors, such 
as  nevirapine and efavirenz, is anticancerous. Ideally NVP and ZDV (a nucleoside reverse 
transcriptase inhibitor) should be used in HAART combinations (BHIVA, 2008; Hecht et 
al., 2015).  In the absence of hormones, the present results concur on nevirapine and 
zidovudine showing antiproliferative activity in a time-dependent manner (Fig 2.10). 
Levonorgestrel has been shown to exhibit antiproliferative activity in a number of 
cancerous cells through attenuation of the apoptotic pathway (Zhao et al., 2015; 
Wildemeersch et al., 2015; Haoula et al., 2011). Co-treatment of HeLa cells with 
nevirapine and 1.0µg/ml, 2.0µg/ml or 4.0µg/ml levonorgestrel continues to show 
antiproliferative activity as there are significant differences relative to untreated cells (Fig 
2.12). The same antiproliferative activity is observed for ZDV.  
In vivo, abacavir (ABC) is converted into carbovir monophosphate and ultimately to 
carbovir triphosphate (Yuen et al., 2008). While it has since been established that carbovir 
has potent antiretroviral activity, its toxicity limits its direct administration (McGuigan et 
al., 2013; Yuen et al., 2008). In the absence of hormones, no significant difference in cell 
proliferation was observed between ABC-treated cells and the untreated control. This 
observation concurs with McGuigan et al. (2013), who reported that ABC and its prodrugs 
do not exhibit antiproliferative activity upon lone administration. ABC treatment shows a 
non-significant decrease in relative percentage in cell viability upon 48 h of treatment (Fig 
2.10), a situation which diminishes after 72 h of treatment. This decrease in HeLa cell 
viability could be due to time-dependent accumulation  of carbovir, a metabolic product of 
ABC which is cytotoxic. The intracellular half-life of ABC ranges up to about 40 h (Yuen 
et al., 2008; Jackson et al., 2012) possibly reiterating the relative percentage decrease in 
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HeLa cell viability after 48 h. Co-treatment of ABC with 0.5µg/ml ethinylestradiol 
demonstrates an increase in HeLa cell viability with time (Fig 2.14). Co-treatment of ABC 
with 1.0µg/ml, 2.0µg/ml and 4.0µg/ml LNG show antiproliferative effect in HeLa cells 
with significant differences observed for 1.0µg/ml, 2.0µg/ml and 4.0µg/ml LNG co-
treatment (Fig 2.12). This observation further concurs with antiproliferative effects of  
LNG on HeLa cells (Webster et al., 2001). On the contrary, co-treatment of ABC with 
ethinylestradiol does not show significant differences (relative to the control cells) in HeLa 
cell viability at all exposure concentrations (0.5µg/ml, 1.0µg/ml and 2.0µg/ml), a 
phenomenon attributable to the established proliferative effect of EE in various cancer cells 
(Scaling et al., 2014; Pesiri et al., 2015). 
Olivero et al. (1995) demonstrated induction of S-phase arrest in HeLa cells treated with a 
combination of ZDV and 3TC (a reverse transcriptase inhibitor) or those treated with ZDV 
alone. The dose-limiting toxicity of ZDV has been attributed to its incorporation into 
DNA, hence resulting in genomic instability (Olivero et al., 1995). The present results 
show that, in the absence of contraceptive hormones, ZDV treatment resulted in a time-
dependent decrease in HeLa cell proliferation over the 72 h of exposure (Fig 2.10), thus 
possibly implying a genomic effect as previously observed in other studies (Yu et al., 
2009; Olivero et al., 2013). This antiproliferative effect is also evident upon ZDV co-
administration with levornorgestrel, with a significant difference observed after co-
treatment with 1.0µg/ml, 2.0µg/ml and 4.0µg/ml LNG. The present observations suggest 
that co-administration of ZDV and ethinylestradiol on HeLa cells leads to a concentration-
dependent antiproliferative effect (Fig 2.14), thus demonstrating significant differences 
from the control with 1.0µg/ml and 2.0µg/ml EE treatment. These results are interesting, as 
they contradict the established proliferative effect of ethinylestradiol, thus suggesting a 
protective effect against cancer cell growth. 
Lamivudine (3TC)-treated HeLa cells demonstrate no significant differences compared to 
untreated cells upon 24 h and 48 h of treatment in the absence of hormones (Fig 2.10). 72 h 
treatment of HeLa cells with 3TC demonstrates a significant decrease in cell proliferation. 
This could be a result of the gradual effect of 3TC on the S-phase arrest with increasing 
concentration, as discussed by Olivero et al. (1995). Results for 72 h co-treatment of 3TC 
with 1.0µg/ml, 2.0µg/ml and 4.0ug/ml levonorgestrel suggest increase in cell proliferation 




In the absence of contraceptive hormones, there is a time-dependent decrease in cell 
viability for stavudine  (d4T: a nucleoside reverse transcriptase inhibitor used in HAART 
regiments)-treated HeLa cells relative to untreated cells (Fig 2.10). This may suggest 
antiproliferative activity of d4T which concurs with observations by McGuigan et al. 
(2013) who showed that d4T had cytostatic activity against murine L1210 cells while the 
d4T phosphorodiamidates had anticancer activity activity against HeLa cells. In normal 
human mammary epithelial cell (NHMEC), d4T is associated with centromere 
amplification at concentrations ten-fold the plasma level following 24 h treatment (Yu et 
al., 2009). This observation may provide a plausible explanation for the present 
observations, since toxicological assay concentrations higher than plasma levels were used. 
The World Health Organisation guidelines (2016) and British HIV Association (BHIVA), 
2008) suggest a gradual withdrawal of d4T-based treatments which are still being practised 
in some low-resource settings, because of the perceived high d4T toxicity. The presently 
observed time-dependent decrease in relative absorbance after HeLa cells treatment with 
d4T suggests concurrence to its demonstrated anticancer properties (McGuigan et al., 
2013). Co-administration of levonorgestrel and stavudine to HeLa cells shows no 
significant difference in proliferation (Fig 2.12).  
In the present section, the effect of single antiretroviral drugs on HeLa cell proliferation 
has been described in order to understand the mechanistic effects of contraceptive 
hormones on the different nucleoside reverse transcriptase inhibitors and nevirapine (a 
non-nucleoside reverse transcriptase inhibitor). As discussed earlier, in practice, 
combination antiretroviral treatment is the predominantly used intervention among HIV 
positive patients. Highly active antiretroviral treatment with ABC+ZDV+3TC, 
ZDV+3TC+NVP and d4T+3TC+NVP in the absence of hormones shows a significant 
time-dependent decrease in human cervical cancer cell proliferation (Figure 2.11).  
Multi-drug therapy in cancer treatment has been shown to be less toxic in small 
combination doses while at the same time exhibiting a high therapeutic effect (Bulusu et 
al., 2016). Pauzi et al. (2016) demonstrated the synergistic cytotoxic effect of bromelain 
and cisplastin against the MDA-MB-231 cancer cell line. Co-administration of gamitrinib 
and doxorubicin synergistically enhanced apoptosis in selected human prostate, kidney, 
cervix and lung cell lines (Park et al., 2014). Whether such anticancer properties are 
exhibited by combination antiretroviral treatment relative to single antiretroviral drug 
administration has not been explored.  
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ZDV+3TC+NVP and d4T+3TC+NVP are highly active antiretroviral regimens that have 
found widespread use in most low- and medium-resource countries (WHO, 2016). In the 
present study, human cervical epithelial cells treated with these regimens in the absence of 
hormones depict the phenomenon of antiproliferative effect of combination cytotoxic or 
cytostatic substances, in concurrence with Park et al. (2014) and Pauzi et al. (2016).  
Similarly, the triple nucleoside reverse transcriptase inhibitor ABC+ZDV+3TC, which has 
found widespread use in low-resource settings, also depicts such a synergistic effect, as it 
results in a decrease in relative absorbance with time. However, this decrease is not 
significantly different compared to the control cells (Figure 2.11). Some epidemiological 
findings have associated HAART with CIN regression (Adler et al., 2012; Firnhaber  et al., 
2012;  Omar et al., 2011; Chen et al., 2014; Minkoff et al., 2010).  The presently observed 
decrease in HeLa cell proliferation upon ZDV+3TC+NVP and d4T+3TC+NVP 
administration could possibly explain these epidemiological observations suggesting 
cervical intraepithelial neoplasia regression on initiating HAART.  
Co-treatment of ZDV+3TC+NVP and d4T+3TC+NVP (highly active antiretroviral 
regimens) with 2.0µg/ml LNG significantly reduces the proliferative rate of HeLa cells 
relative to untreated cells. On the other hand, co-administration with 4.0µg/ml LNG 
increases the viability of ABC+3TC+NVP and ZDV+3TC+NVP (Fig 2.13), thus 
suggesting the proliferative effect of LNG with increase in concentration. Co-treatment of 
ABC+3TC and ZDV+3TC with 1.0µg/ml, 2.0µg/ml and 4.0µg/ml LNG reduces HeLa cell 
proliferation, hence resulting in a significantly different proliferation rate relative to the 
uncontrolled cells (Fig 2.13).  
Co-treatment of d4T+3TC+NVP with 0.5µg/ml ethinylestradiol shows a significant 
decrease in HeLa cell proliferation relative to the control cells (Fig 2.15). While lone 
administration of ZDV+3TC+NVP shows a significant decrease in HeLa cell proliferation 
(Fig 2.10), co-administration with 0.5µg/ml EE results in increased cell proliferation. The 
present observations therefore suggest increased proliferation with co-administration of 
0.5EE in ZDV+3TC+NVP-treated HeLa cells. No significant differences in HeLa cell 
proliferation were observed in all treatments with combination antiretroviral treatment co-
administered with 1.0µg/ml EE. 1.0µg/ml EE co-treatment with ZDV+3TC+NVP and 
d4T+3TC+NVP show no significant difference relative to the control cells, thus suggesting 
increased proliferation with 1.0µg/ml ethinylestradiol administration. Interestingly 
2.0µg/ml ethinylestradiol reduced proliferation for ABC+3TC and ZDV+3TC. Treatment 
with 0.5µg/ml and 1.0µg/ml of ethinylestradiol demonstrates increased proliferation in 
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combination antiretroviral treated cells. These observations are in tandem with 
observations by Wang et al. (2004), who showed the antiapoptotic effect of oestrogen on 
HeLa cells, a phenomenon suggestive of cervical intraepithelial neoplasia progression 
and/or tumour cell proliferation. 
While the antiproliferative effect is suggestive of metabolic activities that lower cell 
proliferation relative to untreated cells, there is need to compliment the present 
observations with apoptosis studies. This is because, at optimal rates, apoptosis is 
physiologically beneficial, while excessive apoptosis may result in pathophysiology 
(Dexheimer, 2013; Matt and Hofmann, 2016). Some observations have suggested that 
HAART causes serious non-AIDS events (SNEs) including but not limited to malignancies 
(Hsu et al., 2013; Serrano-Villar et al., 2014). It becomes imperative to investigate 
concurrently the effect of antiretroviral drug induced apoptosis and the effect of 
contraceptive hormones on human cervical epithelial cancer cell proliferation. 
While the MTT assay is widely used for toxicity assays, it has its own limitations. Cells in 
the early stage of apoptosis may still have the ability to reduce MTT, hence possibly giving 
false positive results on ability to reduce the MTT (Sieuwerts et al., 1995, Sylvester 2011, 
van Meerloo et al., 2011). It is thus usual to compliment proliferative assays with apoptosis 
assays when evaluating the effect of a treatment on cell death and proliferation. However, 
if time had permitted, it would have been interesting to carry more replicates of 
experiments to lower the standard error observed in some of the results. The present 
research design is premised on women continuing combined hormonal contraceptive 
(constituted of ethinylestradiol and levonorgestrel) use before initiating HAART. In 
practice, some women may initiate hormonal contraceptive use jointly with antiretroviral 
drugs. This may entail an alternative design typified by co-administering ethinylestradiol 
or levonorgestrel with antiretroviral drugs for 72 h. It is also hypothetically possible that 
some women will start HAART prior to hormonal contraceptive use. Such an approach 
warrants a design that will treat human cervical epithelial cancer cells firstly with 
antiretroviral drugs followed by co-treatment with levonorgestrel or ethinylestradiol. Time 
permitting, these alternative research designs would have been of interest. 
2.4.1. Conclusion 
The investigation of proliferative effects of hormonal contraceptives if co-administered 
with single antiretroviral drugs provided an insight into the varied mechanistic effects. 




Table 2.3: Antiproliferative effect of co-administering hormonal contraceptives with 
combination antiretroviral drugs on HeLa cells  
HeLa cells were treated with combination antiretroviral drugs for 24, 48 and 72 h and 
proliferation rates compared with untreated cells. The cells were also treated with 
contraceptive hormones for 24 h followed by co-treatment with combination antiretroviral 
drugs for a further 48 h. After the total exposure time (72 h), proliferation for each hormone 
concentration co-treatment was compared to untreated cells. Non-significant changes are 








Treatment for drugs 
only 
 
       24 h     48 h  72 h 
    
ABC+3TC - - - 
ZDV+3TC + + - 
ABC+ZDV+3TC - + + 
ZDV+3TC+NVP + ++ ++ 


















ZDV+3TC+LNG + + + 
ABC+ZDV+3TC+LNG - + - 
ZDV+3TC+NVP+LNG ++ ++ - 
d4T+3TC+NVP+LNG + ++ + 
    
Co-treatment with 
ethinylestradiol 
   0.5µg/ml      1.0µg/ml 2.0µg/ml 
 
   
ABC+3TC+EE - - + 
ZDV+3TC+EE - - + 
ABC+ZDV+3TC+EE - - - 
ZDV+3TC+NVP+EE - - - 
d4T+3TC+NVP+EE + - - 
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In the absence of hormones, there is a time-dependent decrease in HeLa cell proliferation 
upon treatment with ZDV+3TC+NVP and d4T+3TC+NVP. ZDV+3TC+NVP and 
d4T+3TC+NVP constitute part of highly active antiretroviral regimens which have found 
predominant use in low-resource regions including sub-Saharan Africa. The 
antiproliferative effect of these HAART combinations is suggestive of cytotoxicity.  
1.0µg/ml, 2.0µg/ml and 4.0µg/ml LNG show antiproliferative activity upon co-treatment 
with ABC+3TC, ZDV+3TC and d4T+3TC+NVP.  2.0µg/ml LNG co-administration with 
ABC+ZDV+3TC results in decreased proliferation relative to untreated cells, thus 
suggesting an anticancer effect. While the reduced proliferation may suggest anticancer 
potential, the contrary may be true where the rate of cell death may be excessive, thereby 
leading to serious non-AIDS events due to induction of pathophysiological pathways. Co-
administration of 0.5µg/ml ethinylestradiol with d4T+3TC+NVP demonstrates increased 
cell viability relative to untreated cells. Co-administration of combination antiretroviral 
drugs with 0.5µg/ml EE show increased cellular proliferation compared to cells treated 
with drug combinations only, thus suggesting a proliferative effect of EE on antiretroviral 
drug treated human cervical epithelial cancer cells. 
 
Among the limitations of the MTT is the influence of test compounds that interfere with 
the glycolysis pathway and overestimation of metabolically active mitochondria (van 
Tonder et al., 2015; Wang et al., 2010). Early-stage apoptotic cells may be recognised as 
proliferating cells because they still have some ability to reduce MTT (Wang et al., 2010). 
Further, it is important to note that cell death by apoptosis does not necessarily imply 
inhibition of cellular regeneration (Fan and Bergmann, 2008a; Ryoo et al., 2004; Ryoo and 
Bergmann, 2012; Shi et al., 2012). However MTT is still widely used as a preliminary 
indicator that there is metabolic activity taking place. It may therefore be fascinating to 
relate DNA damage and apoptotic cell death to HeLa viability following co-administration 
of antiretroviral drugs with contraceptive hormones. This may plausibly explain the 
relationship between cell death and cellular remodelling upon co-administration of 
antiretroviral drugs with either ethinylestradiol or levonorgestrel. In the next chapter, the 
role of nucleoside reverse transcriptase inhibitors (abacavir, zidovudine, lamivudine and 
stavudine) and nevirapine (a first-generation non-nucleoside reverse transcriptase inhibitor) 







GENOTOXICITY OF ANTIRETROVIRAL DRUGS ON CHINESE HAMSTER 
OVARY AND HUMAN CERVICAL CANCER EPITHELIAL CELLS 
3.1. Introduction 
During the cell cycle, checkpoint regulatory mechanisms ensure stability of DNA. 
Checkpoint failure can lead to accumulation of damaged DNA (Christmann et al., 2003, 
Matt and Hofmann, 2016). Genotoxicity assays are important tools for determining the 
potential of compounds to compromise the cell‟s genome, ultimately resulting in health 
conditions such as cancer (Onwuamah et al., 2014; Baumstark-Khan et al., 2000). 
Presently, no single test is capable of detecting all possible genotoxic effects of a 
compound, hence the use of a battery of assays (Moreno-Villanueva et al., 2011). The 
major limitation of most of these assays is the high percentage of false positives (Kusakabe 
and Tateno, 2011; Moreno-Villanueva et al., 2011). This entails the need to carry out a 
multiple other simple but reliable tests among which the fluorometric analysis of DNA 
unwinding (FADU) is increasingly finding its use (Baumstark-Khan et al., 2000). The 
major advantages of this method are reproducibility, speed, lack of experimenter bias and 
cost effectiveness (Baumstark-Khan et al., 2000; Moreno-Villanueva et al., 2011).   
 
NRTIs act by interfering with reverse transcriptase through non-competitive inhibition by 
attaching on the viral and host DNA (Olivero et al., 2013). These drugs incorporate into 
nuclear and mitochondrial DNA of the host cell, thus resulting in viral DNA replication 
arrest and genomic instability (Olivero et al., 2013). Zidovudine (ZDV) has been 
associated with several types of genotoxic damage through incorporation into DNA, 
thereby replacing thymidine (Wu et al., 2013). ZDV has been shown to induce formation 
of micronuclei, chromosomal instability and shortening of telomeres (Wu et al., 2013; Yu 
et al., 2009). Using the mouse micronucleus test, de Moraes Filho et al. (2016) 
demonstrated that the HAART regimen Combivir (ZDV+3TC) + EFV increases 
micronucleus frequency. Concurrently, they also demonstrated that the ratio of 
polychromatic erythrocyte (PCE) to normochromatic erythrocyte (NCE) was also higher 
for this treatment, hence suggesting that combivir + EFV is mitogenic (de Moraes Filho et 
al., 2016; Schwarzbacherová, et al., 2016). Interestingly, in vivo studies carried out on 
mice with Combivir + EFV did not observe any significant DNA damage with the 
genotoxicity and micronucleus test (de Moraes Filho et al., 2016).  
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Brambilla et al. (2012) published a review with a compendium of retrievable data on 
genotoxicity of 48 drugs, among which were 3TC, NVP, ZDV and ABC. Results 
considered met the standards of the battery of assays consisting of a gene mutation test in 
bacteria, an in vitro cytogenetic chromosomal damage test and an in vivo test 
demonstrating rodent haematopoietic cell chromosomal damage. 3TC was positive for 
some genotoxicity assays but negative for carcinogenicity. NVP was negative for 
genotoxic assays but positive for carcinogenicity assays. ZDV was positive for both 
genotoxic and carcinogenic assays. Similarly, Momot et al (2014) evaluated nucleoside 
excision repair in ZDV-induced chromosomal deregulation in mice and demonstrated 
induction of centrosome amplification as well as loss of Xpa and p53 genes. Interestingly 
p53 haploid insufficiency strongly protected Xpa
[+]
 from ZDV-induced chromosomal 
amplification damage. In mice and rats, ABC was shown be carcinogenic, although no data 
were retrieved for genotoxicity tests (Brambilla et al., 2012). Perinatal exposure to 
ZDV+3TC, ABC+ZDV+3TC and ZDV+3TC+NVP was shown to induce genotoxicity in 
newly born monkeys and such toxicity was persistent when followed up to 3 years from 
birth (Olivero et al., 2013). 
The reverse transcriptase telomerase is responsible for synthesis of DNA repeats. Studies 
on human HT29 cells have shown that NRTIs including ZDV, d4T and ABC inhibit 
telomerase, while nevirapine (a NNRTI) does not exhibit inhibitory characteristics 
(Hukezalie et al., 2012). In Chinese hamster ovary cells (CHO), 3TC and d4T induce 
chromosome amplification in a concentration-dependent manner. In normal human 
mammary epithelial cells (NHMEC), d4T is associated with centromere amplification at 
concentrations ten-fold the plasma level, following 24 h treatment (Yu et al., 2009). These 
unintended effects warrant the need for further studies on the off-target consequences of 
HAART (Hukezalie et al., 2012). The present study thus enquires into the effect of these 
NRTIs and NVP on double-strand breaks in human cervical epithelial cancer cells. 
Unlike nucleoside analogues, NNRTIs are not incorporated into viral DNA and they do not 
need to be phosphorylated in order to elicit their desired function. Rather, NNRTIs bind 
directly and noncompetitively to the reverse transcriptase enzyme (Barry et al., 1999). 
Exposure of nevirapine (a non-nucleoside reverse transcriptase inhibitor of interest in this 
study) or zidovudine to Allium cepa root cells induces cytogenetic changes as shown by the 
mitotic index and chromosomal aberrations tests (Onwuamah et al., 2014). NVP has been 
implicated in serious skin and liver injuries in patients undergoing antiretroviral 
therapeutic treatment (Kranendonk et al., 2014; Madigan et al., 2009). One major 
73 
 
metabolite of NVP, 12-hydroxy-NVP, has been shown to have sulfotransferase 1A1-
dependent mutagenicity using the new SULTIA-competent Ames strains (Kranendonk et 
al., 2014). Such observations necessitate an introspection of the potential of NVP to cause 
DNA strand breaks in addition to these cytogenetic and mutagenic changes. 
Each of our human body cells is constantly exposed to thousands of DNA-damaging 
processes in a day. If uncontrolled, such damage may impair important metabolic 
processes, such as DNA-repair mechanisms and apoptotic removal of DNA damaged cells 
(Martin and Henry, 2013; Toettcher et al., 2009). Common DNA damages include base 
and sugar alterations, single- and double-strand breaks, cross-links and base-free damages 
(Christmann et al., 2003; Dexheimer, 2013, Matt and Hofmann, 2016). Our cells have 
evolved inherent repair mechanisms to compensate for various types of DNA damage. 
Such mechanisms include base and excision repair, mismatch repair, nucleotide excision 
repair and double-strand break (DSB) repair (Christmann et al., 2003; Dexheimer, 2013; 
Matt and Hofmann, 2016).  DNA repair may result in removal of damaged cells by 
apoptosis while deregulation of DNA repair (DDR) may result in pathophysiology and 
disease. Examples of diseases include neurodegenerative disease, premature aging, tissue 
dysfunction and cancer (Matt and Hofmann, 2016). In this section, an evaluation of the 
effect of antiretroviral drugs on double-strand breakage in normal (CHO) and human 
cervical epithelial cancer cells is examined.  
Double-strand breaks present one of the most hazardous types of DNA damage which 
often lead to cell death (Christmann, 2003; Dexheimer, 2013). Deregulation or erroneous 
execution of one site of DNA double-strand break repair may be sufficient to cause 
deletions or chromosomal aberrations resulting in cancer (Dexheimer, 2013).  It is 
therefore intriguing to evaluate whether or not and to what extent if any do these 
antiretroviral drugs induce DNA strand-breaks. While DSBs repair can be attained through 
homologous recombination and non-homologous end joining mechanisms, it is inevitable 
that some cells may evade these repair mechanisms (Dexheimer, 2013; Christmann, 2003). 
To this effect, the invaluable role of apoptosis comes into play in programmed cell death to 
eliminate those cells with undesirable characteristics. The CHO epithelial cells provide a 
good model for non-cancerous epithelial cells while the HeLa cells have been widely used 
as model for human cervical epithelial cancer cells in toxicity assays (Orczyk et al., 2005). 
             
Originally designed to detect X-ray-induced DNA strand breaks, the fluorometric analysis 
of DNA unwinding (FADU) has since found widespread use, owing to its reproducibility 
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and lack of experimental bias (Birnboim, 1990; Baumstark-Khan et al., 2000). FADU is 
now widely used for evaluating the potential of different chemicals to induce double-strand 
breaks in cultured cell lines, including the HeLa cells (Koczo et al., 2009) and  CHO cells 
(Baumstark-Khan et al., 2000). The ability of menadione to induce strand-break in cell 
lines has promoted its wide as a positive control in DNA strand break assays (Koczo et al., 
2009). A variety of cell lysis methods, such as optical, mechanical, acoustic, electrical, and 
chemical lysis, are among the current techniques for single-cell lysis (Brown and Audet, 
2009). In this section, the fluorometric analysis of DNA unwinding (FADU)  is the method 
of choice for double-strand break analysis. 
  
3.1.1. Objectives of the chapter 
a. To observe the morphological changes that occur in human cervical epithelial 
cancer cells treated with low doses and high doses of antiretroviral drugs followed 
by growth in drug-free medium over a period of time. 
b. To evaluate the genotoxic effect of single antiretroviral drug treatment (ABC, 
ZDV, 3TC, d4T and NVP) on CHO cells. 
c. To evaluate the genotoxic effect of single antiretroviral drug treatment (ABC, 
ZDV, 3TC, d4T and NVP) on human cervical epithelial cells. 
3.2.0. Materials and Methods 
3.2.1. Materials 
Cell culture media (DMEM without phenol red and RPMI 1640 without phenol red) were 
purchased from Life Technologies (United Kingdom). Antiretroviral drugs (abacavir, 
lamivudine, nevirapine, stavudine and zidovudine), phosphate-buffered saline (PBS), 
penicillin-streptomycin, sodium pyruvate, dimethylsulfoxide (DMSO), non-essential 
amino-acids, glutamine, charcoal-treated foetal bovine serum (FBS) were obtained from 
Sigma (United Kingdom). The cold trypsinisation solution (trypsin 0.2g/l, 135mM NaCl, 
3mM KCl, 5mM Na2HPO4, 1mM KH2PO4, 5mM tris(hydroxymethyl)aminomethane, 
0.45mM EDTA) was prepared in the laboratory with all reagents supplied from Sigma. 
Twenty-four well plates were purchased from Nunc Denmark. The CHO and HeLa cell 
lines were obtained curtusy of the University of East London tissue culture laboratory. 
 
3.2.2 Cell culture and maintenance  
HeLa cells were maintained as described in Chapter 2 using DMEM without phenol red.  
CHO cells were maintained in 75cm
2
 flasks. The cells were grown in RPMI 1640 (without 
phenol red) supplemented with 10% charcoal-treated FBS, 1% non-essential amino acid 
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solution, 1% sodium pyruvate, 2mM glutamine and 1% (v/v) penicillin/streptomycin 
[10,000 U/ml penicillin, 10,000 µg/ml streptomycin].  The cells were incubated at 37
o
C 
and 5% atmospheric CO2. The cells were split every 3 to 4 days at approximately 75% 
confluence.  
 
3.2.3 Cryopreservation of CHO cells 
Cells were grown to about 75% confluence in T75 culture flasks. The cell medium was 
aspirated from the T75 culture flask with growing cells, the cells washed with 5ml PBS 
and the PBS aspirated. 2ml of trypsin/EDTA was added to cover the surface of the flask 
and the flask was returned to the incubator for about a minute. Trypsin was quenched by 
adding 8ml of medium to the flask, followed by gently pipetting up and down 4 times 
while washing the sides and middle part of the flask in order to harvest the highest number 
of cells. The cells were transferred to a 15ml centrifuge tube and spun at 1000rpm for 
about 5 minutes. The supernatant was removed, cells re-suspended in 1ml of fresh freezing 
medium and transferred to a cryotube in fresh sterile freezing medium consisting of 5% 
DMSO and 20% FBS in RPMI 1640. The cells were first placed at 4
o
C for 4-6h, 
transferred to -80
o
C overnight and then transferred to liquid nitrogen the next day. Upon 
resuscitation, up to 10 passages were used for experimental assays. 
 
3.2.4. Effect of drug concentration on morphology of HeLa cells 
In an attempt to determine the effect of antiretroviral treatment on human cervical 
epithelial cell morphology, 500µl of 1.0 x 10
4 
cells/ml were seeded in 24-well plates and 
allowed to attach over 24 h. The medium was aspirated and the cells were treated with 
low-dose (50µg/ml) or high-dose concentrations of 300µg/ml of ABC, ZDV, 3TC and 
dT4. Cognisant of morphological changes observed in Chapter 2, the low- and high-dose 
concentrations of NVP were maintained at 50µg/ml and 200µg/ml, respectively. The 
reagent blank wells consisted of medium only.  The vehicle control and all treatment 
medium were adjusted to a final concentration of 0.25% (v/v) DMSO.  Drug-treated 
medium was replaced with fresh medium after 72 h and the cells were observed for a 
further 72 h thus making a total period of 144 h post treatment. The cells were treated with 
culture medium without ARVs for a further 288 h to assess whether the cells could 
accomplish normal growth.  Morphological changes were followed up by an EVOS® 





3.2.5 Fluorimetric Analysis of DNA Unwinding 
The method used is an adaptation with modification from Baumstark-Khan et al (2000) 
and Birnboim (1990).  The principle of the method is dependent on the ability of some 
substances to introduce strand-breakage in DNA. Under alkaline conditions, the rate of 
DNA unwinding is dependent on the number of strand-breaks that often results from 
various treatments. Neutralisation of the condition by addition of acid stops the unwinding 
of DNA (Birnboim, 1990). Estimation of the remaining double-strand DNA is measured by 
using a fluorescent dye, which in the present study is Hoeschst 33258 (bisbenzamide). 
DNA breakages are thus inversely proportional to fluorescence. Briefly, 1000µl of 
2.0x10
5
cells/ml HeLa or CHO cells were seeded in a 24-well plates and left for 48 h to 
allow adherence and confluence of cells. The medium was aspirated and 1000µl of 
working ARV solutions were reconstituted in appropriate medium (DMEM for HeLa cells 
and RPMI 1640 for CHO cells) to a final concentration of 50µg/ml of each drug. The cells 
were treated in triplicate wells. For the positive control, the cells were treated with 50µM 
menadione. After incubation for 1, 2 and 4 h, cells were subjected to 1.0ml cold 
trypsinisation (trypsine 0.2g/l, 135mM NaCl, 3mM KCl, 5mM Na2HPO4, 1mM KH2PO4, 
5mM tris(hydroxymethyl)aminomethane, 0.45mM EDTA) and transferred to ice-cold 
Bijoux plastic tubes. CHO and HeLa cells were then treated in three groups, namely blank 
(B), total (T) and drug-treated (P) fluorescence (adapted from Baumstark-Khan et al., 2000 
and Birnboim, 1990).   
 
3.2.5 (i) Blank fluorescence (B)  
This sample measures the background fluorescence contributed by other compounds other 
than double-stranded DNA. This includes background fluorescence from bisbenzimide 
(Hoeschst 33258). This sample therefore depicts the lowest fluorescence. To determine 
blank fluorescence, the cell extract was sonicated under alkaline conditions in order to 
break all DNA and to bring about complete unwinding of the low–molecular-weight DNA 
fragments. 0.5ml of suspended cells were lysed by addition of 0.5ml of 0.1 Maq.NaOH. 
The cells were sonicated at 100W for 15 seconds and incubated at 20
o
C for the whole 
unwinding period (30 min) and subsequently neutralized by addition of 0.5ml of 1 Maq. 







3.2.5 (ii) Total Fluorescence (T) 
The T sample depicts the total double-strand DNA in untreated cells. The cell extract was 
sonicated under neutral conditions to prevent unwinding of the DNA. The difference T 
minus B (T- B) provides an estimate of the amount of double-stranded DNA (dsDNA) in 
untreated cell extracts. Suspended cells (0.5 ml) of the T-samples were lysed by addition of 
0.5 ml of 0.1 Maq. NaOH immediately followed by neutralization through addition of 0.5 
ml 1 M hydrochloric acid. The subsequent addition of acid therefore prevents DNA 
unwinding in these samples. The cells were then incubated at 20
o
C for the whole 
unwinding period (30min) and sonicated (100W, 15s) (After: Baumstark-Khan et al., 2000 
and Birnboim, 1990). 
 
3.2.5 (iii) Flourescence for drug treated cells (P) 
The third sample set (P) is used to estimate the unwinding rate of drug-treated DNA. The 
cells were exposed to alkaline conditions that bring about partial unwinding of DNA that is 
dependent on the extent of breakage. Suspended cells (0.5ml) of the test samples were 
lysed by gentle addition of 0.5ml of 0.1 aq. NaOH without mixing, followed by incubation 
at 20
o
C for 30 minutes. During this unwinding period, the alkali diffuses into the viscous 
lysate to give a final pH around 12.4. The tubes were shielded from light and vibrations.  
After DNA unwinding, the P-samples were neutralized by addition of 0.5ml of 1.0 Maq. 
HCl (pH 7.1–7.4). The mixture was sonicated to render the samples homogeneous, thus 
minimizing renaturation of DNA and reducing the fraction of DNA molecules containing 
both single- and double-stranded regions (After: Baumstark-Khan et al., 2000 and 
Birnboim, 1990). 
 
3.2.5 (iv) Measurement of double-stranded DNA (dsDNA) 
500µl of fluorochrome-containing buffer (5.0 x10
-6
 M bisbenzimide in PBS) was added to 
all samples. This fluorochrome dye stains the cells to determine the fraction of DNA 
breakage. After mixing well, the relative fluorescence intensities of the samples were read 
by using a spectrofluorimeter operating at 350nm (excitation) and 455nm (emission). The 
fraction of ds-DNA (F) was calculated as follows: F = (P - B)/ (T - B) where: 
(P-B) = Fluorescence of treated sample 






3.2.6 Data Analysis 
Differences between the control (untreated cells) and each of the treatments were analysed 




3.3.1. Morphology of drug-treated cells 
By the end of 144 h, untreated cells grew well in a monolayer, while cells treated with 
50µg/ml of each drug showed no morphological differences compared to control cells. 
After this initial 144 h treatment, control and low-dose treated cells maintained a polygonal 
morphology. Interestingly, high-dose treatment of cells with NVP, ZDV and ABC resulted 
in growth with some clumped cells (Figure 3.1). High-dose NVP-treated cells depicted a 
number of cells growing in clumps, with some becoming shrunken and spherical, while 
ABC and ZDV had fewer clusters. High-dose cells treated with 3TC and d4T did not show 
apparent morphological changes, although they appeared less dense than all other 
treatments. After further 288 h of treatment, control cells and those treated with low-dose 
concentrations (50µg/ml) accomplished normal morphology. Interestingly, for untreated 
and low-dose treated cells, as space became limiting, the cells were observed to be growing 
in layers characterised by a low degree of clumping. After the total exposure time, those 
HeLa cells previously treated with higher doses of ZDV, NVP and ABC continued to show 
























    
    
Fig 3.1: Morphological changes observed in HeLa cells treated with antiretroviral drugs for 
72 h followed by culturing in drug-free medium for a further 72 h. Cells were observed under 
an inverted microscope scale bars represent 100µm. (A) Untreated control  (B) 200µg/ml 
NVP (C) 250µg/ml ZDV (D) 250µg/ml ABC. Arrows indicate regions in which cells appear 









3.3.2 FADU results for antiretroviral treatment of CHO and HeLa cells 
The cells were treated with 50µg/ml of each antiretroviral drug for 1 h, 2 h, and 4 h 
followed by FADU analysis. The decrease in fluorescence intensity with increasing 
exposure time to all nucleoside reverse transcriptase inhibitors and nevirapine indicates 
time-dependency in DNA strand-breaks in both the non-cancerous cell line (CHO) and the 





































Fig 3.2: DNA strand-breaks induced by antiretroviral drugs in CHO cells. Cells were seeded 
and allowed to grow to confluence over 48 h. The cells were treated with 50µg/ml of each 
antiretroviral drug for 1 h, 2 h, and 4 h, followed by FADU analysis. There is a time-
dependent DNA double-strand break in both cell lines. Data were analysed by ANOVA 
followed by Dunnett’s multiple comparison test. Data represent mean ±SEM, n=3. The 
relative fluorescence of drug-treated cells was compared to the untreated cells, where a, b and 
























































Fig 3.3: DNA strand-breaks induced by antiretroviral drugs in HeLa cells. Cells were seeded 
and allowed to grow to confluence over 48 h. The cells were treated with 50µg/ml of each 
antiretroviral drug for 1 h, 2 h, and 4 h, followed by FADU analysis. There is a time-
dependent DNA double-strand break in both cell lines. Data were analysed by ANOVA 
followed by Dunnett’s multiple comparison test. Data represent mean ±SEM, n=3. The 
relative fluorescence of drug-treated cells was compared to the untreated cells, where a, b and 

















































A time-dependent effect of ABC, ZDV, 3TC and dT4 on double-strand breakage was 
observed in both Chinese hamster ovary epithelial cells and human cervical cancer 
epithelial cells. Treatment of cells with fresh medium for 50µg/ml of each drug treatment, 
followed by fresh medium, resulted in cell growth with no obvious morphological changes. 
At lower concentrations, no morphological differences were observed between treated cells 
and the untreated control for all drug treatments. This observation suggests that, although 
treatments of HeLa cells with 50µg/ml ABC, d4T, 3TC, ZDV and NVP induce a time-
dependent double-strand DNA breakage in HeLa cells, the cells are able to accomplish cell 
division and growth with time. Whether or not the DNA-damaged cells are removed by 
apoptosis is the subject of the next chapter. However, the presently observed normal 
morphology with low-dose treatments is suggestive of high DNA-repair efficiency. As 
Dexheimer (2013) puts it, although our cells are constantly exposed to detrimental 
endogenous and exogenous agents, DNA-damage repair mechanisms help cells to remove 
different damaged cells. Alternatively or concurrently where cells have not been repaired, 
apoptosis (a phenomenon to be investigated in the next chapter) is of paramount 
importance in systematically eliminating damaged cells to ensure that they do no express 
undesirable characteristics such as oncogenes. 
 
Using cell-culture techniques, it would have been interesting to carry out analysis on the 
formation of foci based on the BALB/c 3TC transformation assay. To this effect, the 
BALB/c 3T3 may prove useful and fascinating because this test is currently accepted as the 
only in vitro model used as an alternative to animal models for carcinogenesis testing 
(Collacci et al., 2011). This has proved effective in screening substances with no apparent 
genotoxic evidence but presenting alerts for carcinogenicity (Colacci et al., 2011, 
Maeshima et al., 2009; Sasaki et al., 2012). 
 
Since NRTIs are incorporated into mitochondrial and nuclear DNA of the host cell, these 
have a higher potential to cause genomic instability (Olivero et al., 2013). The present 
observations concur with that phenomenon. While NRTIs lead to DSBs, nevirapine, which 
acts by non-competitive inhibition, also results in significant DSBs in both the CHO and 
HeLa cells. This observation resonates well with in vitro studies which showed mutagenic 
changes and chromosomal aberrations in Allium cepa cells treated with NVP (Onwuamah 
et al., 2014). 12-Hydroxy-NVP, a nevirapine metabolite, has also been demonstrated to be 
mutagenic with the new SULTIA-competent Ames strains (Kranendonk et al., 2014). On 
84 
 
the contrary, in vivo studies carried out on mice demonstrate that NVP did not cause any 
significant DNA damage in genotoxicity and the micronucleus test (de Moraes Filho et al., 
2016). Interestingly, NVP did not show inhibitory characteristics in HT29 cells, while the 
NRTIs (ABC, ZDV and d4T) inhibited human telomerase which is responsible for 
synthesis of DNA repeats (Hakuzalie et al., 2012). Such inhibition interferes with repair of 
the damaged DNA. Such a lack of inhibition of the telomerase in nevirapine-treated cells is 
suggestive of an efficient DNA-repair mechanism which is necessary to counter 
deleterious effects of DSBs.  Although ABC was shown be carcinogenic but with no data 
on genotoxicity (Brambilla et al., 2012), the present results show the potential of ABC to 
induce DNA strand-breaks. In addition, 3TC, which was shown to be positive for some 
genotoxicity assays but negative for carcinogenicity (Brambilla et al., 2012). The present 
study has further shown that 3TC is able to induce DSBs in both CHO and HeLa cells. 
 
Malignancy may be defined as the permanent transition of a tissue from normal to one 
which divides and proliferates limitlessly, thereby injuring adjacent cells (Stoddart, 1983). 
Carcinogenesis occurs through three main stages namely initiation, promotion and 
progression (SØdring et al., 2016; Stoddart, 1983; Vincent and Gatenby, 2008). The 
tumour microenvironment is defined by a heterogenous mass of cells and their 
extracellular environment to which the cells contribute (SØdring et al., 2016). Cultured 
cells are thus not equivalent to in vivo defined cells. In the present study, the tissue culture 
models used provide a primary insight into the plausible mechanism through which ARVs 
induce dsDNA damage. However, in vivo studies may be of interest in a bid to qualify the 
present observations.  
 
ARVs have been shown to induce DSBs in HeLa cells.  This preliminary evidence 
suggests the transforming potential of these drugs. Interestingly, it has since been 
established that transforming agents may be necessary but not always sufficient to cause 
malignancy (Stoddart, 1983; SØdring et al., 2016). Under normal conditions, cells have 
evolved a highly efficient mechanism for DNA repair, a phenonomenon known as DNA 
damage response (DDR) (Vincent and Gatenby, 2008; Dexheimer, 2013; Matt and 
Hofmann, 2016). While the present results depict DSBs on CHO and HeLa cells treated 
with NRTIs (ABC, ZDV, 3TC and d4T) of interest is whether the repair efficiency 
prevents the proliferation of mutational cells. Time permitting, it would have been 
interesting to carry out BALB/c 3TC assays to assess formation of foci and possibly the 
initiation/promotion potential of ARVs.  Similarly, should the damaged cells be removed 
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by apoptosis, the process should be optimal to prevent excessive loss of cells and tissue 
damage. Following treatment with 50µg/ml of each antiretroviral drug, CHO and HeLa 
cells maintained normal morphology. This is suggestive of a mechanism which removes 
damaged cells and/or a high DNA-repair efficiency. 
 
Initiators are substances that cause primary injury to the DNA (Vincent and Gatenby, 2008 
Stoddart, 1983). In the present study, there is evidence that NRTIs have the potential to 
cause DNA damage, hence they may possibly present as initiators. It has since been 
established that substances that may not be carcinogenic may act as promoters for 
proliferation of the damaged cells. Promotion requires agents that enhance cell division. 
Promoters thus accelerate transformation to a malignant genotype (Stoddart, 1983; SØdring 
et al., 2016). While NRTIs have been shown to cause DSBs, whether or not other 
commonly used drugs such as hormonal contraceptives impact on the extent of DNA 
damage remains obscure. The family of simple RNA viruses to which HIV belongs have 
been implicated in oncogenesis (Stoddart, 1983). Viral oncogenes have been shown to be 
closely associated with human malignant disease and it has been established that HPV 
types 16 and 18 play a role in cervical epithelial cell oncogenesis (Thierry, 2009; zur 
Hausen, 1999). Whether or not HIV acts as a promoter of carcinogenesis in human cervical 
epithelial cells treated with NRTIs is beyond the scope of the present research but could 
also prove fascinating. This is cognate to the currently observed increase in AIDS defining 
cancers. Once promoted, the cells develop malignant characteristics that enable indefinite 
multiplication and this stage is referred to as progression (SØdring et al., 2016; Stoddart, 
1983; Vincent and Gatenby, 2008). Since the present study is limited to cell culture 
experiments, such an inference into progressive malignancy is unattainable.  
 
In separate studies described earlier, the observed genotoxic effect of ZDV lone 
administration (Olivero et al., 2013; Yu et al., 2009) is of interest relative to the non-
genotoxic observations for Combivar + EFV observed with in vivo studies (de Moraes 
Filho et al., 2016). This particularly raises a question as to whether combination 
antiretroviral drugs reduce genotoxicity, a phenomenon to be explored in the next chapter. 
While there are other programmed cell death mechanisms such as necroptosis and 
autophagy, apoptosis is the predominant method of programmed cell death including 
removal of DNA damaged cells (Dexheimer, 2013; Matt and Hofmann, 2016). In the next 
chapter, this study therefore evaluates the extent of apoptosis in ARV-treated human 
cervical epithelial cells and the effect of co-treatment with contraceptive hormones. This is 
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cognisant of WHO guidelines that empower women on antiretroviral treatment to have the 
right choice of contraceptive. 
  
3.4.1. Conclusion 
Nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) act by incorporation into 
the viral DNA and thereby acting as chain terminators (Flepp et al., 2001). The present 
results demonstrate that ABC, 3TC, ZDV and d4T, which fall into this class, have a 
potential to induce time-dependent DNA double-strand breaks. NVP, a non-nucleoside 
reverse transcriptase inhibitor, also induces a time-dependent DNA-strand breakage. The 
present results show that treatment of HeLa cells with 50µg/ml of each drug followed by 
culture in medium does not show obvious morphological differences compared to 
untreated cells. While human cells have developed specific DNA-repair systems, some 
cells evade these repair mechanism (Dexheimer, 2013; Matt and Hofmann, 2016). The 
present observations suggest that, at 50µg/ml of each drug, the DNA damage is 
subsequently repaired in these cells, thus enabling them to maintain normal morphology. 
Whether or not there are detrimental effects of this ARV treatment with time requires 

















EFFECT OF CONTRACEPTIVE HORMONES ON ANTIRETROVIRAL DRUG 
INDUCED APOPTOSIS IN HUMAN CERVICAL CANCER EPITHELIAL CELLS 
4.1. Introduction  
Apoptosis is a mechanism of programmed cell death characterised by morphological and 
biochemical transformations that enable apoptotic cell removal by phagocytic cells (Martin 
and Henry, 2013). To this effect, cell removal from the tissues is in an orderly manner 
without disruption and leakage of cellular contents (Logue et al., 2009; Martin and Henry, 
2013). This ensures that there is no inflammation triggered through release of immune-
activating alarmins (Martin and Henry, 2013; Henry et al., 2013). One major physiological 
change associated with cells undergoing apoptosis is transposition of phosphatidylserine 
(PS) from the inner to the outer surfaces of the plasma membrane (Logue et al., 2009; 
Brummatti et al., 2008). Pro-apoptotic signals stimulate this transposition through the 
aminophospholipid cation translocase via a calcium-dependent pathway (Logue et al., 
2009; Matt and Hofmann, 2016). Other changes that occur during apoptosis include cell 
shrinkage, cleavage of chromosomal DNA into fragments, membrane blebbing, loss of 
electrical potential across the inner membrane of the mitochondria and transposition of 
cytochrome c from mitochondrial intermembrane space to the cytosol (Martin and Henry, 
2013; Brummatti et al., 2008). Initiator caspases in apoptosis are caspases 2, 8, 9 and 10 
while executioner caspases are 3, 6 and 7 (Logue et al., 2009; Martin and Henry, 2013). 
The detailed role of these caspases was outlined in Chapter 1. 
 
Flow cytometry is dependent on the ability of laser- and arc-based flow cytometers to 
measure different parameters based on scatter and fluorescence. The major advantage is 
that it measures the parameters on each particle in the suspension rather than dependence 
on just the average value (Logue et al., 2009, Henry et al., 2013). Fluorescent dyes can 
conjugate to surface receptors and cytoplasmic determinants, hence enabling identification 
of subpopulations of the cells based on their fluorescence characteristics. Annexin V binds 
efficiently to phosphatidylserine (PS) in the presence of Ca
2+
 ions and to a lesser extent to 
phosphatidylcholine and sphingomyelin (Henry et al., 2013; Brummatti et al., 2008). 
Cognisant of this high affinity to PS, annexin V is used as a probe for identification and 
quantification of apoptotic cells (Logue et al., 2009; Henry et al., 2013; Brummatti et al., 
2008). It is common practice to add propidium iodide (PI) so as to distinguish cells that 
88 
 
have lost plasma membrane integrity, although PI can be omitted in situations where 
annexin is combined to immunochemical labels (Logue et al., 2009).  
 
Cells in different phases of apoptosis exhibit differential ability of picking up annexin V 
and PI stains. This has necessitated the use of dot plots in four-quadrant flow cytometer 
analysis. Cells that are both annexin V-negative and PI-negative represent viable cells and 
these are located on the lower left quadrant. Cells in the early stages of apoptosis that are 
positive for annexin V but negative for PI constitute the lower right quadrant. These cells 
have externalised PS but are not yet capable of taking vital dyes such as PI. Cells in the 
upper right quadrant are annexin V and PI-positive. These depict cells in late apoptosis that 
have lost plasma membrane integrity (Logue et al., 2009).  The upper left quadrant has 
dead cells and debri that are PI-positive and annexin V-negative.  Other methods of choice 
for apoptosis assay include the terminal deoxynucleotidyltransferase-mediated dUTP nick 
end labelling (TUNEL) for DNA fragmentation analysis and determination of caspases, by 
western blot or fluorimetry. These methods are time consuming and are prone to observer 
bias. On the contrary, the annexin V-binding assay is unbiased, quick, and reliable (Logue 
et al., 2009). In this section, the method of choice is annexin V/PI staining.  
 
Unlike apoptosis, necrosis refers to uncontrolled cell death. It is characterised by sudden 
cell death, loss of membrane integrity and release of alarmins (Martin and Henry 2013). 
While necrosis is not typically associated with caspase activation, an exception is 
pyroptosis, in which cell death is a result of activation of caspases (1, 4 and 5). These are 
inflammatory caspases (Martin and Henry, 2013).  On the other hand, necroptosis is 
another form of programmed cell death whose activation can be induced by death ligands, 
such as TNFα and Apo2/TRIAL (Matt and Hofmann, 2016).  Necroptosis is characterised 
by lack of activation of caspases but instead receptor-interacting kinases 1 and 3 (RIPK1 
and RIPK3) activate the process (Matt and Hofmann, 2016). Normally, DNA damage that 
is not repaired results in cell removal by apoptosis. However, as outlined in the previous 
chapter, DNA damage may alter important processes such as DNA replication or 
transcription (Dexheimer, 2013; Lowe and Lin, 2000; Toettcher et al., 2009). 
 
Genomic and non-genomic signals mediated by cell and nuclear membrane receptors have 
been associated with oestrogen-induced cell proliferation. Oestrogen-dependent 
mitochondrial oxidative phosphorylation and gene transcription support the notion of 
mitochondria as oestrogen targets (Chen et al., 2003; Felty and Roy, 2005). While 
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mitochondria provide a major source of oxygen species in epithelial cells, oestrogen redox 
cycling in the absence of mitochondria also generates ROS. Antioxidants inhibit oestrogen-
dependent cell growth (Chen et al., 2003; Felty and Roy 2005). Both oestrogens and ROS 
target PKC, MEK, ERK A-Raf, Akt and transcription factors AP-1, NF-κB and CREB 
involved in oestrogen-dependent cell proliferation (Felty and Roy, 2005). Ethinylestradiol 
enhances nuclear genome transcription and inhibits transforming growth factor beta in 
(TGFβ)-induced apoptosis in hepatic cells (Chen et al., 2003). While this phenomenon is 
suggestive of oestrogen-induced proliferative diseases including cancer, there is paucity of 
information regarding the role of ethinylestradiol on HeLa cell apoptosis upon co-
administration with antiretroviral drugs. 
Treatment of normal human cervical epithelial cells (hECEs) with 10nM 17β-oestradiol 
blocks apoptosis induced by P2X7-receptor ligands. 17β-Oestradiol attenuates apoptotic 
effects in hECEs immortalised with HPV-16. In both normal and cervical cancer cells 
(HT3 and CaSki), the antiapoptotic effects of 17β-oestradiol involve attenuation of 
caspase-9 and terminal caspase-3 activity (Wang et al., 2004). Ethinylestradiol is a 
derivative of 17β-oestradiol and an important constituent of some combined oral 
contraceptive pills (Fruzzeti and Bitzer, 2010). It is therefore intriguing to evaluate the 
effect of ethinylestradiol on antiretroviral drug-induced proliferation in human cervical 
epithelial cells. Webster et al. (2001) demonstrate that oestrogen and progesterone can 
increase apoptosis of E2 and E7 protein-induced apoptosis.  
 
4.1.1. Objectives of the chapter 
a. To evaluate the antiapoptotic effect of single antiretroviral drugs in human cervical 
epithelial cancer cells.  
b. To determine the effect of co-administering levonorgestrel or ethinylestradiol on 
single antiretroviral drug-induced apoptosis in human cervical epithelial cells.  
c. To evaluate the antiapoptotic effect of combination antiretroviral drugs in human 
cervical epithelial cancer cells.  
d. To determine the effect of co-administering levonorgestrel or ethinylestradiol on 






4.2.0. Materials and Methods 
4.2.1 Materials 
The Annexin V-FITC Apoptosis detection Kit (BMS 500FI/300CE) was obtained from 
eBioscience. Antiretroviral drugs (abacavir, lamivudine, nevirapine, stavudine and 
zidovudine), camptothecin, and phosphate-buffered saline (PBS) were obtained from 
Sigma (United Kingdom). T25 culture flaks were purchased from Nunc Denmark. The 
HeLa cell line was obtained curtusy of the University of East London tissue culture 
research laboratory. 
 
4.2.2 Cell culture and maintenance 
HeLa and Chinese hamster ovary cells are adherent cells whose culture and maintenance 
were as described in Chapter 2 and Chapter 3 respectively. 
 
4.2.3 Treatment and harvesting of cells for annexin-V staining 
Cells were treated and harvested as adapted from BD Bioscience‟s method for Annexin V 
staining of adherent cells for flow cytometry. Briefly, approximately 5.0 x 10
5
cells were 
seeded in T25 cell culture flasks and left overnight to attach. The medium was replaced 
with single and combination antiretroviral drugs at final concentrations of 50µg/ml for 
each drug. The cells were treated with antiretroviral drugs only or co-administered with 
either 0.5µg/ml ethinylestradiol (EE) or 4.0µg/ml levonorgestrel (LNG) for 48 h. 5µM 
Camptothecin served as a positive control for apoptosis induction. Vehicle-treated cells 
with 0.25% (v/v) DMSO constituted the negative control. The final DMSO concentration 
in all cell treatments was maintained at 0.25% (v/v).  After treatment, the cell culture 
medium was aspirated. 1.0ml of trypsin was added to the culture flask and left for 2 min at 
room temperature in order to detach adherent cells. Where needed, the sides of the flask 
were gently tapped to facilitate detachment of adherent cells. 4ml of medium were added 
and the contents gently mixed by pipetting up and down. The contents were transferred to 
15ml centrifuge tubes and centrifuged at 1000 revolutions per minute (rpm) for 3 minutes. 
The supernatant was discarded and cells were resuspended in 5ml PBS.  
 
4.2.4 Annexin V-FITC protocol 
HeLa cells were harvested and washed in PBS. About 2-5 x 10
5 
cells/ml were suspended in 
200µl binding buffer. 5µl of annexin V-FITC was added to 195µl cell suspension, mixed 
and incubated in the dark for 10 minutes on ice. The cells were then washed with 200µl 
binding buffer and suspended in 190µl binding buffer. 10µl of propidium iodide was added 
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and the samples analysed for apoptosis using a BD Accuri™ C6 Flow Cytometer. The 
general procedure is outlined in Figure 4.1.     
 
4.2.5 Flow cytometry analysis 
Firstly, unstained control cells were run with the voltages adjusted to place the unstained 
samples in the first quadrant of the dot plots. The voltage was fixed at this stage and was 
not changed. Each single colour (Annexin V-FITC and PI) control was run to adjust 
compensation and remove spectral overlap from interfering FL channels. The experimental 
samples were run by measuring Annexin V-FITC emission on the FL1 channel and the PI 
emission on FL2.  
 
 
Fig 4.1: Outline of the experimental design for investigating the effect of antiretroviral drug 
co-administration with contraceptive hormones on human cervical epithelial cancer cell 
apoptosis. HeLa cells were treated with single antiretroviral drugs or a combination of ARVs 
at final concentrations of 50µg/ml for each drug. Cells were treated with drugs only or with 
drugs and ethinylestradiol (EE) at 0.5µg/ml or with drugs and levonorgestrel (LNG) at 
4.0µg/ml for 48 h. Four-way dot plots into live, early apoptotic, late apoptotic, and dead cells 





4.2.5. Data Analysis 
Descriptive statistics were computed on Excel. For comparison among different treatments, 
data was analysed by ANOVA followed by Tukey‟s multiple comparison test (P≤0.05). 
 
4.3.0. Results 
The experimental results for apoptosis analysis are presented in this section. 
 
4.3.1 Annexin-V/PI staining for apoptosis 
Using the conventional four-way dot plots, the present study determined the fractions for 
live, early apoptotic, late apoptotic, and necrotic cells after treatment of HeLa cells with 
single and combination antiretroviral drugs for 48 h. For nucleoside reverse-transcriptase 
inhibitors, the working stock was diluted in medium because all the four drugs (ABC, 
ZDV, 3TC and d4T) are water-soluble. NVP is soluble in DMSO. The final vehicle 
concentration for DMSO in the medium was adjusted to 0.25% for single antiretroviral 
treatment, combination antiretroviral treatment and untreated control. 
 
4.3.2 Controls and treatment with hormones only 
HeLa cells treated with 5µg/ml camptothecin, 4.0µg/ml levonorgestrel, 0.5µg/ml 
ethinylestradiol or left in untreated medium were incubated for 48 h.  Table 1 presents the 
descriptive statistics for three different treatments (n=3) while Figure 4.2 depicts four-way 
dot plots for untreated control, positive control, levonorgestrel-treated and ethinylestradiol-
treated cells. Fig 4.2 also depicts the statistical comparison among controls and hormone 
treated cells. Untreated cells undergo a reduced rate of apoptosis with no late apoptotic and 
dead cells, while camptothecin induced drastic apoptosis (Table 1). 
 
Table 4.1: Descriptive statistics for treatment of HeLa cells with controls and 
contraceptive hormones 
Cell type (%)   Live   Early  
apoptotic  
 Late  
apoptotic  
 Dead 
Untreated  89.43±2.06 10.57±2.06 0.00±0.00 0.00±0.00 
+ve control  25.83±2.06 68.97±2.29 4.47±0.31 0.73±0.06 * 
LNG only  85.53±1.00 11.37±2.19 1.13±0.31 1.30±0.10 
EE only  85.67±1.46 10.50±1.28 1.30±0.10 2.50±0.10 
HeLa cells were treated with 5µg/ml camptothecin, levonorgestrel (4.0µg/ml), ethinylestradiol 
(0.5µg/ml) or left in the untreated medium and incubated for 48 h. Cells were stained with annexin V 
and PI. Four-way dot plots into live, early apoptotic, late apoptotic and dead cells quantified the cells. 
Data represent mean ± SD (n=3). Asterisk indicate significant differences in apoptosis (early + late 
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Fig 4.2: Flow cytometry analysis for hormone treatments and controls. The four-way dot plots 
depict single representatives (n=1) of untreated HeLa cells [a], HeLa cells pre-treated with 
4.0µg/ml levonorgestrel (LNG) [b] and 0.5µg/ml ethinylestradiol (EE) [c]. Untreated cells 
constitute the negative control. The cells were incubated for 48 h followed by staining with 
annexin V and PI. Annexin V and PI-negative cells in lower left quadrant (Q1-LL) depict viable 
cells in the population (n=1). Cells in the lower right quadrant (Q1-LR) are in the early stages of 
apoptosis. These HeLa cells are annexin V-positive and PI-negative. Cells located in the upper 
right quadrant (Q1-UR) are positive for both annexin V and PI. These cells are in late stages of 
apoptosis (secondary necrosis). Cells in the upper left quadrant (Q1-UL) represent dead cells. (d): 
Effect of levonorgestrel and ethinylestradiol on HeLa cell apoptosis. For each individual 
experiment, apoptotic cells are a sum of early and late apoptosis. Data were analysed by one-way 
ANOVA. The Tukey’s test adjusted for multiple comparisons among different treatments. Data 














4.3.3. Flow cytometry results for single-drug antiretroviral treatment 
HeLa cells were treated with different antiretroviral drugs at final concentrations of 
50µg/ml of each single antiretroviral drug. Cells were treated with drugs only or with drugs 
and ethinylestradiol at 0.5µg/ml or with drugs and levornogestrel at 4.0µg/ml for 48 h. 
Four-way dot plots into live, early apoptotic, late apoptotic and dead cells quantified the 
cells (Figures 4.3-4.7). For statistical comparison, rate of apoptosis was considered as the 
sum of early and late apoptotic cells in each individual treatment (n=3). The one-way 
ANOVA non-parametric approach analysed the data. To assess the differences among the 
different treatments, the Tukey‟s multi-comparison test was applied. Significant 
differences were reported where P≤0.05. Table 4.2 summarises descriptive statistics for 
each single drug treatment of the HeLa cells in three independent experiments. 
 
Table 4.2: Descriptive statistics for treatment of HeLa cells with single antiretroviral drugs 
for apoptosis assay 





Untreated 89.43±2.06 10.57±2.06 0.00±0.00 0.00±0.00 
     
ABC  61.43±0.78 27.17±0.21 5.13±0.56    6.37±0.35  *  
ABC+LNG 58.50±1.32 27.90±0.87 6.47±0.32    7.17±0.23  * 
ABC+EE 70.47±0.82 27.57±0.64 1.37±0.15    0.60±0.10  * 
     
ZDV 57.33±0.61 31.50±0.44 5.63±0.55    5.57±0.25  * 
ZDV+LNG 69.90±1.93 21.40±1.28 5.37±0.49    3.33±0.21  * 
ZDV+EE 63.77±2.23 30.67±2.25 3.13±0.06    2.50±0.10  * 
     
3TC 56.27±2.47 23.20±0.89 7.97±1.23   12.33±0.58 * 
3TC+LNG 74.40±2.74 16.93±2.12 4.03±0.40    4.67±0.35  * 
3TC+EE 58.87±2.12 33.07±1.99 3.83±0.12    4.23±0.06  * 
     
d4T 53.90±3.33 27.13±0.46 11.93±1.46    7.70±0.24 * 
d4T+LNG 64.13±2.24 24.00±1.42 7.70±0.53    4.17±0.26  * 
d4T+EE 81.00±1.99 16.03±1.33 1.30±0.17    2.00±0.08  * 
     
NVP 48.70±3.24 31.83±1.29 6.80±0.90  12.03±1.85 * 
NVP+LNG 71.10±2.89 21.60±2.49 2.80±0.30    4.50±0.36  * 
NVP+EE 68.63±1.16 22.93±0.85 2.03±0.21    6.40±0.70  * 
HeLa cells were pre-treated with single antiretroviral drugs with and without levonorgestrel 
(LNG) or ethinylestradiol (EE) for 48 h. The cells were stained with annexin V and PI. Four-way 
dot plots into live, early apoptotic, late apoptotic, and dead cells quantified the cells. Data 
represent mean ± SD (n=3). Asterisks indicate significant differences in apoptosis (early + late 




Compared to untreated cells, treatment with ABC alone significantly increases apoptosis 
(P≤0.05). Co-treatment with ethinylestradiol significantly reduces ABC-induced apoptosis, 
while levonorgestrel co-administration did not show an effect (Figure 4.3). The decrease in 
apoptosis with ethinylestradiol co-administration suggests the possibility of increased risk 
of mutation of the DNA-damaged cells following treatment with abacavir. Treatment of 
HeLa cells with ZDV alone or its co-administration with either levonorgestrel and 
ethinylestradiol increases apoptosis compared to untreated cells (Figure 4.4). Co-
administration of ZDV and levonorgestrel drastically decreases the apoptotic population, 
while ethinylestradiol co-administration has no effect on ZDV-induced apoptosis. This 
shows an increased risk of zidovudine DNA-damaged cells having to mutate and escape 
apoptosis, hence leading to continuous growth of the cancerous cells. HeLa cells undergo 
increased apoptosis after 3TC treatment, compared to untreated cells. Levonorgestrel 
downregulates 3TC-induced apoptosis, while ethinylestradiol co-administration does not 
show any significant difference (Figure 4.5), thus suggesting increased risk of evasion of 
apoptosis with levonorgestrel administration.  
 
Co-administration of levonorgestrel or ethinylestradiol with stavudine (d4T) significantly 
reduces d4T-induced apoptosis, a phenomenon that may explain decreased toxicity. 
Ethinylestradiol results in a more drastic decrease in d4T-induced apoptosis compared to 
levonorgestrel (Figure 4.6). While NVP increases apoptosis in HeLa cells levonorgestrel 
and ethinylestradiol down regulates NVP-induced apoptosis (Fig 4.7). Cognisant of the 
observed increased DNA damage upon treatment of human cervical epithelial cancer cells 
with stavudine and nevirapine noted in Chapter 3,  these present results depict an increased 
risk of mutation and apoptosis evasion with both levonorgestrel and ethinylestradiol co-
administration with either stavudine or nevirapine.  
 
The observed results show the varied effect of contraceptive hormones on antiretroviral 
drug-induced apoptosis. These results outline the mechanistic effect of single antiretroviral 
drugs and hormones on human cervical epithelial cancer proliferation. However, in 
practice, antiretroviral drugs are administered in combination.  The next section therefore 
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Fig 4.3: Flow cytometry analysis of HeLa cells pre-treated with abacavir (ABC) with or without 
levonorgestrel (LNG) or ethinylestradiol (EE). Treatment was with ABC only (a), ABC with LNG 
(b) or ABC with EE (c) for 48 h followed by staining with annexin V and PI. Annexin V and PI 
negative cells (Q1-LL) depict viable cells in the population (n=1). Cells in the lower right 
quadrant (Q1-LR) are in the early stages of apoptosis. These HeLa cells are annexin V-positive 
and PI-negative. Cells located in the upper right quadrant (Q1-UR) are positive for both annexin 
V and PI. These cells are in late stages of apoptosis. Cells in the upper left quadrant (Q1-UL) 
represent dead and necrotic cells. (d): Effect of LNG and EE on ABC-induced apoptosis in HeLa 
cells. Apoptotic cells are a sum of both early and late apoptotic cells. Data were analysed by one-
way ANOVA. The Tukey’s test adjusted for multiple comparisons among different treatments. 
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Fig 4.4 Flow cytometry analysis of HeLa cells pre-treated with zidovudine (ZDV) with or without 
levonorgestrel (LNG) or ethinylestradiol (EE). Treatment was with ZDV only (a), ZDV with LNG 
(b) or ZDV with EE (c) for 48 h followed by staining with annexin V and PI. Annexin V and PI 
negative cells (Q1-LL) depict viable cells in the population (n=1). Cells in the lower right 
quadrant (Q1-LR) are in the early stages of apoptosis. These HeLa cells are annexin V-positive 
and PI-negative. Cells located in the upper right quadrant (Q1-UR) are positive for both annexin 
V and PI. These cells are in late stages of apoptosis. Cells in the upper left quadrant (Q1-UL) 
represent dead and necrotic cells. (d): Effect of LNG and EE on ZDV-induced apoptosis in HeLa 
cells. For each individual experiment, apoptotic cells are a sum of both early and late apoptosis. 
Data were analysed by one-way ANOVA. The Tukey’s test adjusted for multiple comparisons 























                               
             













































                                                                                                                                                 
 
Fig 4.5 Flow cytometry analysis of HeLa cells pre-treated with lamivudine (3TC) with or without 
levonorgestrel (LNG) or ethinylestradiol (EE). Treatment was with 3TC only (a), 3TC with LNG 
(b) or 3TC with EE (c) for 48 h followed by staining with annexin V and PI. Annexin V and PI 
negative cells (Q1-LL) depict viable cells in the population (n=1). Cells in the lower right 
quadrant (Q1-LR) are in the early stages of apoptosis. These HeLa cells are annexin V-positive 
and PI-negative. Cells located in the upper right quadrant (Q1-UR) are positive for both annexin 
V and PI. These cells are in late stages of apoptosis. Cells in the upper left quadrant (Q1-UL) 
represent dead and necrotic cells. (d): Effect of LNG and EE on 3TC-induced apoptosis in HeLa 
cells. For each individual experiment, apoptotic cells are a sum of both early and late apoptotic 
cells. Data were analysed by one-way ANOVA. The Tukey’s test adjusted for multiple 




                                                          




















                        
 

















































Fig 4.6 Flow cytometry analysis of HeLa cells pre-treated with stavudine (d4T) with or without 
levonorgestrel (LNG) or ethinylestradiol (EE). Treatment was with d4T only (A), d4T with LNG 
(B) or d4T with EE (C) for 48 h followed by staining with annexin V and PI. Annexin V and PI 
negative cells (Q1-LL) depict viable cells in the population (n=1). Cells in the lower right 
quadrant (Q1-LR) are in the early stages of apoptosis. These HeLa cells are annexin V-positive 
and PI-negative. Cells located in the upper right quadrant (Q1-UR) are positive for both annexin 
V and PI. These cells are in late stages of apoptosis. Cells in the upper left quadrant (Q1-UL) 
represent dead and necrotic cells. D: Effect of LNG and EE on d4T-induced apoptosis in HeLa 
cells. For each individual experiment, apoptotic cells are a sum of both early and late apoptotic. 
Data were analysed by one-way ANOVA. The Tukey’s test adjusted for multiple comparisons 
among different treatments. Data represent means ±SD of three independent experiments (*P 





















         
                     
 
















































Fig 4.7 Flow cytometry analysis of HeLa cells pre-treated with nevirapine (NVP) with or without 
levonorgestrel (LNG) or ethinylestradiol (EE). Treatment was with NVP only (a), NVP with LNG 
(b) or NVP with EE (c) for 48 h followed by staining with annexin V and PI. Annexin V and PI 
negative cells (Q1-LL) depict viable cells in the population (n=1). Cells in the lower right 
quadrant (Q1-LR) are in the early stages of apoptosis. These HeLa cells are annexin V-positive 
and PI-negative. Cells located in the upper right quadrant (Q1-UR) are positive for both annexin 
V and PI. These cells are in late stages of apoptosis. Cells in the upper left quadrant (Q1-UL) 
represent dead and necrotic cells. (d): Effect of LNG and EE on NVP-induced apoptosis in HeLa 
cells. For each individual experiment, apoptotic cells are a sum of bot early and late apoptotic 
cells. Data were analysed by one-way ANOVA. The Tukey’s test adjusted for multiple 










4.3.4. Flow cytometry results for combination antiretroviral treatment 
HeLa cells were treated with different combinations of antiretroviral drugs at final 
concentrations of 50µg/ml for each single drug. Cells were treated with combination drugs 
only or with combination drugs and ethinylestradiol at 0.5µg/ml or with drugs and 
levornogestrel at 4.0µg/ml for 48 h. Four-way dot plots into live, early apoptotic, late 
apoptotic and dead cells quantified the cells (Figures 4.8 to 4.12). For statistical 
comparison, apoptotic cells were considered as the sum of early and late apoptotic cells in 
each individual treatment (n=3). Data were analysed by the one-way ANOVA followed by 
Tukey‟s multi-comparison test. Significant differences were reported where P≤0.05. Table 
4.3 summarises descriptive statistics for each combination antiretroviral drug treatment of 
the HeLa cells in three independent experiments. 
 
Table 4.3: Descriptive statistics for treatment of HeLa cells with combination 
antiretroviral drugs for apoptosis assay 






Untreated   89.43±2.06 10.57±2.06 0.00±0.00 0.00±0.0    
     
ABC+3TC 69.77±1.76 18.07±0.35 8.17±1.27 4.00±0.20 * 
ABC,3TC+LNG 59.83±1.29 30.90±0.79 6.80±0.35 2.47±0.15 * 
ABC,3TC+EE 71.20±2.25 23.57±2.31 4.03±0.06 1.20±0.00 * 
     
ZDV+3TC 78.27±1.69 14.37±1.02 2.37±0.40 5.03±0.29 *  
ZDV,3TC+LNG 51.10±0.40 34.43±3.79 10.10±0.89 4.77±0.15 * 
ZDV,3TC+EE 55.43±2.54 38.03±2.53 2.97±0.06 3.53±0.06 * 
     
ABC+ZDV+3TC 74.80±0.75 18.57±0.55 3.03±0.21 3.67±0.25 * 
ABC,ZDV,3TC+LNG 61.73±0.35 29.00±0.26 6.10±0.26 2.97±0.25 * 
ABC,ZDV,3TC+EE 60.10±1.91 35.13±1.89 3.77±0.12 1.00±0.10 * 
     
ZDV,3TC,NVP 83.47±2.40 10.53±1.82 1.93±0.38 4.07±0.23  
ZDV,3TC,NVP+LNG 57.63±4.21 31.40±3.99 7.53±0.45 3.43±0.12 * 
ZDV,3TC,NVP+EE 66.33±1.31 27.93±1.27 2.87±0.06 2.87±0.06 * 
     
d4T+3TC+NVP 76.40±2.82 15.63±2.44 2.00±0.26 5.97±0.15 * 
d4T,3TC,NVP+LNG 53.20±2.12 34.37±1.69 9.87±0.35 2.57±0.15 * 
d4T+3TC,NVP+EE 71.37±0.38 22.13±0.06 2.73±0.21 3.77±0.15 * 
HeLa cells were pre-treated with combination antiretroviral drugs with and without 
levonorgestrel (LNG) or ethinylestradiol (EE) for 48 h. The cells were stained with annexin V and 
PI. Four-way dot plots into live, early apoptotic, late apoptotic and dead cells quantified the cells. 
Data represent mean ± SD (n=3). Asterisks indicate significant differences in apoptosis (early + 




Relative to single antiretroviral drugs, the present results depict a reduction in the rate of 
apoptosis with combinatorial treatment. This non-drastic apoptosis suggests a protective 
effect as too-drastic apoptosis may result in cell loss and possibly tissue damage. 
Compared to untreated cells, treatment with a double combination of ABC+3TC 
significantly increases apoptosis. Co-treatment with levonorgestrel drastically increases 
ABC+3TC-induced apoptosis while ethinylestradiol co-treatment does not have a 
significant effect on AB+3TC-induced apoptosis (Figure 4.8). Treatment of HeLa cells 
with ZDV+3TC significantly increased apoptosis compared to untreated cells (Figure 5.9). 
Co-treatment with both levonorgestrel and ethinylestradiol increases ZDV+3TC-induced 
apoptosis. 
 
ABC+ZDV+3TC treatment significantly increases the rate of apoptosis relative to 
untreated cells. HeLa cells undergo further increased apoptosis after treatment with 
ABC+ZDV+3TC in the presence of either 4.0µg/ml levonorgestrel or 0.5µg/ml 
ethinylestradiol (Figure 4.10). ZDV+3TC+NVP treatment does not significantly affect 
HeLa cell apoptosis relative to untreated cells (Fig 4.11). The decreased apoptosis suggests 
evasion of human cervical epithelial cancer cell death in the presence of this regimen. 
However, co-treatment of ZDV+3TC+NVP with 4.0µg/ml and 0.5µg/ml ethinylestradiol 
drastically increases apoptosis in ZDV+3TC+NVP-treated cells (P<0.05). There is a 
significant difference in apoptosis between d4T+3TC+NVP-treated cells and untreated 
cells. 4.0µg/ml levonorgestrel drastically increases d4T+3TC+NVP-induced apoptosis. 
0.5µg/ml ethinylestradiol also increases apoptosis in d4T+3TC+NVP-treated cells, 
although this is at a much lower percentage compared to 4.0µg/ml levonorgestrel (Fig 
4.12). Overall, these results show that there is a significant increase in ABC+ZDV+3TC- 
and d4T+3TC+NVP-induced apoptosis in human cervical epithelial cancer cells. However, 
treatment with ethinylestradiol and levonorgestrel drastically increases this combination 





















                                                
                                       
 
























































Fig 4.8: Flow cytometry analysis of HeLa cells pre-treated with a combination of ABC and 3TC 
with or without levonorgestrel (LNG) or ethinylestradiol (EE). Treatment was with ABC+3TC 
(a), ABC+3TC with LNG (b) or ABC+3TC with EE (c) for 48 h followed by staining with annexin 
V and PI. Annexin V and PI negative cells (Q1-LL) depict viable cells in the population (n=1). 
Cells in the lower right quadrant (Q1-LR) are in the early stages of apoptosis. These HeLa cells 
are annexin-V positive and PI-negative. Cells located in the upper right quadrant (Q1-UR) are 
positive for both annexin V and PI. These cells are in late stages of apoptosis. Cells in the upper 
left quadrant (Q1-UL) represent dead and necrotic cells. (d): Effect of LNG and EE on 
ABC+3TC-induced apoptosis in HeLa cells. For each individual experiment, apoptotic cells are a 
sum of both early and late apoptotic cells. Data were analysed by one-way ANOVA. The Tukey’s 
test adjusted for multiple comparisons among different treatments. Data represent means ± SD of 























                                                                                                                                                               
 
Fig 4.9: Flow cytometry analysis of HeLa cells pre-treated with a combination of ZDV and 3TC 
with or without levonorgestrel (LNG) or ethinylestradiol (EE). Treatment was with ZDV+3TC 
(a), ZDV+3TC with LNG (b) or ZDV+3TC with EE (c) for 48 h followed by staining with annexin 
V and PI. Annexin V and PI negative cells (Q1-LL) depict viable cells in the population (n=1). 
Cells in the lower right quadrant (Q1-LR) are in the early stages of apoptosis. These HeLa cells 
are annexin-V positive and PI-negative. Cells located in the upper right quadrant (Q1-UR) are 
positive for both annexin V and PI. These cells are in late stages of apoptosis. Cells in the upper 
left quadrant (Q1-UL) represent dead and necrotic cells. (d): Effect of LNG and EE on 
ZDV+3TC-induced apoptosis in HeLa cells. For each individual experiment, apoptotic cells are a 
sum of both early and late apoptotic cells. Data were analysed by one-way ANOVA. The Tukey’s 
test adjusted for multiple comparisons among different treatments. Data represent means ± SD of 
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Fig 4.10: Flow cytometry analysis of HeLa cells pre-treated with a combination of ABC, ZDV and 
3TC with or without levonorgestrel (LNG) or ethinylestradiol (EE). Treatment was with 
ABC+ZDV+3TC (a), ABC+ZDV+3TC with LNG (b) or ABC+ZDV+3TC with EE (c) for 48 h 
followed by staining with annexin V and PI. Annexin V and PI negative cells (Q1-LL) depict 
viable cells in the population (n=1). Cells in the lower right quadrant (Q1-LR) are in the early 
stages of apoptosis. These HeLa cells are annexin V-positive and PI-negative. Cells located in the 
upper right quadrant (Q1-UR) are positive for both annexin V and PI. These cells are in late 
stages of apoptosis. Cells in the upper left quadrant (Q1-UL) represent dead and necrotic cells. 
(d): Effect of LNG and EE on ABC+ZDV+3TC-induced apoptosis in HeLa cells. For each 
individual experiment, apoptotic cells are a sum of both early and late apoptotic cells Data were 
analysed by one-way ANOVA. The Tukey’s test adjusted for multiple comparisons among 


















































































       
                                                                                                                                                                                                                                                                                                                                  
                                                                                 
Fig 4.11: Flow cytometry analysis of HeLa cells pre-treated with a combination of ZDV, 3TC and 
NVP with or without levonorgestrel (LNG) or ethinylestradiol (EE). The cells were treated by 
ZDV+3TC+NVP (a), ZDV+3TC+NVP with LNG (b) or ZDV+3TC+NVP with EE (c) for 48 h 
followed by staining with annexin V and PI. Annexin V and PI negative cells (Q1-LL) depict 
viable cells in the population (n=1). Cells in the lower right quadrant (Q1-LR) are in the early 
stages of apoptosis. These HeLa cells are annexin V-positive and PI-negative. Cells located in the 
upper right quadrant (Q1-UR) are positive for both annexin V and PI. These cells are in late 
stages of apoptosis. Cells in the upper left quadrant (Q1-UL) represent dead and necrotic cells. 
(d): Effect of LNG and EE on ZDV+3TC+NVP-induced apoptosis in HeLa cells. For each 
individual experiment, apoptotic cells are a sum of both early and late apoptotic cells. Data were 
analysed by one-way ANOVA. The Tukey’s test adjusted for multiple comparisons among 
different treatments. Data represent means ±SD of three independent experiments (*P≤0.05).    
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Fig 4.12: Flow cytometry analysis of HeLa cells pre-treated with a combination of d4T, 3TC and 
NVP with or without levonorgestrel (LNG) or ethinylestradiol (EE). The cells were treated by 
d4T+3TC+NVP (A), d4T+3TC+NVP with LNG (B) or d4T+3TC+NVP with EE (C) for 48 hr 
followed by staining with annexin V and PI. Annexin V and PI negative cells (Q1-LL) depict 
viable cells in the population (n=1). Cells in the lower right quadrant (Q1-LR) are in the early 
stages of apoptosis. These HeLa cells are annexin V-positive and PI-negative. Cells located in the 
upper right quadrant (Q1-UR) are positive for both annexin V and PI. These cells are in late 
stages of apoptosis. Cells in the upper left quadrant (Q1-UL) represent dead and necrotic cells. D: 
Effect of LNG and EE on d4T+3TC+NVP-induced apoptosis in HeLa cells. For each individual 
experiment, apoptotic cells are a sum of both early and late apoptotic cells. Data were analysed by 
one-way ANOVA. The Tukey’s test adjusted for multiple comparisons among different 
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4.4. Discussion  
The overlap of some early apoptotic cells into the bottom left quadrant suggest signal spill-
over from the FITC into the PI read out channel. This could also have been influenced by 
the gating strategy, hence possibly contributing to a false-negative in some early apoptotic 
cells. Most flow cytometers detect PI fluorescence in the FL2 channel. However it is 
recommended to detect the PI signal in the FL3 emission, as this minimises the 
compensation needed to correct for signal spill-over (Immunochemistry Technologies, 
n.d.). The present study detected PI fluorescence in the FL2 channel. False negative results 
for early apoptotic cells could also have resulted from excessive incubation periods in 
some independent experiments. 
 
Treatment of HeLa cells with single 50µg/ml of each single antiretroviral drug was shown 
to induce apoptosis drastically in human cervical epithelial cancer cells. In Chapter 3, it 
was demonstrated that all the five antiretroviral drugs (abacavir, zidovudine, lamivudine, 
stavudine and nevirapine) have genotoxic effects in HeLa and Chinese hamster ovary cells. 
It was shown that NRTIs induce double-strand breakage. This increased apoptosis is 
possibly due to membrane-associated activation of apoptotic response to DNA damage-
induced cell death. This could be attributed to deregulation of DNA response coupled with 
intrinsic stimuli of mitochondrial apoptotic pathway associated with genotoxic stress (Matt 
and Hofmann, 2016; Czabotar et al., 2014). In Chapter 3, it was shown that nevirapine, 
which acts by non-competitive inhibition of DNA polymerase, also induces HeLa cell 
double-strand breaks. NVP administration also significantly increases apoptosis compared 
to untreated cells, a phenomenon that concurs with its reported carcinogenicity (Brambilla 
et al., 2012). These observations therefore suggest that human cervical epithelial cells are 
inevitably exposed to some form of DNA damage from the antiretroviral drugs. If 
uncontrolled, such damage may impair important metabolic processes such as DNA-repair 
mechanisms and apoptotic removal of DNA-damaged cells (Toettcher et al., 2009). Our 
cells have evolved inherent repair mechanisms to compensate for various types of DNA 
damage. Apoptosis is programmed cell death, which aids removal of damaged cells, hence 
the observed increase in apoptosis following exposure to antiretroviral drugs. 
 
The present results demonstrate that treatment with ABC alone drastically increases 
apoptosis (early + late apoptosis) in HeLa cells. Although co-administration with EE 
significantly reduces ABC-induced apoptosis (from 32% to 29%), the relative rate of 
apoptosis is still drastically higher compared to untreated cells whose mean percentage is 
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11%. In their compendium, Brambilla et al. (2012) highlight that ABC was shown to be 
carcinogenic. In addition to inhibition of telomerase in HT29 cells (Hakuzalie et al., 2012), 
in Chapter 3, it was shown that ABC induces double-strand breaks in HeLa cells. The 
present results suggest that, in the advent of these unwanted effects, the apoptotic pathway 
is triggered to get rid of unrepaired cells. However, as shown in Chapter 2, over a period of 
72 h there is no significant difference in proliferation between MTT proliferation assays 
for ABC-treated and untreated cells. These results therefore suggest apoptosis-induced 
proliferation by adjacent HeLa cells in response to cell cycle arrest as they initiate 
apoptosis. Alternatively, this could be due to compensatory proliferation (CP) as mitogens 
are secreted in response to cells lost by apoptosis (Ryoo et al., 2004; Fan and Bergmann, 
2004). This is therefore suggestive of regenerative hyperplasia as cells become excessively 
mitogenic in a bid to replace lost cells.   
 
A number of studies are in concurrence with the observed proliferative effects of 
oestrogens on cancer cells. As outlined earlier, Mosli et al. (2013) demonstrated that in 
vitro exposure of non-transformed prostate epithelial cells (BPH-1) to catechol oestrogens 
(CEs) had a neoplastic effect. They further demonstrated that the CE 4-hydroxyestradiol 
(4-OHE2) showed more carcinogenicity relative to the parent hormone 17β-oestradiol (E2). 
It has also been shown that oestrogen has proliferative effects in normal and MCF-7 breast 
cancer cells (Scaling et al., 2014; Pesiri et al., 2015). In MC7 10A cells, oestrogen 
stimulation in the presence of GPER-selective agonist G-1 was shown to increase the 
mitogenic index (Scaling et al., 2014).  
 
As observed in Chapter 2, upon co-administration of ABC with 1.0µg/ml, 2.0µg/ml and 
4.0µg/ml LNG, the reduction in cell viability suggests antiproliferative activity. In a related 
study, LNG was shown to inhibit human endometrial stromal cell (HESC) and human 
endometrial glandular cell (HEGC) proliferation while inducing apoptosis in both cell lines 
(Zhao et al., 2015). The levonorgestrel intra-uterine system (LNG-IUS) has since been 
shown to induce regression of complex endometrial hyperplasia (Wildemeersch et al., 
2015; Haoula et al., 2011; Zhao et al., 2015). LNG-IUS down-regulates expression of 
PRA, PRB, ER-α and ER-β (Vereide et al., 2006; Gomes et al., 2009). Complex atypical 
hyperplasia was also shown to decrease after progestin therapy (Gunderson et al., 2014; 
Kudesia et al., 2014).  This suggests that, the observed decrease in enzymatic reduction of 
MTT results from the increased rate of apoptosis. Interestingly, at 0.5µg/ml and 1.0µg/ml 
of EE, ABC-treated HeLa cells show no significant difference in reduction of MTT, 
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relative to untreated cells. The present results suggest that LNG does not have an effect on 
apoptosis induced cellular remodelling in ABC-treated cells, while EE increases HeLa cell 
viability. 
 
Compared to untreated cells, ZDV significantly increases apoptosis in HeLa cells from 
11% to 37%. While EE does not alter the rate of ZDV-induced apoptosis, LNG 
significantly decreases the rate of ZDV-induced apoptosis to 27%. This rate still seems a 
bit higher, as rates of 15-20% seem sufficient for cancer cell elimination and/or 
antiproliferative activity. As shown in Chapter 3, ZDV also induces a time-dependent 
DNA double-strand breakage in both HeLa and CHO cells. ZDV has been shown to inhibit 
telomerase in human HT29 cells (Brambilla et al., 2012). Furthermore, ZDV was also 
shown to exhibit cytogenetic changes in Allium cepa root cells (Onwuamah et al., 2014). 
Compounded with the well-established genotoxic effect of ZDV (Momot et al., 2014, Yu 
et al., 2009), the presently-observed drastic apoptosis associated with its lone 
administration seems a natural elimination method for cells with undesired genetically 
modified characteristics. In Chapter 2, this study evaluated the role of EE and LNG on 
HeLa cell viability. Lone administration of ZDV was shown to have a time-dependent 
decrease in reduction of MTT. LNG co-administration maintains the anti-proliferative 
effects at all concentrations (1.0µg/ml, 2.0µg/ml and 4.0µg/ml), thus depicting apoptosis-
dependent decrease in MTT reduction. Upon co-administration of ZDV with 0.5µg/ml EE, 
HeLa cells do not depict a difference in reduction of MTT, relative to untreated cells. 
Cognisant of the significant increase observed in HeLa cells apoptosis upon this co-
treatment of ZDV with 0.5µg/ml EE, these observations are suggestive of EE resulting in 
improved viability of HeLa cells as they regenerate themselves (Ryoo et al., 2004). Further 
increases in EE concentration to 1.0µg/ml and 2.0µg/ml significantly reduce the rate of 
proliferation, thus suggesting increased cell loss and possibly tissue damage. 
 
Lone administration of 3TC drastically increases apoptosis in HeLa cells from 11% to 
31%. Co-administration with EE does not show a difference in the rate of apoptosis while 
LNG drastically reduces 3TC-induced apoptosis to 21%. McGuigan et al. (2013) 
demonstrated the cytostatic activity of 3TC on HeLa cells. As shown in Chapter 3, the 
potential of 3TC to induce double-strand breaks in HeLa and CHO cells was also 
demonstrated. The present observations on lone 3TC administration suggest apoptotic 
removal of genotoxically damaged HeLa cells cognisant of the role of apoptosis in removal 
of DNA-damaged cells (Matt and Hofmann, 2016). From cell viability assays in Chapter 2, 
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administration of 3TC only depicts a time-dependent decrease in cell proliferation. Co-
administration of 3TC with LNG does not show a difference in rate of reduction of MTT 
relative to the control. Since the present results have shown a significant increase in the 
rate of apoptosis, this non-significant relationship therefore suggests cellular remodelling 
for compensatory proliferation. Similarly, the increase in cell viability upon 3TC co-
administration with 0.5µg/ml and 1.0 EE suggests EE-induced cellular remodelling and 
possibly regenerative hyperplasia. 
 
In Chapter 3, it was shown that d4T induces double-strand breaks in both HeLa and CHO 
cells. This suggests that eversion of DNA-repair triggers the observed drastic apoptosis 
observed in these HeLa cells treated with d4T. Co-treatment with both 4.0µg/ml LNG and 
0.5µg/ml EE reduces d4T-induced apoptosis from a mean of 39% to 31% and 17% 
respectively. While EE-induced apoptosis seems optimal (<20%) for beneficial inhibition 
of cancer cell proliferation, the MTT proliferation assay (Chapter 2) depicts no difference 
if compared to untreated cells. This is suggestive of EE-induced proliferation and 
mitogenic activity. Alternatively, it is important to note that cells in early apoptosis may 
still have the potential to reduce MTT in the assay and thus may be quantified as live cells 
(Brummati, 2008; Ryoo and Bergmann, 2012; Shi et al., 2012). In addition to too-drastic 
apoptosis, co-treatment with LNG similarly suggests apoptosis induction of cellular 
remodelling in d4T-treated cells as shown by no significant differences observed in the 
MTT proliferation assay.   
 
In Chapter 3, a time-dependent induction of double-strand breaks in both HeLa and CHO 
cells treated with NVP was observed. Its metabolite, 12-hydroxy-NVP, has been shown to 
be mutagenic (Kranendonk et al., 2014). The present results depict a drastic increase in 
HeLa cell apoptosis upon treatment with NVP, possibly following deregulation of DNA 
repair for some excessively damaged cells. Both EE and LNG decrease NVP-induced 
apoptosis in HeLa cells. From Chapter 2, lone administration of 50µg/ml NVP shows a 
time-dependent decrease in reduction of MTT. Similarly, co-treatment with 0.5µg/ml EE 
and all concentrations of LNG (1.0µg/ml, 2.0µg/ml and 4.0µg/ml) also depict significant 
antiproliferative activity, thus suggesting that 0.5µg/ml EE and 4.0µg/ml LNG reduces 
NVP-induced apoptosis. This reduction from 39% to 25% and 24%, respectively, may 
suggest attainment of optimal apoptosis levels sufficient to eliminate cancer cells without 
too drastic cell loss and possibly tissue damage. 
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17β-Oestradiol has antiapoptotic effects in normal and cancer cell lines (HT3 and CaSki, 
respectively) through attenuation of caspase-9 and terminal caspase-3 activity (Wang et al., 
2004). Our results showed that ethinylestradiol, a derivative of 17β-oestradiol, also 
significantly reduces ABC, d4T and NVP-induced apoptosis. On the contrary, no 
significant change was observed for ZDV and 3TC co-treatment with ethinylestradiol. 
While this later observation may suggest non-attenuation of caspases 3 and 9 described for 
17β-oestradiol, an evaluation of the mechanism(s) of apoptotic pathways in single drug co-
administration with ethinylestradiol could be interesting. Webster et al. (2001) 
demonstrated an increased level of apoptosis induction by HPV types 16E2 and E7 
proteins in the presence of progesterone. Interestingly, in the present study, levonorgestrel 
(a synthetic progestogen) had no significant effect on ABC-induced apoptosis, while it 
significantly decreases 3TC, ZDV, d4T and NVP-induced apoptosis. While investigation 
of the mechanism for this decrease in apoptosis was beyond the scope of this research, 
such an investigation may offer a plausible in vitro explanation of cancerous cell viability 
and regeneration following co-administration of antiretroviral drugs and combined oral 
contraceptive hormones. 
 
The present results also demonstrate the varied effect of contraceptive hormones 
(levonorgestrel and ethinylestradiol) on antiretroviral drug-induced apoptosis in HeLa 
cells. These results demonstrate that EE but not LNG decreases ABC-induced apoptosis in 
HeLa cells. On the hand, LNG but not EE decreases ZDV- and 3TC-induced apoptosis in 
HeLa cells.  Both EE and LNG reduce d4T- or NVP-induced apoptosis in HeLa cells. The 
observed decrease in apoptosis following co-administration of contraceptive hormones 
suggests their association with increased risk for cells to mutate and escape apoptosis. EE 
has a more drastic effect than LNG on d4T-induced apoptosis. This suggests that different 
contraceptive hormones exhibit different potential of altering antiretroviral-induced 
apoptosis. This also suggests apoptosis dependence on the nature of the antiretroviral drug 
that induces the baseline apoptosis. Similarly, this allows understanding of varying 
neoplastic and cancer cell proliferation with differing antiretroviral drug treatments. The 
problem remains that of establishing the optimum levels of apoptosis. This is because, in 
all single-drug treatments (with or without hormone co-treatment), apoptosis is increased 
in HeLa cells compared to the control cells. Cognisant of the fact that too much apoptosis 
may be pathological while optimum rate is beneficial (Matt and Hofmann, 2016; Logue et 
al., 2009; Brummatti et al., 2008), there is need to outline the desired balances for 




While discussion of single-drug effect is important for understanding the mechanistic 
effect of antiretroviral toxicity, combination antiretroviral treatment is the modern day 
approach to HIV/AIDS treatment, since single ARV treatment has been widely 
discontinued due to development of viral resistance (WHO, 2010; BHIVA, 2008). In 
practice, administration of these drugs is predominantly in triple combinations as discussed 
previously. Alternatively, the double combinations ABC+3TC and ZDV+3TC can be 
administered in combination with a protease inhibitor (AIDSinfo, 2017). 
 
One may argue that the results from Figures 4.9, 4.10, 4.11 and 4.12 become of marginal 
interest in the light of the combinatorial effect (that is, more drug treatment leads to more 
cell death). It is however imperative to note that combinatorial, not single, antiretroviral 
treatment is the modern-day preferred treatment method (AIDSinfo, 2017).  Overall, 
results for combination antiretroviral treatment demonstrate a decreased effect on apoptosis 
relative to single antiretroviral treatment. To this effect, the effect of contraceptive 
hormones on highly active antiretroviral drug-induced apoptosis becomes of interest. 
While these results may suggest evasion  of apoptosis compared to single drug treatment, 
the combinations ABC+3TC, ZDV+3TC, ABC+ZDV+3TC and d4T+3TC+NVP still 
depict a relatively high rate of apoptosis compared to untreated HeLa cells. However, there 
is a drastic decrease in apoptosis, resulting in no significant difference in apoptosis 
between ZDV+3TC+NVP-treated and untreated cells. Co-administration of both 4.0µg/ml 
levonorgestrel and 0.5µg/ml ethinylestradiol drastically increased triple combination 
antiretroviral drug (ABC+ZDV+3TC, d4T+3TC+NVP and ZDV+3TC+NVP)-induced 
apoptosis. Similarly, the two hormones increase ZDV+3TC-induced apoptosis in HeLa 
cells. While 4.0µg/ml levonorgestrel co-treatment significantly increases ABC+3TC-
induced apoptosis in HeLa cells, there are no differences observed following 0.5µg/ml 
ethinylestradiol co-treatment. The present results suggest increased human cervical cancer 
cell death by apoptosis following co-administration of all combination antiretroviral drugs 
(ABC+3TC, ZDV+3TC, ABC+ZDV+3TC, d4T+3TC+NVP and ZDV+3TC+NVP) with 
levonorgestrel.  
 
While combination treatments increase apoptosis relative to untreated cells in the absence 
of hormones, of interest is their overall lower apoptotic effects compared to single 
antiretroviral treatments. With the exception of ABC+3TC, that induces more than 20% 
apoptosis, the rest of the treatments cause average apoptosis percentages below 20%. 
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Curiously, this study thus reported lower toxicities for combination antiretroviral drug 
treatment compared to single drug treatment. Bulusu et al. (2016) maintain that drug 
combination therapy has demonstrated more effective cell growth inhibition than 
administration of either agents alone in cancer treatment. During cancer treatment, multi-
drug therapy was shown to be less toxic in small combination doses, while at the same 
time exhibiting a high therapeutic effect (Bulusu et al., 2016). The observed decrease in 
cervical neoplastic transformation and reduced cancer cell proliferation among some 
patients undergoing HAART (Adler et al., 2012; Finhaber et al., 2012;  Omar et al., 2011; 
Minkoff et al., 2010) could be due to the additive and/or synergistic effect of the 
constituent antiretroviral drugs. However, in the present study, it is interesting to note that 
the combination ZDV+3TC+NVP does not alter the rate of apoptosis in the absence of 
contraceptive hormones. These results therefore envisage that, in the absence of hormonal 
contraceptives, in vitro evidence suggests that ZDV+3TC+NVP treatment results in 
evasion of apoptosis thus leading to growth of the human cervical epithelial cell. Co-
administration of ZDV+3TC+NVP with both ethinylestradiol and levonorgestrel increase 
the rate of apoptosis thus suggesting a protective effect of both hormones through 
increased elimination of the cancerous cells. 
 
The combination drug ABC+3TC is commonly used in first-line treatment simultaneously 
with a protease inhibitor (BHIVA, 2008). In this in vitro study, it was shown that 
ABC+3TC induces apoptosis in human cervical epithelial cancer cells. As demonstrated in 
Chapter 2, there is a time-dependent decrease in HeLa cell viability upon lone 
administration of ABC+3TC-treated cells as depicted by the MTT assay. Interestingly, as 
demonstrated in Chapter 2, co-administration of 0.5µg/ml or 1.0µg/ml of EE does not 
significantly alter cell viability (from MTT) of ABC+3TC treated cells, despite the high 
percentage rate of apoptosis observed with co-treatment for 48 h. Induction of apoptosis 
does not necessarily imply inhibition of cellular remodelling (Shi et al., 2012). Apoptosis 
induction may lead to mitogen stimulation which, in turn, stimulates proliferation of 
adjacent cells in a bid to replace lost cells through compensatory proliferation (CP) also 
known as apoptosis-induced proliferation (Ryoo and Bergmann, 2012; Fan and Bergmann, 
2008b). As discussed earlier, a number of studies have also demonstrated the proliferative 
effect of oestrogens on different cancer cells (Pesiri et al., 2015; Scaling et al., 2014; 




This in vitro observation concurs with some epidemiological observations suggesting no 
effect of HAART on neoplasia progression (Ezechi et al., 2014; Shrestha et al., 2010; 
Sirera et al., 2008). It is however imperative to note that, in the MTT assay, cells in early 
apoptosis still have the ability to reduce MTT, possibly resulting in false positive 
proliferative assay (Shi et al., 2012; Brummati et al., 2008). Although the MTT assay is 
relatively faster (Sieuwerts et al., 1995; Sylvester 2011) complimenting this assay with the 
viable cell count would have gone some way to improve the viability analysis. On the 
contrary, it has since been established that cervical cancer is a hormone dependent tumour 
that may be activated by oestrogens that act as cofactors (Practice Committee of American 
Society for Reproductive Medicine, 2008; Jiang et al., 2016).  
 
Modern day approaches in combined hormonal contraception is to reduce the amount of 
oestrogens in COCs as much as is possible without affecting efficacy of the contraceptive 
pill (Blackburn et al., 2000). Otherwise, apoptosis-dependent regeneration of cells may 
lead to regenerative hyperplasia (Ryoo and Bergmann, 2012). Co-administration with 
4.0µg/ml LNG further increases apoptosis in ABC+3TC-treated cells and this is associated 
with decreased cell proliferation, hence suggestive of increased cancer cell death. 
However, it may be important to titrate for LNG concentrations that do not depict too 
drastic apoptosis in vivo, cognisant of the established protective effect of progestin against 
endometrial hyperplasia (Vereide et al., 2014; Gomes et al., 2009). Similarly, the 
levonorgestrel intra-uterine system (LNG-IUS) has since been shown to induce regression 
of complex endometrial hyperplasia (Wildemeersch et al., 2015; Haoula et al., 2011; Zhao 
et al., 2015). 
 
Combivir (ZDV+3TC) is another double antiretroviral combination used in combination 
ARV treatment in conjunction with a protease inhibitor. In the present study, 
administration of this combination significantly increases apoptosis of human cervical 
epithelial cells from a mean of 11% to 17 (P<0.05). The MTT proliferation assay for 
ZDV+3TC-treated cells described in Chapter 2 depicts a time-dependent decrease in 
proliferation. These observations suggest a predominantly apoptotic-dependent 
antiproliferative activity of ZDV+3TC devoid of compensatory proliferation. If maintained 
within optimal levels, apoptosis is physiologically beneficial in removal of unwanted cells, 
while excessive apoptosis may lead to pathophysiology such as loss of cells and tissue 
damage (Matt and Hofmann, 2016; Dexheimer, 2013). In the absence of contraceptive 
hormones, the present results suggest a protective effect of ZDV+3TC against the 
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proliferation of human cervical epithelial cancer cells. Co-administration with 4.0µg/ml 
LNG or 0.5µg/ml EE drastically increases ZDV+3TC induced apoptosis (P<0.05) to 
averages of 45% and 41% respectively. The proliferation assay for ZDV+3TC co-
administration with 4.0µg/ml LNG depicts no difference in viability compared to untreated 
cells (Chapter 2). On the contrary, no difference is observed in the reduction of MTT 
between untreated cells and those exposed to 0.5µg/ml EE co-treatment with ZDV+3TC. 
In view of the high rate of apoptosis in these 0.5EE treated cells, this present observation 
suggests cellular remodelling activity of EE. If uncontrolled, this compensatory 
proliferation could be one way in which EE acts as a co-factor for continuous human 
cervical epithelial cell proliferation characterised by regenerative hyperplasia.  
 
The combination ABC+ZDV+3TC is a triple NRTI commonly used in HIV/AIDS 
treatment. Upon its lone administration, the regimen ABC+ZDV+3TC significantly 
increases the rate of apoptosis in HeLa cells (P<0.05) from 11% to 21% . In Chapter 2, it 
was demonstrated that treatment of HeLa cells with this combinatorial regimen depicts a 
time-dependent decrease in viable cells, hence suggesting the beneficial anticancer effect 
of its lone administration. Upon co-administration with either 4.0µg/ml LNG or 0.5µg/ml 
EE, the corresponding MTT reduction assays in Chapter 2 show no statistical difference 
compared to untreated cells, thus suggesting that apoptosis did not inhibit remodelling. 
This again suggests apoptosis-induced remodelling by those cells which are undergoing 
apoptotic changes (Ryoo and Bergmann, 2012; Jiang and Wang, 2016). In the present 
experimental set-up, it remains obscure whether this perceived contraceptive hormone-
stimulated cellular regeneration remains under control to avoid hyperplasia and possibly 
cancer. 
 
For triple combination treatments, overall in the absence of hormones, only the HAART 
regimen ZDV+3TC+NVP did not significantly change the rate of apoptosis if compared to 
untreated control cells. This suggests that the antiproliferative effect of ZDV+3TC+NVP 
observed with the MTT assay in Chapter 2 is predominantly due to inhibition of 
proliferation relative to untreated cells, since inability to reduce MTT is an indicator of 
reduced cellular viability or metabolic activity (Sieuwerts et al., 1995; Sylvester 2011; van 
Meerloo et al., 2011; Shi et al., 2012). One way of such inhibition could be through the 
cell cycle arrest. These  observations concur with the decrease in cervical neoplastic 
transformation and reduced cancer cell proliferation among some patients undergoing 
HAART (Adler et al., 2012; Firnhaber et al., 2012;  Omar et al., 2011; Chen et al., 2014; 
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Minkoff et al 2010). Bulusu et al. (2016) and Murugan et al. (2016) postulate that the 
additive and/or synergistic effect of combinatorial drug delivery may be beneficial through 
reduction in toxicity of individual drugs. Co-administration with either levonorgestrel or 
ethinylestradiol drastically increases apoptosis in ZDV+3TC+NVP-treated human cervical 
epithelial cells (P<0.05), thus suggestive of increased cancer cell loss. This increased 
toxicity upon co-administration of hormonal contraceptives is suggestive of causality of 
cervical intraepithelial neoplasia progression or other serious non-AIDS events observed 
with some cohort studies (Lillo et al., 2001; McKenzie et al., 2011). 
 
The HAART regimen d4T+3TC+NVP has been among the recommended ARVs in low-
resource settings until recently, when the World Health Organisation recommended 
withdrawal of d4T due to its observed toxicity (WHO, 2010). However the regimen still 
finds use in low-resource countries. Lone administration of d4T+3TC+NVP increases 
HeLa cell apoptosis from 11% to 18%, a percentage moderate enough to impact non-
drastic cell loss with limited cell tissue damage. Coupled with the time-dependent decrease 
in HeLa cell proliferation as shown in Chapter 2, this is suggestive of the beneficial 
antiproliferative effect of this combinatorial treatment. Co-treatment with 0.5µg/ml EE and 
4.0µg/ml LNG further significantly increases apoptosis to 25% and 44%, respectively. 
This is also supported by a decrease in HeLa cell MTT viability assay in Chapter 2 where 
there is a corresponding loss of MTT reduction rate at these co-administered 
concentrations. The too-drastic loss of cells following this co-administration of hormones 
is suggestive of increased cell loss and possibly tissue damage. 
 
Although combination ARV treatment with regimens ZDV+3TC, ABC+ZDV+3TC and 
ZDV+3TC+NVP was shown to induce genotoxicity in new-born monkeys (Olivero et al., 
2013), overall the present results demonstrate higher toxicity for single-drug treatment 
compared to combination treatment. The range of apoptosis (early + late) in single drug 
treatment is 31-39% (n=5, mean=35.6%) while the range for combination treatment is 12-
26% (n=5; mean=18.9%). In separate in vivo studies carried out on mice, Combivir + EFV 
did not observe any significant DNA damage with the genotoxicity and micronucleus test 
(de Moraes Filho et al., 2016). Such reduced toxicity results in limited but beneficial 
elimination of cancerous cells through apoptosis and/or cell cycle arrest. In the absence of 
contraceptive hormones, our results for combination ARV treatment of HeLa cells suggest 
anticancer activity as depicted by the time-dependent decrease in cell proliferation 
observed in Chapter 2. On the contrary, the higher rate of apoptosis observed with single-
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drug treatment is suggestive of increased loss of cells and possibly tissue damage. These 
observations are in support of the established reduced toxicity of combination ARV 
treatment, compared to single drug therapy which was used prior to 2000 (BHIVA, 2008; 
WHO, 2010).  
 
4.4.1. Conclusion 
Table 4.4 below summarises the effect of antiretroviral drug co-treatment with 































Table 4.4: Effect of antiretroviral drug co-treatment with hormones on HeLa cell apoptosis 
 
The table summarises the effect of single and combination antiretroviral drug co-treatment 
with levonorgestrel and ethinylestradiol on HeLa cell apoptosis following a 48 h treatment. 
The results show the comparison of each treatment to the untreated control where: (+) 
represents significant differences with ≤ 25% increase in  apoptosis (early+late) compared to 
the untreated control, while (++) shows a more drastic increase in the rate of apoptosis (> 
25% compared to the untreated control) and (-) demonstrates no significant difference 
between the drug-treated cells and the untreated control. The rate of apoptosis among drug-













Single drug No hormone Effect of LNG 
on drug induced 
apoptosis 
Effect of EE on 
drug induced 
apoptosis  
    
ABC   ++ ++ ++ 
ZDV   ++           ++ ++ 
3TC   ++            + ++ 
d4T   ++           ++ + 
NVP   ++            + + 
 
   
Combination 
drug 
 No hormone Effect of LNG 
on drug induced 
apoptosis 











ZDV+3TC    + ++ ++ 
ABC+ZDV+3TC    + ++ ++ 
ZDV+3TC+NVP    - ++ ++ 
d4T+3TC+NVP    + ++ + 
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While single-drug treatment evaluation provides an insight into the mechanistic approach 
to understanding the role of hormonal contraceptives on antiretroviral drug-induced 
apoptosis, combination antiretroviral therapy is of interest, as it is the predominantly 
administered form of therapy. Single NRTIs and NVP drastically induce HeLa cell 
apoptosis compared to combination ARV treatment. In the absence of contraceptive 
hormones, the present results depict a protective effect of combination antiretroviral 
treatment against the proliferation of human cervical epithelial cancer cells through 
moderate rates of increased apoptosis relative to untreated cells. NTRIs combination drug-
induced apoptosis is drastically increased with 4.0µg/ml levonorgestrel co-treatment. 
Similarly 0.5µg/ml EE drastically increases all combination drug-induced apoptosis, with 
the exception of cells treated with ABC+3TC. This too drastic increase in human cervical 
epithelial cancer cell apoptosis is suggestive of increased cell loss and possibly tissue 
damage.  
 
Curiously, it was observed that, despite the drastic induction of apoptosis by EE, ABC+3T, 
ZDV+3TC, ABC+ZDV+3TC and ZDV+3TC+NVP did not significantly differ to the 
untreated control in their effects on the reduction of MTT.  This is suggestive of a cellular 
remodelling effect of EE and possibly regenerative hyperplasia. Treatment with LNG only 
demonstrates such non-proliferative difference upon co-administration with   
ABC+ZDV+3TC and ZDV+3TC+NVP. This suggests that the increased cytotoxic activity 
of LNG in combination with other regimens (ABC+3T, ZDV+3TC and d4T+3TC+NVP) 
does not positively impact on tissue regeneration through proliferation or compensatory 
hyperplasia but it rather results in increased human cervical cancer cell loss. Interestingly, 
at 2.0µg/ml, LNG showed antiproliferative activity with all drug combination, thus 













ANTIRETROVIRAL DRUG-INDUCED TRANSFORMATION OF U937 CELLS 
TO ADHERENT CELLS 
5.1.0. Introduction 
The increased use of highly active antiretroviral therapy (HAART) has resulted in  
dramatically increased survival of HIV-infected individuals. A downside of the success of 
antiretroviral therapy (ART) is the premature onset and increased risk of certain 
inflammatory age-related diseases associated with low levels of chronic immune activation 
(Hsu et al., 2013). Such activation is thought to contribute to what is described as serious 
non-AIDS events (SNAEs) (Mafuva and Morgan, 2016, Hsu and Sereti, 2013). SNAEs 
include malignancies, cardiovascular events, bone diseases as well as renal and hepatic 
diseases (Hsu and Sereti, 2013; Serrano-Villar et al., 2014;  Lapadula et al., 2015). HIV, 
microbial translocation, Hepatitis B virus (HBV) and Hepatitis C virus (HCV) may lead to 
immune activation (Hsu et al., 2013; Lapadula et al., 2013).  
 
HIV infection may result in a decline in CD4 T cells (immunodeficiency, hence directly 
contributing to SNAEs). Antiretroviral toxicities have also been suggested in direct 
contribution to SNAEs (Hsu et al., 2013). Blood monocytes contain CD4 molecules (Zhen 
et al., 2014). The expression of CD4 molecules in human monocytes enables the use of the 
CD4 count as a standard diagnosis in quantifying monocytes (Zhen et al., 2014; Filion et 
al., 1990). The normal CD4 cell count in a healthy individual ranges from 500-
1500cells/mm
3
. HIV infection results in CD4 levels below 500 cells/mm
3
. HAART 
treatment should be initiated as soon as one is diagnised as HIV
+
 (AIDSinfo, 2017). 
 
Acute myeloid leukaemia (AML) results from  an increased number  of myeloid cells 
whose maturation has been arrested, hence resulting in haematopoietic insufficiency (Le 
Dieu et al., 2009). Induction of differentiation in AML cells may provide an alternative 
therapeutic strategy (Meshkini et al., 2009, Parihar et al.,  2009). A number of compounds 
have been shown to differentiate AML cells towards granulocyte and/or macrophage 
morphology (Studzinski, 2001; Deng et al., 2014). In addition to differentiation, all-trans-
retinoic acid and phorbol 12-myristate 13-acetate (PMA) cause apoptosis in leukaemia 
cells (Meshkini et al., 2009). To this effect, PMA has found widespread use as a positive 
control in monocyte differentiation studies (Meshkini et al., 2009, Parihar et al.,  2009).  
There is paucity of information regarding the role of antiretroviral treatment on monocyte 
differentiation, as this may provide a therapeutic strategy for the cancer cells. An 
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introspection into this may provide a plausable explanation for SNAEs associated with 
antiretroviral therapy or the ARV potential anticancer activity envisaged in Chapter 4. 
 
The U937 cell line, a derivative of a histolytic lymphoma, is widely used in differentiation 
studies involving immune activation, such as monocyte conversion to macrophages and 
dentric cells. Differentiation can be induced by different stimuli  including PMA, other 
chemical compounds and hormones (Minafra et al., 2011; Song et al, 2015; Vrana et al., 
1999). PMA-dependent transformation of U937 cells is both concentration- and time-
dependent. U937 conversion into macrophages or dendritic cells in the presence of PMA is 
dependent on the in vitro micro-environment (Garcìa et al., 1999; Martinez & Gordon, 
2014; Studzinski, 2001). For example, Garcìa et al. (1999) demonstrated that in the 
presence of PMA, NF-kappa B (NFκB) proteins that regulate immune responses, 
inflamatory responses, cellular growth as well as apoptosis, U937 differentiation is 
inhibited. Similarly PU.1, a transcription protein containing oligonucleotides, inhibited 
differentiatiation (Garcìa et al., 1999). Whether or not combination ARVs elicit 
differentiation pathways requires further evaluation. Seeding densities have been shown to 
affect growth with cell counts below 2x10
4
/ml depicting poor cellular differentiation for 
HL60 cells (Studzinski, 2001). These observations demonstrate that variations in the in-





 cells/ml have been recommended for monocyte differentiation studies, 
although some other variations have been successful (Vrana et al., 1999; Studzinski, 2001). 
 
Macrophages are adherent cells that constitute a heterogenous group of cells associated 
with innate immunity. Hao et al. (1999) describe uncharacterised adherent cells derived 
from U937 as „macrophage-like‟ cells.  M1 macrophages eliminate pathogens, virus-
infected cells and cancer cells. These M1 macrophages are associated with reactive oxygen 
species (ROS) and inducible nitric oxide (iNOS) production (Housinkveld and van der 
Burg, 2011). M2 macrophages have been associated with tumour promotion. These M2 
macrophages polarise T cells, hence dampening immune response (Housinkveld and van 
der Burg, 2011; Martinez and Gordon, 2014). While classification of the transformed 
adherent cells by immunological methods is beyond the scope of this research, it is 
interesting to enquire into the ability of the transformed cells to produce reactive oxygen 
species. The present study evaluates the ability of antiretroviral transformed U937 cells to 
produce the superoxide anion (•O2
¯
). The superoxide anion has since been associated with 
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regulation of apoptosis,  proliferation and immune response  (Hancock et al., 2000;  Choi 
et al., 2006). 
 
Reactive oxygen species (ROS) are a heterogenous group that includes radicals such as the 
superoxide anion (•O2
¯
), hydroxyl radical (OH•) and nitric oxide (NO•). Non-radical ROS 
include hydrogen peroxide (H2O2), hydroxide ion (OH
–
), singlet oxygen (
1
O2) and peroxy 
nitrite (OONO
-
). ROS  can exhibit both intra- and extracellular messanger properties that 
include induction of apoptosis,  gene expression and cell signalling (Hancock et al., 2000; 
Vara and Pula, 2014). ROS  can regulate cell proliferation, cell differentiation and immune 
response (Hancock et al., 2000). The superoxide anion, together with other reactive oxygen 
species such as H2O2, has been predominantly asssociated with oxidative burst (Hancock et 
al., 2000, Choi et al., 2006). There should be physiological balances between reactive 
oxygen species produced as an immune response and their degradation. Superoxide 
dismutase (SOD) catalyses the following reaction: 
2(•O2
¯
) + 2H2O →2H2O2 + O2 
Catalase, a member of the glutathione peroxidases, then catalyses the following reaction: 
2H2O2 →2H2O + O2  
 
Respiratory burst, which is increased generation of reactive oxygen species, has been 
associated with NADPH-catalysed production of oxygen species by phagocytic cells. High 
ROS levels may lead to DNA damage and/or oxidative stress (Meshkini et al., 2009) thus 
possibly associated with SNAs. It has since been established that PMA-induced 
differentiation of U937 to macrophages results in increased nitroblue tetrazolium (NBT) 
reduction. To this effect, the modified colorimetric nitroblue tetrazolium (NBT) assay has 
been used to determine quantitatively the production of superoxide by phagocytic cells. 
This method is ideal for determination of even trace  amounts superoxide anions produced 
in monocytes and macrophages (Choi et al., 2006; Deng et al., 2014). 
 
U937 Differentiation can be induced by various agents that induce signal transduction 
pathways, such as hormones and PMA (Minafra et al., 2011; Song et al., 2015; Vrana et 
al., 1999). There are limited in vitro studies on single and combination antiretroviral-
induced  premonocyte differentiation into adherent cells. In this section, the role of single 
and combination antiretroviral treatment on U937 differentiation into adherent cells with 
„macrophage-like‟ characteristics and ultimately the effect of this drug treatment on the 
ability to reduce NBT was assessed.  
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5.1.1. Objectives of the chapter 
a. To evaluate the morphological changes on U937 cells after 72 h single and 
combination antiretroviral treatment. 
b. To evaluate single and combination ARV potential to transform premonocyte 
U937 cells into adherent cells following 72 h treatment. 
c. To measure the amount of intracellular superoxide anion produced duing 72 h 
treatment of adherent cells with single and combination antiretroviral treatment.   
5.2. Materials and methods 
5.2.1 Materials 
Cell culture medium (RPMI-1640 without phenol red) was purchased from Life 
Technologies (United Kingdom). Antiretroviral drugs [abacavir (ABC), lamivudine (3TC), 
nevirapine (NVP), stavudine (d4T) and zidovudine (ZDV)], nitroblue tetrazolium (NBT), 
penicillin-streptomycin, sodium pyruvate, dimethylsulfoxide (DMSO), superoxide 
dismutase, glutamine, charcoal-treated foetal bovine serum (FBS), 7ml Bijou bottles, and 
phorbol 12-myristate 13-acetate (PMA) were obtained from Sigma (United Kingdom). 
Twenty-four-well plates were purchased from Nunc Denmark. The U937 cell line was 
obtained courtesy of the University of East London tissue culture research laboratory. 
 
5.2.2 U937 cell culture and maintenance 
U937 cells  were grown in RPMI 1640 supplemented with 10% FBS,  2mM glutamine, 1% 
sodium pyruvate and 1% antibiotic solution with 10000U of penicillin and 10mg/ml 
streptomycin. The cells were incubated at 37
o
C and 5% atmospheric CO2. The suspended 
cells were split every 3 to 4 days. 
 
5.2.3 Cryopreservation of U937 cells 
The non-adherent U937 cells were transferred to a 15ml centrifuge tube. The cells were 
then spun at 1000 rpm for 5 min and the cells reconstituted by the freezing medium 
[complete medium supplemented with 5% (v/v) DMSO]. The supernatant was removed, 
cells re-suspended in 1ml of fresh freezing medium consisting of 5% DMSO and 20% FBS 
in RPMI-1640. The cells were transferred into a cryotube. They were stored overnight at -
80
o
C and transferred to liquid nitrogen. Upon resuscitation, up to 10 passages were used 






5.2.4 Transformation of U937 to adherent cells 
500µl of 2.0x10
5
cells/ml were seeded in 24-well plates. The cells were left for 24 h at 37
o
C 
and 5% CO2 to allow adaptation of cells to the environment. 500µl of 100µg/ml ABC, 
ZDV, d4T, 3TC and NVP were added thus bringing the final concentration in each well to 
50µg/ml and the total volume to 1.0ml. Conditioned medium was normalised to 0.25% 
(v/v) DMSO. The vehicle control consisted of conditioned medium normalised to 0.25% 
(v/v) DMSO. U937 cells were also treated with the following combinations of 
antiretroviral drugs: ABC+3C, ZDV+3TC, ABC+ZDV+3TC, ZDV+3TC+NVP and 
d4T+3TC+NVP. 500µl of medium with a final volume of 100µg/ml of each antiretroviral 
drug in the combination were added, thus bringing the final concentration of each drug to 
50µg/ml. The cells were seeded in triplicate for each drug combination. One well was used 
to determine the cell count in non-adherent (floating cells), while the second was used to 
determine the number of adherent cells using the trypan blue cell counting technique. The 
number of dead cells was also estimated concurrently in both adherent and non-adherent 
cells. The third served as a reserve in case of an error in processing one of the wells.  The 
cells were then incubated for 72 h and the number of adherent cells was estimated. The 
experiment was repeated three times (n=3). Morphological transformation was assessed  
using the EVOS
®
 inverted microscope (Method adapted with modification from Vrana et 
al., 1999). 
 
5.2.5 Non adherent and adherent cell estimation 
Suspended non-adherent cells (1.0ml) were collected from each treatment well after 72 h 
of treatment and transferred to a Bijou bottle. Each treatment well was washed twice with 
500µl of warm medium (37
o
C) and the medium transferred into a Bijou bottle. This 
brought the total volume of suspended cells to 2ml. The number of cells were estimated 
using the trypan blue method. To estimate adherent cells, suspended cells were removed 
and the wells washed twice with 500µl of warm PBS, which was decanted. 200µl of 
trypsin-EDTA were added and the plates were gently shaken. The plates were placed in an 
incubator for 2 minutes. 800µl of medium was added and the 1.0ml with detached cells 
added to a bijou bottle. The wells were washed again twice with 500µl of medium, thus 
bringing the total volume of cells in each Bijou bottle for each treatment to 2.0ml. The 






5.2.6 The trypan blue dye exclusion assay 
Adherent, floating and dead cells were determined by the trypan blue/haemocytometer 
method 72 h post treatment.  Dead cell count depicts the sum of dead cells derived from 
both adherent and floating cells. The percentage of adherent cells was calculated relative to 
the total live cell count. Briefly, under sterile conditions, 100µl of the suspended cells was 
added to a micro-tube and these were diluted with an equal volume of trypan blue. A 
moistened coverslip was slid backwards and forwards on the haemocytometer chamber 
until Newton‟s rings were seen on the coverslip.   Both sides of the chamber were filled 
with the suspended cells by capillary action. The cells were viewed under an EVOS
®
 
inverted microscope while being counted using a tally counter. The number of cells was 
multiplied by the dilution factor. The total cell count in each of the wells was estimated by 
multiplying the cell count by 2.0 ml (the total volume of the suspended cells in each well). 
 
5.2.7. Nitroblue tetrazolium assay procedure 
The assay procedure was adapted from Choi et al. (2006) with modifications as depicted in 
Deng et al. (2014) and Meshkini et al. (2009). Briefly, 2.0 x 10
5
 U937 cells were 
suspended in RPMI 1640 medium supplemented with 10% FBS and 10 000U of penicillin 
and 10mg/ml streptomycin (Sigma). 500µl per well of the suspended U937 cells were 
seeded in in a 24 well plate and incubated at 37
o
C and 5% CO2 for 24 hours. After 24 h 
incubation, 500µl of 100µg/ml of ABC, ZDV, d4T, 3TC and NVP were added in triplicate 
wells bringing the final concentration of each drug to 50µg/ml. Two sets of wells were 
treated with PMA at a final concentration of 10ng/ml so as to promote differentiation into 
macrophages. Untreated cells were exposed to medium only. The cells were then incubated 
at 37
o
C and 5% CO2 for 72 h. Concurrently, treatment with antiretroviral drug 
combinations, namely ABC+3TC, ZDV+3TC, ABC+ZDV+3TC, ZDV+3TC+NVP, 
d4T+3TC+NVP, was also carried out. 500µl of 2.0x10
5
cells/ml were seeded in 24-well 
plates. The plates were incubated for 24 h at 37
o
C and 5% CO2. 500µl of medium with a 
final volume of 100µg/ml of each antiretroviral drug in the combination were added thus 
bringing the final concentration of each drug to 50µg/ml. The treated cells were incubated 
for 72 h with morphological observations carried out after 24, 48 and finally 72 h.  
 
The medium and the suspended cells were aspirated. Suspended cells and the whole 
medium were removed and the cells washed once with PBS. The wells were incubated 
with 100µl of 2mg/ml NBT and 100µl of 600ng/ml PMA for 1 hour. One set of PMA 
transformed cells was treated with 100µl of 2mg/ml NBT, 600ng/ml of PMA and 30µg/ml 
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superoxide dismutase (SOD) to constitute the control. After incubation, the cells were 
washed twice with warm PBS, then once with methanol and air dried to ensure that 
extracellular NBT is completely removed. 120µl of 2Maq. KOH was added to solubilize 
cell membranes followed by addition of 140µl of DMSO to dissolve the blue formazan 
with gentle shaking for 10 minutes at room temperature. 100µl of the dissolved formazan 
was transferred from each of the triplicate wells to a 96-well plate and the absorbance read 
at 620nm (After: Choi et al., 2006 and Lin et al., 2014). To cater for differences in the total 
transformed cells, cell numbers were normalised and the relative absorbance compared per 
1.0x10
5
 (100 000) cells. 
 
5.2.8. Data Analysis 
Descriptive statistics were computed on Excel. The total number of viable cells (adherent + 
non-adherent) for each treatment was compared to vehicle treated cells using the unpaired 
t-test.  Differences between the control  and each of the the treatments for NBT assay were 




5.3.1 Morphology of antiretroviral- and PMA-treated cells 
Following 72 h of exposure to single antiretroviral treatment, the morphological 
appearance of the cultured cells was captured using an EVOS
®
 inverted microscope at 24 h 
intervals. After 24 h of treatment with 10ng/ml PMA, granule formation was depicted with 
trace amount of cells attached on the cell culture plates. After 48 h, the majority of the 
PMA treated cells were attached to the well plates. After 72 h, PMA-treated cells a typical 
appearance characterised by some lobular and spherical nuclei, vacuole-containing 
cytoplasm and were granulated (Figure 5.1). These cells were less dense and more sparsely 
distributed. The cell density on seeding was 0.2x10
6
 increasing to 0.37x10
6
 72 h post 
treatment, thus suggesting that the lower density of PMA-treated cells relative to the 
control is due to differentiation rather than cytotoxicity. The negative control group treated 
cells with medium only and the vehicle-treated cells (0.25% v/v DMSO) were 
undifferentiated,  characterised by round large nuclei with defined round and regular cell 
margins.  
 
Following ZDV treatment, attachment of some of the cells became apparent after 48 h and, 
by 72 h, there were a number of distinctly larger granulated attached cells with spherical 
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nuclei (Figure 5.2). A higher proportion of cells (86%) were adherent, with most assuming 
an amorphous and granular structure for  ZDV. The ZDV wells had more granulated cells 
than did d4T ABC, 3TC and NVP (Figure 5.3). By 72 h post-treatment, fewer granule-
containing cells were observed among ABC, 3TC and NVP treated cells. No apparent 
granulation was observed in the untreated cells. At 48 h post-treatment, combination-
treated cells with ABC+ZDV+3TC, ZDV+3TC+NVP and d4T+3TC+NVP began to attach 
on the culture plate while other cells remained in suspension. By 72 h post-treatment, the 
triple combination-treated cells appeared larger with dark granules and lobular nuclei 
(Figure 5.2). In comparison, very few granulated cells were observed among ABC+3TC 
and ZDV+3TC treated cells (Figure 5.3). Overall these observations show a time-
dependent induction of differentiation in U937-treated cells.  A high degree of granulation 
characterised with lobular nuclei was observed for ZDV only and triple combination 
(HAART)-treated cells (Figure 5.1). Fewer lobular nucleated and fewer granulated cells 























           
          
                                                                        
Fig 5.1: Morphological appearance of U937 cells over a 72 h treatment with PMA. Cells were 
treated with 10ng/ml PMA and incubated at 37
O
C and 5% CO2 for 72 h. The photographs 
were captured with an EVOS
®
 microscope after 24 h PMA treatment (a), 48 h PMA 
treatment  and 72h PMA treatment (c). Untreated cells were captured after 72 h treatment 
(d). The PMA-treated cells  decreased in density with time while untreated cells were more 
















                                                                               
            
         
Fig 5.2: Morphological appearance of cells after 72 h treatment with PMA, ZDV, d4T+3TC+NVP, 
ZDV+3TC+NVP  and ABC+ZDV+3TC.  Cells were treated with PMA or combination drugs at a 
final concentration of 50µg/ml for each drug and incubated at 37
O
C and 5% CO2 for 72 h. A high 
degree of granulation was observed for ZDV, d4T+3TC+NVP and  ZDV+3TC+NVP stimulated 
cells. ABC+ZDV+3TC  treatment  resulted in a mixture of granular and agranular cells. Arrows 
indicate typical transformed cells with some distinct granulated morphology and a lobular 






      
      
       
Fig 5.3: Morphological appearance of cells after 72 h treatment with d4T, 3TC, NVP,  ABC, 
ABC+3TC and ZDV+3TC. Cells were treated with single or combination drugs at a final 
concentration of 50µg/ml for each drug and incubated at 37
o
C and 5% CO2 for 72 h.   (a) cells 
treated with d4T do not depict obvious morphological difference from untreated cells in 
Figure 5.1. (b) cells treated with 3TC with some appearing darker as shown by arrows (c) 
Cells treated with NVP depicting small spherical cells without obvious morphological 
transformation characteristics. (d) cells treated with with ABC, arrows indicate lytic cells  (e) 
cells treated with ABC+3TC arrows indicate granular morphology  (d) ZDV+3TC treated 
cells with arrows depicting granular cells. The scale bars represent 100µm (After: Mafuva 






5.3.2 Transformation of  U937 cells to adherent cells 
Table 5.1 and Figure 5.4 present the descriptive statistics and graphical presentation for 
single drug-treated cells, respectively. The total number of viable cells for each treatment 
was compared to the total live cells in the vehicle-treated cells using the one-way ANOVA 
followed by Dunnett‟s multiple comparison test (P≤0.05). Adherence from single drug 
treatment was 3.2% for ABC, 86.0% for ZDV, 21.0% for lamivudine 3TC, 47.2% for dT4 
and 12.5% for NVP (Fig 5.4) (Mafuva and Morgan, 2016). The total cell counts for ZDV, 
3TC and d4T are lower than those for ABC and NVP (Table 5.1). However the number of 
dead cells is lower for ZDV (3.0x10
4
 cells), 3TC (3.0x10
4
 cells) and d4T (4.0x10
4
 cells) if 
compared to both ABC (9.0x10
4
 cells) and NVP (1.2x10
5
 cells). ZDV and 3TC dead cell 
counts estimates are similar to untreated cells control (3.0x10
4




Table 5.2 and Figure 5.5 present the descriptive statistics and graphical presentation for 
combination drug treatment, respectively. The total number of viable cells for each 
treatment was compared to the total live cells in the vehicle-treated cells using one-way 
ANOVA followed by Dunnett‟s post-test (P≤0.05). The percentage adherence was 13.5% 
for ABC+3TC, 7.9% for ZDV+3TC, 40.1% for ABC+ZDV+3TC, 42.1% for 
ZDV+3TC+NVP and 39.9% for d4T+3TC+NVP (Mafuva and Morgan, 2016). The 
number of dead cells was higher in all 5-combination treatments when compared to 
untreated and DMSO vehicle-treated cells. Overall, the number of dead cells is lower for 
triple combination-treated U937 cells (ABC+ZDV+3TC=9.0X10
4
 cells and 
d4T+3TC+NVP=8.0X10
4 
cells), compared to the double combinations ABC+3TC and 




 dead cells respectively. On the contrary, 
ZDV+3TC+NVP result in increased cell death (1.9x10
5










Table 5.1 Descriptive statistics for U937 cells pre-treated with single antiretroviral drugs 
U937 cells were treated with 10ng/ml PMA as the positive control (+ve) or treated with single 
antiretroviral drugs or left untreated (-ve) for 72 h. Total live cells represent the sum of 
adherent and non-adherent cells for each individual treatment. The numbers represent the 
estimated total cell count (mean ± SD, n=3) (After: Mafuva and Morgan, 2016) 
 
Fig 5.4: Differential conversion of U937 to adherent cells by single antiretroviral treatment. 
U937 cells were treated with 10ng/ml PMA as the positive control (+ve), single antiretroviral 
drugs, or left untreated (negative control) for 72 h. Vehicle cells or treated with 0.25% DMSO 
for 72 h. The numbers represent the estimated cell count (mean ± SD, n=3). The total number 
of viable cells (adherent + non-adherent) for each treatment was compared to vehicle treated 
cells by the one-way ANOVA followed by the Dunnett’s multiple comparison. Data that are 
statistically significant are indicated by a, b, and c where, (a<0.05, b<0.01, c<0.001) (After: 
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0.00 0.00 89.19 3.16 86.03 21.05 47.22 12.50 
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Table 5.2 Descriptive statistics for U937 cells pre-treated with combination ARDs. 
U937 cells were treated with 10ng/ml PMA as the positive control (+ve) or treated with 
combination antiretroviral drugs or left untreated (-ve) for 72 h. Total live cells represent the 
sum of adherent and non-adherent cells for each individual treatment. The numbers 
represent the estimated total cell count (mean ± SD, n=3) (After: Mafuva and Morgan, 2006 ) 
 
Fig 5.5: Differential conversion of U937 to adherent cells by combination antiretroviral 
treatment. U937 cells were treated with 10ng/ml PMA as the positive control (+ve), 
combination antiretroviral drugs, or left untreated (negative control) for 72 h. Vehicle cells 
were treated with 0.25% DMSO (w/v) for 72 h. The numbers represent the estimated cell 
count (mean ± SD, n=3). The total number of viable cells (adherent + non-adherent) for each 
treatment was compared to vehicle treated cells using the one-way ANOVA followed by the 
Dunnett’s multiple comparison. Data that are statistically significant are indicated by a, b, 






















































































































0.00 0.00 83.33 12.95 7.89 40.11 42.07 39.89 
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5.3.3 NBT reduction assay for the superoxide anion determination 
The NBT reduction assay was carried out after 72 h of  treating U937 cells with single and 
combination antiretrovirals and compared to vehicle treated (control) cells. Comparison of 
means between the negative control and different treatments was done using one-way 
ANOVA followed by Dunnet‟s multicomparison test (α=0.05). For single drug treatment, 
ZDV- and PMA-treated cells differed significantly compared to the negative control 
(Figure 5.6a). This  demonstrates a corresponding increase in production of superoxide for 
ZDV-treated cells. Cognisant of the impact of differences in transformed cells, cell 
numbers were normalised and the relative absorbance compared per 1.0x10
5
 (100 000) 
cells. This was deduced from the adherent cell numbers shown in Table 5.1 compared to 
the the absorbances summarised in Figure 5:5a. Curiously, it was shown that ABC, 3TC 
and NVP had higher relative absorbances per 1.0x10
5
  cells compared to ZDV, despite 
ZDV inducing a higher percentage of transformed cells. The ability of ABC-treated cells to 
reduce NBT was even higher per 1.0x10
5



















































































































Fig 5.6:  Effect of single antiretroviral treatment on U937 superoxide anion production.  (a) 
Differential ability to reduce NBT of U937 cells treated with 50µg/ml of each single 
antiretroviral drug and left for 72 h. Data were analysed by the unpaired t-test (mean ± SD, 
n=3). Asterisks (*) indicate data that are significantly different compared to the negative 
control (*P<0.01, ** P< 0,001, **P<0.0001). (b) Absorbance of the single ARV-treated cells 
standardised to 1.0x10
5













)  (b) 
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Following combination ARV treatment, significant differences from the control were 
observed for ABC+ZDV+3TC-, ZDV+3TC+NVP- and 4T+3TC+NVP-treated cells 
(Figure 5.6a), thus depicting increased •O2
¯
 production in treated cells. There were no 
differences obtained for ABC+3TC and ZDV+3TC cells and the negative control. The 
relative absorbances for the different combination-treated cells were standardised and 
compared per 1.0x10
5
 (100 000) cells. This was calculated from the adherent cell numbers 
shown in Table 5.2 against the absorbances shown in Figure 5:6a. It was shown that 
ABC+3TC and ZDV+3TC had higher relative absorbances per 1.0x10
5
 cells, compared to 
triple combinations, despite the triple combinations having an overall cumulative increase 



















































































































































































Fig 5.7: Effect of combination antiretroviral treatment on U937 superoxide anion production.  
(a) Differential ability to reduce NBT of U937 cells treated with 50µg/ml of each drug in 
combination for 72 h. The cells were treated with combination antiretroviral drugs and 
incubated at 5% CO2 and 37
o
C. Data were analysed by one-way ANOVA followed by 
Dunnett’s multiple comparison test (α=0.05). Data (means ± SD, n=3), indicate data that are 
significantly different compared to the negative control (*P≤0.001, ** P≤0,0001). (b) 
Absorbance of combination ARV-treated cells standardised to 1.0 x 10
5














Hasegawa et al. (2009) demonstrated that peripheral monocyte turnover associated with 
tissue macrophage death correlates with AIDS progression.The present study demonstrates 
the varied transformation potential of single and combination antiretroviral drugs on U937 
cells to adherent cells with „macrophage-like‟ morphology. Furthermore, evaluation of the 
ability to reduce NBT demonstrates the discordance between transformation efficiency and 
•O2
¯ 
generation. Although the pathogenesis of SNAEs remains obscure, antiretroviral 
toxicities have been suggested as causative among other factors. A reduced use of ZDV 
and d4T has previously been suggested cognisant of their recently perceived toxic effects 
(Housinkveld and van der Burg, 2011). As a result, the WHO guidelines of 2010 suggest a 
gradual withdrawal of d4T in combination regimens. Following 72 h treatment of cells 
with 10ng/ml of PMA, the cells were less sparsely distributed. 2x10
5
 cells were seeded in 
each well at the start of the experiment. For single drug treatment, 72 h post PMA 
treatment there were 3.7x10
5
 live cells (adherent and non-adherent), a number higher than 
the initially seeded cells. However, this cell count was far much lower than vehicle-treated 
cell count (1.98x10
6
 cells). Cognisant of the observed granular morphology, this suggests 
lack of proliferation as the cells differentiate (Perihar et al., 2009). The positve control thus 
miatains a low total cell count because the cells are predominantly differentiating rather 
than proliferating.   
Although the total cell counts for ZDV, 3TC and d4T are lower than that for ABC and 
NVP. A lower number of dead cells for ZDV (3.0x10
4
 cells), 3TC (3.0x10
4
 cells) and d4T 
(4.0x10
4
 cells) if compared to both ABC (9.0x10
4
 cells) and NVP (1.2x10
5
 cells) was 
observed. Interestingly, ZDV and 3TC dead cell counts estimates are similar to untreated 
cells control (3.0x10
4
 cells) and 0.25% DMSO-treated cells (3.0x10
4
 cells), hence 
suggesting that the lower cell count is predominantly due to differentiation rather than 
toxicity. Higher numbers of dead cells for ABC (0.9x10
4
) and NVP (1.2x10
5
) are 
suggestive of increased toxicity. Overall, triple combinations result in a lower number of 
dead cells 72 h post-treatment with triple ARV combinations relative to double 
combination-treated cells (Table 5.2). The exception to this phenomenal observation is 
ZDV+3TC+NVP, which results in higher dead cells relative to ZDV+3TC (Table 5). 
Coupled with morphological and higher  percentages of adherent cells, these observations 
suggest that overall triple combination antiretroviral therapy has reduced cytotoxicity and 
higher transformation potential, compared to single and double ARV-treated cells.  
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Interestingly, the present results demonstrate the highest transformation of U937 cells upon 





 cells is higher for ABC, despite it having the least transforming potential. 
Similarly, triple combinations of drugs showed a higher transformation potential but less 
•O2
¯
 production per 1.0x10
5
 cells compared to ABC+3TC and ZDV+3TC. These 
observations suggest that toxicity is generally higher per cell for single- and double-
combination-treated cells, despite the higher transformation potential into macrophage-like 
cells in triple combination-treated cells. The cumulative increased production of •O2
¯
 by 
the triple combination-treated U937 cells is of interest. This is not unusual for transformed 
U937 cells, as differential production of reactive oxygen species has been reported for 
PMA-transformed U937 cells (Choi et al., 2006; Meshkini et al., 2009). The present results 
demonstrate an increased accumulation of superoxide anion in myoloid cancer cells. This 
increased •O2
¯
 generation suggests an inflammatory response, as ROS generation has been 
associated with removal of cancer cells and immune response ( Hancock et al, 2001; Held, 
2015; Choi et al., 2006).  M1 macrophages have been less associated with elimination of 
pathogens, virus-infected cells and cancer cells as well as generation of reactive oxygen 
species. On the contrary, M2 macrophages have been associated with tumour promotion 
(Housinkveld and van der Burg, 2011; Martinez  and Gordon, 2014). 
A number of factors have been reported to influence the transformation of U937 cells to 
adherent cells. Firstly, it has been established that transformation by PMA is dose-
dependent (Garcìa et al., 1999; Martinez & Gordon, 2014; Studzinski, 2001). Here, only 
concentrations of 50µg/ml were used to treat the cells, as this concentration falls within the 
EC15-EC20 for each drug as optimised in Chapter 2 on HeLa cells. Secondly, monocyte 
transformation is also time-dependent (Deng et al., 2014; Garcìa et al., 1999). U937 
transformation has been reported following 96 h or more treatment time with a variety of 
stimulants (Lin et al., 2014). Similarly, variations of the cell culture medium with time 
may affect cell growth and differentiation (Meshkini et al., 2009). While ZDV and dT4 
show significant differences compared to untreated cells, the standard absorbance per 
1.0x10
5
 cells is lower for ZDV compared to the negative control. This shows a reduced 
superoxide production per unit cell, thus demonstrating that the increased superoxide 
production is due to the cumulative effect from many cells. Interestingly, the percentage 
standardised absorbances for ABC, NVP and 3TC are higher or closer to the positive 
control, thus suggesting an increased superoxide production per unit cell, thus 
demonstrating that the increased superoxide production is due to the cumulative effect of 
all cells. The surface area on which cells adhere may be a limiting factor in rapidly 
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multiplying cells. As cells multiply and cover the whole surfaces of 24-well plates, some 
cells may become clustered as the surface becomes limiting, hence affecting adhesion of 
the cells. 
Low dead cell counts associated with a reduced viable cell count have been associated with 
cell cycle arrest (Koczor et al., 2009). The results in Fig 5.4 show an increased number of 
dead cells for ABC (0.9x10
5
 cells) and NVP (1.20x10
5
 cells) thus suggesting cytotoxic 
activity if compared to untreated cells (0.4x10
5
 cells) and DMSO vehicle-treated cells 
(0.3x10
5
) cells. On the contrary, ZDV (0.3x10
5
 cells), 3TC (0.3x10
5
 cells) and d4T 
(0.4x10
5
) have fewer dead cells, although they present an overall decrease in cell count. 
This is suggestive of the cytotoxic effects of the drugs. Similarly, for combination drug 
treatment ABC+3TC (1.1x10
5
 cells) ZDV+3TC (2.1x10
5




cells) and d4T+3TC+NVP (0.8x10
5
 cells) are higher in 
total dead cell count,  compared to the untreated control (0.3x10
5
 cells) and NVP vehicle 
treated  (0.3x10
5
 cells). These observations suggest an antiproliferative effect resulting 
from combination ARV stimulation.  
Overall, compared to other treatments, ZDV and triple combinations were shown to 
transform higher percentages of U937 monocytes to  adherent cells with a corresponding 
high cumulative •O2
¯
 generation potential. In the present study, the transformed cells were 
not immunologically characterised with markers such as IL6 (a marker for tumour 
progression) IL10 (a marker for anticancer macrophage) and CD14 (a marker for monocyte 
transformation into macrophage). Such characterisation could help to determine whether 
each transformation is associated with either M1 or M2 macrophage-like cells. The present 
observations also demonstrate that antiretroviral drug treatment induces differential 
generation of reactive oxygen species in U937 cells. Cognisant of the anticancer and 
antiinflamatory responses associated with macrophages that generate reactive oxygen 
species, the present results suggest the anticancer activity of ZDV and triple combination 
antiretroviral-derived macrophages. 
Previously in Chapter 3, time-dependent genotoxic DNA strand breakage was 
demonstrated in both CHO and HeLa cells following treatment with single NRTIs (ABC, 
3TC, d4T and ZDV), as well as NVP. The present results demonstrate an increased 
superoxide anion production for standardised U937 cells after treatment with ABC,3TC 
and NVP (Figure 5.6b). This is suggestive of ROS and oxidative stress-dependent toxicity 
leading to the observed antiproliferative activity of these single drugs. ZDV treatment 
depicts a transformation-dependent antiproliferative effect, as demonstrated by the 
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accumulation of  transformed (adherent) cells relative to non-adherent cells  72 h post-
treatment (Figure 5.4). Interestingly, these ZDV-transformed cells cumulatively produce a 
significantly high amount of superoxide anion compared to the control (Figure 5.6a).  
Interestingly, as depicted in Figure 5.7, HAART increases production of superoxide anion  
compared to the control. As depicted in Figure 5.5, ZDV+3TC+NVP (42.1%) suggest both 
cytotoxic and transformation-dependent antiproliferative activity, as shown by a high 
number of dead cells (0.19x10
6
) and a high percentage of transformed cells. The high 
percentage of transformed cells observed with ABC+ZDV+3TC (40.11%) and 
d4T+3TC+NVP (39.89%) is suggestive of the therapeutic effect of HAART on 
haematopoietic malignancies. Apart from the triple HAART combinations, ABC+3TC and 
ZDV+3TC are double combinations which are also widely used for HIV treatment in low-
resource settings in patients presenting with other medical conditions. The present results 
demonstrate a lower transformation potential (of U937 cells from non-adherent to 
adherent) of double ARV combination administration compared to  HAART. The relative 
percentage of transformed cells for both double and triple combination cells is less than 
that for PMA-treated cells and this is coupled by a higher number of live cells relative to 
the latter. This suggests that the rate of transformation is lower in the combination ARV-
treated cells relative to PMA treated cells. Lin et al. (2014) demonstrated that, depending 
on the substrate used for stimulation, U937 differentiation may take up to 96 h or more.  
5.4.2 Conclusion 
The present observations indicate the varied potential of ARVs to induce U937 cell 
transformation into adherent cells with „macrophage-like‟ characteristics. Overall, our 
results demonstrate that highly active antiretroviral therapy can transform U937 cells into 
adherent cells whose cumulative production of superoxide anion significantly differs to the 
untreated control. Highly active antiretroviral treatment transformed premonocyte 
lymphoma cells (U937) to monocyte/macrophage-like morphology characterised by an 
increase in superoxide anion production.  If replicated in vivo, this could go some way in 
explaining the SNAEs recognised with long-term HAART (Mafuva and Morgan, 2016). In 
the previous chapter, we demonstrated the beneficial effects of optimum apoptosis 
induction in human cervical cancer cells by triple antiretroviral combinations. In this 
chapter, it has been shown that triple ARV combination treatment of U937 cells results in 
microenvironmental increase in superoxide anion production; these joint observations 
suggest the beneficial effect of highly active antiretroviral therapy on apoptosis induction 
in cancer cells. MI macrophages attract cells of the adaptive immunity in response to 
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signals from bacteria and IFNγ (Housinkveld and van der Burg, 2011). These cells are 
associated with expression of reactive oxygen species (ROS), inducible nitric oxide 
synthatase (iNOS) and activation of Natural Killer cells, hence these are associated with 
inflammatory response (Martinez and Gordon, 2014). These observations further suggest 
endogenous stimulation of apoptosis in human cervical epithelial cells cells due to 
genotoxic effect of single antiretroviral treatment associated with intracellular oxidative 
stress (Elmore 2007; Rastogi and Sinha, 2009), hence resulting in programmed removal of 
damaged cells. This may suggest the further need to  characterise the apoptotic pathways 
attributable to both single and combination treatments associated with antiretroviral drug-
































THESIS CONCLUSION AND FUTURE DIRECTIONS 
6.1.0. Overall conclusion 
AIDS-associated cancers present an emerging challenge in cancer epidemiology (Engels et 
al., 2006; Phatak et al., 2010). The present results demonstrate the differential ability of 
antiretroviral drugs in induction of apoptosis and their effect on cervical epithelial cancer 
cell viability. This study has also shown the varied effects of contraceptive hormones 
(ethinylestradiol and levonorgestrel) on cervical cancer cell viability and apoptosis if co-
administered with antiretroviral drugs. The main findings with reference to the research 
questions of the present study are summarised in Table 6.1. The themes of the summary 
tables are derived from the research questions that were outlined in chapter 1. Since 
combination antiretroviral treatment is the recommended method of treatment, the main 


























Table 6.1: Overall summary of major findings from the study 
Mild or non-significant changes are shown by (-), while (+) indicates significant changes. 
(++) indicates more drastic changes in the investigated parameter. 
 
Antiproliferative effect 















ZDV+3TC+LNG + + + 
ABC+ZDV+3TC+LNG - + - 
ZDV+3TC+NVP+LNG ++ ++ - 
d4T+3TC+NVP+LNG + ++ + 
    
Antiproliferative effect of 
EE on HeLa cells 
   0.5µg/ml      1.0µg/ml 2.0µg/ml 
 
   
ABC+3TC+EE - - + 
ZDV+3TC+EE - - + 
ABC+ZDV+3TC+EE - - - 
ZDV+3TC+NVP+EE - - - 
d4T+3TC+NVP+EE + - - 
 
   
Genotoxic effect of ARVs on 
HeLa  cells 
1 h 2 h 4 h 
    
ABC + + ++ 
ZDV + + ++ 
3TC + + ++ 
d4T + + ++ 
NVP + + ++ 
    
Effect of hormones on HeLa 
cell drug-induced apoptosis 






















ZDV+3TC+NVP              - ++ ++ 
d4T+3TC+NVP + ++ + 
    






    
PMA treated ++ ++ ++ 
ABC+3TC - - - 
ZDV+3TC - - + 
ABC+ZDV+3TC + + + 
ZDV+3TC+NVP + ++ + 
d4T+3TC+NVP + + + 
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6.1.1. Genotoxic and apoptotic effect of antiretroviral treatment on human cervical 
epithelial cancer cells 
The present study has demonstrated that 50µg/ml of the NRTIs (ABC, ZDV, 3TC and 
d4T) and NVP (a NNRTI) induce time-dependent DNA strand breakages in CHO and 
HeLa cells.  Single ARD treatment of HeLa cells with these NRTIs and NVP drastically 
increase apoptosis, compared to untreated cells. This is suggestive of apoptotic activation 
response via the intrinsic stimuli of mitochondrial apoptotic pathway following genotoxic 
stress (Czabotar et al., 2014; Youle and Strasser, 2008). Co-administration with 4.0µg/ml 
LNG shows no effect on ABC-induced apoptosis. Co-administration with 0.5µg/ml EE 
gradually reduces ABC- and d4T-induced apoptosis while it has no effect on ZDV, 3TC 
and NVP-induced apoptosis. However, in all cases, the rate of apoptosis remains higher 
than untreated cells. This too-drastic apoptosis induction by single ARV treatment is 
indicative of a higher degree of toxicity. Single-drug antiretroviral therapy has been 
gradually replaced with HAART, due to the pathophysiological conditions resulting from 
emergence of resistant mutants (WHO, 2010; BHIVA, 2008). In the present study, single 
antiretroviral drug administration was thus carried out to understand the mechanistic 
differences when compared to combination antiretroviral therapy which is the 
recommended in present-day antiretroviral treatment. 
 
In the absence of hormones, the regimen ZDV+3TC+NVP does not significantly change 
the rate of apoptosis, if compared to untreated control cells.  However, the 72 h MTT assay 
for treatment with ZDV+3TC+NVP shows a decrease in HeLa cell viability. This suggests 
that this antiproliferative effect observed with ZDV+3TC+NVP treatment of HeLa cells is 
predominantly due to inhibition of growth relative to untreated cells, since decrease in 
reduction of MTT is an indicator of cell death and/or proliferation inhibition (Sieuwerts et 
al., 1995; Sylvester 2011; van Meerloo et al., 2011; Shi et al., 2012).  This in vitro 
observation concurs with some epidemiological observations, suggesting no effect of 
HAART on neoplastic progression (Ezechi et al., 2014; Shrestha et al., 2010; Sirera et al., 
2008). ABC+ZDV+3TC and d4T+3TC+NVP significantly changed the rate of HeLa 
apoptosis compared to untreated control cells (P≤0.05), with the overall rate of apoptosis 
below 20%. This plausibly explains the epidemiological observations of a decrease in 
cervical neoplastic transformation and reduced cancer cell proliferation among some 
patients undergoing HAART (Adler et al., 2012; Firnhaber et al., 2012;  Omar et al., 2011; 
Chen et al., 2014; Minkoff et al., 2010). Similarly the double combinations ABC+3TC and 
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ZDV+3TC depict an increase in apoptosis relative to untreated cells thus suggesting 
antiproliferative activity on the HeLa cells. 
 
6.1.2 Effect of combination ARV co-administration with contraceptive hormones on 
HeLa cell proliferation. 
In this study, lone administration of combination antiretroviral drugs has been shown to 
induce optimal rates of apoptosis associated with decreased proliferation of the human 
cervical epithelial cancer cell. The contrary has been shown to occur upon co-
administration of contraceptive hormones (0.5µg/ml EE and 4.0µg/ml LNG) which 
drastically increase the rate of apoptosis. This present study has, however, shown that 
drastic induction of apoptosis by EE in ABC+3TC, ZDV+3TC, ABC+ZDV+3TC and 
ZDV+3TC+NVP did not cause a significant alteration in the viability of cells compared to 
normal cells, as shown by the MTT assay. These results suggest cellular regeneration, 
since induction of apoptosis does not necessarily imply inhibition of remodelling (Shi et 
al., 2012). In both normal and cervical cancer cells (HT3 and Caski), 17β-Oestradiol 
induces anti-apoptotic effects by attenuation of caspases-9 and terminal caspases-3 activity 
(Wang et al., 2004). Here, ethinylestradiol (a derivative of 17β-oestradiol) has been shown 
not to alter cell viability in MTT assay on combination antiretroviral-treated cells, thus 
suggesting a cellular remodelling effect of EE.  
 
4.0µg/ml LNG gives MTT results suggesting such cellular regeneration for the regimen 
ABC+ZDV+3TC only, while depicting antiproliferative activity for all other combination 
regimens (ABC+3TC, ZDV+3TC, d4T+3TC+NVP and ZDV+3TC+NVP). This therefore 
shows an antiproliferative effect of 4.0µg/ml LNG in human cervical epithelial cancer 
cells. While present results show too-drastic apoptosis with 4.0µg/ml LNG, the main focus 
in Public Health becomes to use optimum concentrations of LNG which induce optimal 
apoptosis rather than too drastic apoptosis.  The levonorgestrel intra-uterine system (LNG-
IUS) has since been shown to induce regression of complex endometrial hyperplasia 
(Wildemeersch et al., 2015; Haoula et al., 2011; Zhao et al., 2015). LNG-IUS down-
regulates expression of PRA, PRB, ER-α and ER-β (Vereide et al., 2006; Gomes et al., 
2009). Complex atypical hyperplasia was also shown to decrease after progestin therapy 
(Gunderson et al., 2014; Kudesia et al., 2014). The present results depict the synergistic 
antiproliferative effect of 4.0µg/ml LNG on the HeLa cell in the presence of combination 
antiretroviral drugs. although the rate of apoptosis appears too drastic, thus suggestive of 




HAART-induced apoptosis in HeLa cells is drastically increased with levonorgestrel and 
ethinylestradiol co-treatment for ABC+ZDV+3TC, ZDV+3TC+NVP and d4T+3TC+NVP 
treated cells. This increased toxicity upon co-administration of hormonal contraceptives is 
suggestive of increased tissue causality effect on cervical intraepithelial neoplasia 
progression or other serious non-AIDS events observed with some cohort studies 
correlating HAART to CIN progression (Lillo et al., 2001; McKenzie et al., 2011). 
Overall, there is too-drastic apoptosis for single antiretroviral treatment, compared to 
combination antiretroviral treatment, thereby concurring with the concept that multi-drug 
therapy is less toxic in small combination doses while at the same time exhibiting a high 
therapeutic effect. One would envisage a need for further toxicity research on nucleoside 
reverse transcriptase inhibitor combinations with protease inhibitors, since such regimens 
have also found widespread use. This may help to identify less toxic, hence ideal, HAART 
regimens for hormonal contraceptive users. 
 
Overall, the present results predominantly indicate the proliferative effect of 0.5µg/ml EE 
upon co-administering with combination antiretroviral drugs; the present results concur 
with other studies suggesting the cellular re-modelling effect of oestrogens on cancer cells. 
This is typified by Mosli et al. (2013) who demonstrated that in vitro exposure of non-
transformed prostate epithelial cells (BPH-1) to catechol oestrogens (CEs) had a neoplastic 
effect. Further related studies have shown that oestrogen has proliferative effects in normal 
and MCF-7 breast cancer cells (Scaling et al., 2014; Pesiri et al., 2015). G protein-coupled 
estrogen receptor (GPER), previously known as GPR30, modulates breast cancer 
proliferation downwards. In MC7 10A cells, oestrogen stimulation in the presence of 
GPER-selective agonist G-1 was shown to increase the mitogenic index (Scaling et al., 
2014). 
 
On the other hand, the antiproliferative effect of LNG suggests the non-neoplastic effect of 
its co-administration with combination antiretroviral drugs. Such protective effect has also 
been substantiated by other studies on progestogen-based hormones. Zhao et al. (2015) 
have shown that LNG inhibits human endometrial stromal cell (HESC) and human 
endometrial glandular cell (HEGC) proliferation while inducing apoptosis in both cell 
lines. The levonorgestrel intra-uterine system (LNG-IUS) has since been shown to induce 
regression of complex endometrial hyperplasia (Wildemeersch et al., 2015; Haoula et al., 
2011; Zhao et al., 2015). Complex atypical hyperplasia was also shown to decrease after 
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progestin therapy (Gunderson et al., 2014; Kudesia et al., 2014). Women with complex 
atypical hyperplasia (CAH) and endometrial carcinoma had a response of about 65% upon 
receiving progestin-only treatment (Gunderson et al., 2014). 
 
It is important to investigate the role of other different hormonal contraceptives on human 
cervical epithelial cancer cell proliferation. This is in view of contradictory findings 
depicting the antiproliferative effect of some oestrogens and the proliferative effect of 
progestins. For example, Mazzucco et al (2006) demonstrated that dual receptor activation 
of ERα and ERβ showed reduced cell proliferation, thus suggesting that ERα and ERβ 
modulate each other‟s activity. Two isoforms of progesterone receptor (PR), namely 
progesterone receptor-A (PRA) and progesterone receptor-B (PRB), are associated with 
endometrial differentiation (Vereide et al., 2006). Deregulation of either of the genes has 
been associated with carcinogenesis of the endometrium and progestin therapy failure 
(Gunderson et al., 2014; Kudesia et al., 2014, Vereide et al., 2006). Whether or not 
antiretroviral drug induction of apoptosis is influenced by co-administration of different 
contraceptive hormones may be fascinating. Such investigative screening may provide a 
safe choice of contraception that is dependent on the HAART drug combination. 
 
6.1.3 Apoptosis-induced cellular regeneration 
In the present study, it was observed that, despite the drastic induction of apoptosis by 
0.5µg/ml EE, ABC+3T, ZDV+3TC, ABC+ZDV+3TC and ZDV+3TC+NVP did not 
significantly differ to the untreated control in their ability to reduce MTT. This is 
suggestive of apoptosis-induced remodelling and possibly regenerative hyperplasia. LNG 
only depicted such non-proliferative difference upon co-administration only with the 
regimen ABC+ZDV+3TC. These results concur with the concept that that cell death by 
apoptosis does not necessarily imply inhibition of remodelling (Fan and Bergmann, 2008a; 
Ryoo et al., 2004; Ryoo and Bergmann, 2012; Shi et al., 2012).  Studies in Drosophila 
have shown two types of apoptosis related cellular regeneration. It has been shown that 
proapoptotic proteins can induce proliferation of adjacent cells through a process known as 
compensatory proliferation (CP) so as to regenerate cells (Ryoo and Bergmann, 2012; Fan 
and Bergmann, 2008b; Ryoo et al., 2004). CP requires cell death-inducing genes, mainly 
coding for caspases. As such our present results suggest cellular remodelling, despite the 




Mosli et al. (2013) and Mazzucco et al. (2006) concur that, in addition to the genomic 
pathway, there is evidence that a non-genomic signalling pathway via ERs contributes to 
cell proliferation. This is evidenced by oestradiol-dependent cellular proliferation, which is 
mediated through ERα control of gene transcription and kinase activation (Pesiri et al., 




 are located within the ERα 
ligand-binding domain and contribute to E2-induced proliferation, although the mechanism 
of their action has not been fully elucidated (Pesiri et al., 2015). Likewise, other 
independent research has also evidenced that oestrogen has proliferative effects in normal 
and MCF-7 breast cancer cells (Scaling et al., 2014; Pesiri et al., 2015). The present in 
vitro experimental conditions could have interfered with the proliferative rates of 
ethinylestradiol-treated cells, since significant cellular proliferation was not observed. 
Instead, suggestive observations for cellular regeneration are of interest. 
 
Apoptosis-induced cellular proliferation could plausibly explain the observed non-
significant MTT difference of proliferative rates in 0.5µg/ml EE-treated HeLa cells 
compared to untreated cells. In Drosophila, the initiator caspase Dronc initiates 
compensatory proliferation following death signals, for example from irradiation. This 
process induces compensatory proliferation in neighbouring cells through secretion of 
mitogens (Ryoo and Bergmann, 2012). In these circumstances, apoptosis is initiated but 
subsequently inhibited by Hedgehog signaling, hence leading to arrest of cell death (Fan 
and Bergmann, 2008a; Ryoo and Bergmann, 2012). In higher-level organisms, the 
equivalents of Dronc are initiator caspases -8, -9 and -10 which mimic the former in their 
supposed action in CP (Fan and Bergmann, 2008; Ryoo et al., 2004). This pathway is also 
known as the effector caspase-independent pathway (Ryoo and Bergmann, 2012). In the 
alternative pathway of CP, the effector caspase equivalent, DrICE triggers Hedgehog (Hh) 
signalling for compensatory proliferation. Alternatively, this is referred to as the effector 
caspase-dependent pathway of CP (Fan and Bergmann, 2008(a); Ryoo and Bergmann, 
2012).  
 
In higher level organisms, equivalents of DrICE are effector caspases -3, -6 and -7 (Fan 
and Bergmann, 2008a; Fan and Bergmann, 2008b; Ryoo et al., 2004). It has since been 
demonstrated that 17β-oestradiol attenuates caspase-9 and terminal caspase-3 activity in its 
antiapoptotic effects (Wang et al., 2004), a possible mechanism through which 0.5µg/ml 
EE also results in the currently observed regenerative proliferation.  It has since been 
suggested that cervical cancer is a hormone-dependent tumour that may be stimulated by 
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oestrogens (Practice Committee of American Society for Reproductive Health, 2008; 
Jiang et al., 2016). Regenerative hyperplasia has been associated with apoptosis dependent 
regeneration of lost cells (Ryoo and Bergmann, 2012). Co-administration of ABC+3T, 
ZDV+3TC, ABC+ZDV+3TC and ZDV+3TC+NVP with EE and co-administration of 
ABC+ZDV+3TC with LNG treated cells are thus suggestive of increased loss of cells and 
possibly tissue damage due to regenerative hyperplasia. Otherwise, if effector caspase-
dependent apoptosis is within the optimal levels (not too drastic), it is beneficial in its role 
of eliminating damaged cells and replacing them with a healthy progeny (Ryoo and 
Bergmann, 2012). 
 
6.1.4. Transformation of pre-monocyte U937 to adherent cells 
Results from this study demonstrate that highly active antiretroviral therapy can transform 
U937 cells into adherent cells whose cumulative production of superoxide anion 
significantly differs to the untreated control. Highly active antiretroviral treatment 
transformed premonocyte lymphoma cells (U937) to monocyte/macrophage-like 
morphology characterised by an increase in superoxide anion production. MI macrophages 
attract cells of the adaptive immunity in response to signals from bacteria and IFNγ 
(Housinkveld and van der Burg, 2011). These cells are associated with expression of 
reactive oxygen species (ROS), inducible nitric oxide synthatase (iNOS) and activation of 
Natural Killer cells, hence these are associated with inflammation response (Martinez and 
Gordon, 2014). In previous chapters, it was demonstrated that these U937-transforming 
HAART regimens (ABC+3TC+NVP, ZDV+3TC+NVP and d4T+3TC+NVP) play a role 
in cervical cancer cell apoptosis. These joint observations demonstrate the anticancer 
activity of the triple antiretroviral combinations ABC+3TC+NVP and d4T+3TC+NVP. 
The antiapoptotic effect of ZDV+3TC+NVP suggests its contribution to serious non-AIDS 
events. Further classification of whether these transformed cells exhibit M1 or M2 
macrophage characteristics could go a long way to explain the antiproliferative effect of 
some highly active antiretroviral regiments associated with cervical intraepithelial 
neoplasia regression observed among women initiating HAART. 
 
6.1.5 Overall conclusion  
Overall, it was observed that, despite the drastic induction of apoptosis by ethinylestradiol, 
its co-administration with ABC+3T, ZDV+3TC, ABC+ZDV+3TC and ZDV+3TC+NVP 
did not significantly differ to the untreated control (P≤ 0.05) in viability of cells, as 
measured by the MTT assay. This is suggestive of cellular remodelling effect of 
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ethinylestradiol. Treatment with 4.0µg/ml levonorgestrel demonstrates such non-
proliferative difference upon co-administration with ABC+ZDV+3TC and 
ZDV+3TC+NVP. This suggests that, the observed levonorgestrel cytotoxicity with other 
combinations (ABC+3T, ZDV+3TCand d4T+3TC+NVP) does not positively impact on 
tissue regeneration through proliferation or compensatory hyperplasia but it rather results 
in the beneficial increased human cervical cancer cell loss. Co-administering 2.0µg/ml 
LNG shows antiproliferative activity with all combination antiretroviral treatments on 
HeLa cells. Subject to further clinical research, levonorgestrel-only contraceptives may 
prove a better option for people on highly active antiretroviral treatment.  The 
transformation of U937 cells to „macrophage-like‟ cells by ZDV+3TC+NVP is of interest, 
in view of the antiapoptotic effect of this regimen. This suggests a possibility of 
precipitating serious non-AIDS events. If replicated in vivo, these results could go some 
way to explaining the SNAEs seen with long-term therapy (Mafuva and Morgan, 2016). 
 
6.2.0. Directions for further research 
The present study highlights some preliminary aspects of antiretroviral drug effects on 
cancer cell proliferation. However, limitations in time and financial resources prevented a 
possibility of further interrelated explorations in this seemingly vast reproductive health 
and cancer research area. This section highlights further envisaged future directions 
emanating from the present observations. 
 
6.2.1. Apoptosis and regenerative hyperplasia pathways 
Whether the apoptotic pathway in human cervical cancer epithelial cells is via the intrinsic 
or extrinsic pathways can be evaluated.  As explained earlier, the extrinsic pathway is 
signalled through cell-membrane receptors by death factors such as FAS and TNF 
receptors that result in a cascade leading to activation of caspases -3, -6 and -7 which are 
executors of apoptosis (Matt and Hoffman, 2016; Kang et al., 2012). On the contrary, the 
intrinsic pathway for apoptosis is signalled via an intracellular domain that results in DNA 
digestion (Matt and Hofmann, 2016). The protein Apaf-1 is activated by cytochrome c, thus 
activating caspase-9 which, in turn, activates executioner caspases (Kang et al., 2012). 
Using flow cytometry, determination of whether or not each class of caspases is regulated 
will go a long way in establishing the mechanisms of toxicity and/or the pathway by which 
apoptosis is attained. While the present observations depict proliferative effect of EE, the 
exact pathways through which this occurs was not evaluated. As described earlier, the two 
pathways of CP are the effector caspase-independent and the effector caspase-dependent 
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pathways (Fan and Bergmann, 2008a; Ryoo et al., 2004, Ryoo and Bergmann, 2012). One 
might envisage an experimental design in which the Drosophila is exposed to combination 
antiretroviral drugs mixed through their liquid food supply. After a certain exposure time, 
expression of Dronc, DrICE and p35 can then be determined to evaluate the CP pathways 
that are affected by exposure to antiretroviral drugs with or without hormonal 
contraceptives.  
 
6.2.3 Classification of macrophage-like cells 
The present research has demonstrated that combination ARVs have the varied potential to 
differentiate U937 cells into adherent cells. Cells from the triple combinations 
ABC+3TC+NVP, ZDV+3TC+NVP and d4T+3TC+NVP transformed U937 to cells with 
macrophage-like morphology. These transformed cells were able to generate the 
superoxide anion. Further characterisation assays may be carried out on these adherent 
cells. To investigate phagocytic activity, the transformed cells can be assessed for the 
ability to phagocytose protein-coated latex particles which are commercially marketed as 
pregnancy test kit (Meshkini et al., 2009). Macrophages display CD11b and CD14 surface 
markers. To further assess macrophage-like anatomy, the adherent cells can be incubated 
with anti-CD11b and anti-CD14 antibody and the cells analysed by flow cytometry (Lin et 
al., 2014; Meshkini et al., 2009). Time and financial constraints did not allow continuation 
with such immunological characterisation. 
 
M1 macrophages eliminate pathogens, virus-infected cells and cancer cells. These are 
associated with intracellular reactive oxygen species (ROS) (Housinkveld and van der 
Burg 2011; Martinez and Gordon, 2014). M2 macrophages have been associated with 
tumour promotion. M1 and M2 macrophages are also known as classical and alternative 
macrophages, respectively (Martinez and Gordon, 2014).  Overall, M1 macrophages are 
stimulated by IFN-γ, tumour necrotic factor (TNF) or lipopolysaccharide (LPS). M2 
macrophages have different stimuli namely interleukin (IL-4)and IL-13 for M2a 
macrophage, IC and TLR/IL-1R ligands for M2b macrophage and IL-10 forM2c 
macrophage (Martinez and Gordon, 2014). M1 macrophages generate NO whereas M2 
macrophages make trophic polyamines (Martinez and Gordon, 2014). These and other  






6.2.4. Cohort and case-oriented designs 
While in vitro studies cannot be conclusive on their own, the observed differential potential 
of antiretroviral treatment on apoptosis induction with or without contraceptive hormones 
(levonorgestrel and ethinylestradiol) is of interest. Cohort (follow up) and case-oriented 
(retrospective) designs incorporating exploration on antiretroviral use and history of 
contraception may provide further insight to corroborate these in vitro observations. Figure 
6.1 summarises a typical cohort study design envisaged from these results. A mixed-
method approach during such a follow-up study helps the practitioners to infer into the 
service user‟s lived experience. Such a phenomenological approach makes it easy to 
evaluate the contraceptives used through questionnaires. In addition, cytological screening 
for n1, n2 and n3 depicted in Figure 6.1 enables classification of cervical intraepithelial 
neoplasia and cancer. The main advantage of cohort designs is that they can be reliable as 
they pick up the cause-and-effect relationship through observations over a period of time. 
Observations from these studies can be evaluated in view of the present preliminary in 
vitro observations.  
 
A number of limitations affect cohort studies. Firstly, the design is time-consuming as 
participants need to be followed over long periods, typically 2 years and above. Secondly, 
follow up studies maybe expensive especially in low-resource areas where participants 
may need funding for sundry expenses, such as transport costs to attend their 
appointments. Accounting for confounders related to lifestyle may present challenges on 
its own. Finally, attrition is another problem, whereby participants are lost during the 
course of the research. This could be due to death, truancy, voluntary withdrawal and any 
other unforeseen factors.  
 
The case-oriented design (retrospective study) is an alternative epidemiological design 
which can be used to investigate use of contraceptives among HAART patients. This is 
dependent on sampling patients with their consent as they present to the HAART clinic. 
Here the practitioners work „retrospectively‟. Consenting patients are asked to provide 
information on their previous use of hormonal contraceptives, how long they have been on 
HAART and questions on any other confounding factors such as parity and smoking 
history. To complement the retrospective questions, Papanicolaou (Pap) smear evaluation 
correlates contraceptive and HAART use to CIN progression. This mixed method approach 
can also augment the discourse for our present in vitro observations. The main advantage 
of such an approach is that it is less time-consuming and less expensive in comparison to 
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the former and incorporates user experience. The major disadvantage is its dependency on 
patients‟ memory, as some may not be good in remembering dates on which they initiated 











Fig 6.1: Outline of participant categories in a HAART and contraception cohort study. The 
participants are selected from people attending HAART treatment at a local reproductive 
health clinic. The participants fall into those with a history of contraception use and those 
with no history of contraception use. The participants are then further sub-categorised as 
those exposed to HAART and those not on HAART as they are followed over a period and 
parameters such as Papanicolaou (Pap) smear detected to evaluate cervical dysplasia. N 
represents the total number of participants while n1, n2 and n3 represent number of 
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6.3.0. Implications for reproductive health practice  
The present research demonstrates the variable effects of ethinylestradiol and 
levonorgestrel on combination antiretroviral-induced apoptosis in human cervical cancer 
cells. Hormonal contraceptives have been suggested as co-factors for proliferation of HPV-
infected human cervical cancer cells (Webster et al., 2001). There are limited in vivo 
studies on causality and effect of hormonal contraceptives on cervical cancer progression 
among women on HAART. This section explores the potential of utilising reproductive 
services to enquire into the benefits of evidence-based practice in evaluating neoplasia and 
cervical cancer aetiology among HAART patients.  
 
6.3.1 Reproductive health clinics as research resource centres 
Cognisant of improved cervical cancer screening programs globally, reproductive health 
service providers have generally escalated cervical cancer screening among women. With 
the current increased incidence and prevalence of HIV, these reproductive health services 
may work in conjunction with HIV clinics in monitoring and evaluating the effects of 
contraceptive hormones among HAART patients. Such a phenomenological approach 
enables Public Health practitioners to study the contraception choices and use by women 
considered for cohort or case-oriented studies. While the present study was limited to 
combinations of NRTIs and NVP, an exploration based on family planning clinics would 
provide a holistic approach incorporating all antiretroviral and contraceptive choices 
among different communities. In vitro conditions are not necessarily similar to in vivo 
conditions. In vivo, cohort- and case-oriented designs can be used to evaluate the cause-and 
effect relationship between co-administration of hormonal contraceptives with 
antiretroviral drugs and cervical cancer progression. This allows evaluation of different 
permutations and combinations to be feasibly evaluated against cervical cancer 
development or progression. 
 
6.3.2 Use of voluntary testing and counselling centres 
There are a number of HIV testing and counselling centres in various countries that are 
used as a surveillance strategy. Participants at these centres may be ethically recruited and 
case oriented studies used to explore ever-use of contraceptives. Cohort studies may then 
be used to investigate the effect of HAART among patients using different hormonal 
contraceptives. Through monitoring and evaluation such an approach will enable 
recommendations for safer contraceptive options dependent on the regimen of HAART 
one is on. 
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6.3.3 Further scientific research on other drugs 
While this research focussed on NRTIs and NVP (an NNRTI), in practice, there are 
number of contraceptives alternatives including those tailor-made for some co-existing 
medical conditions among patients receiving HAART. As described in the first chapter 
classes of antiretroviral drugs include NRTIs, protease inhibitors, integrase inhibitors and 
NRRTs. Similarly, there exists a variety of hormonal contraceptives in addition to the 
ethinylestradiol and levonorgestrel COCs discussed in this study. These include but are not 
limited to drospirenone-containing, levonorgestrel-containing and other progestogen-
containing COCs, levonorgestrel-only contraceptives, injectable norethisterone enanthate 
and depot medroxyprogesterone acetate (DMPA). Human epithelial cancer cell 
toxicological studies involving various permutations of these contraceptives and HAART 
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MORPHOLOGY OF HeLa CELLS ON 24 HOUR PRELIMINARY TREATMENT 
WITH ANTIRETROVIRAL DRUGS 
              
                                                                                                                                                                      
(a) Microscopic appearance of HeLa cells after  24 h treatment with abacavir sulfate. At 
100ug/ml and 200µg/ml there is no microscopically obvious morphological change compared 
to untreated cells and there are some dividing cells as evidenced by large nuclei. Large nuclei 
of dividing cells are apparent  as depicted by white arrows. As the concentration increases to 
300µg/ml,  the cells become spindle- and star-shaped while there is a decrease in cell density. 
At 300µg/ml, black arrows indicate cells with protruded membrane and apoptotic bodies.  
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(b) Microscopic appearance of HeLa cells after  24 h treatment with zidovudine. Cells treated 
with 100µg/ml still exhibit the generic HeLa morphological characteristics. Increasing the 
concentration to 200µg/ml and 300µg/ml produces cells that are heterogenous in morphology. 
Large nuclei of dividing cells are apparent  as depicted by white arrows. There is a gradual 














       
       
(c) Microscopic appearance of HeLa cells after  24 h treatment with lamivudine. At 100ug/ml 
the typical HeLa morphology is mantained. At 200ug/ml and 300µg/ml the cells are still 
viable and actively dividing with no obvious morphological changes, although the cells appear 
less dense with 300µg/ml. Large nuclei of dividing cells are aparent  as depicted by white 
arrows. At 200µg/ml, the black arrow indicates cells with protruded membrane and 
apoptotic bodies. The scale bar indicated on the right bottom of each picture represents 

















           
        
(d) Microscopic appearance of HeLa cells after  24 h treatment stavudine. At  100µg/ml and 
200µg/ml cells have semblance to untreated cells regarding the nuclear/cytoplasmic ratio. 
Large nuclei of dividing cells are apparent  as shown by white arrows. At 300µg/ml, the cells 
are still dividing as depicted by the spherical nuclei although the cells seem to be varied as 
depicted by a mixture of some anvil, spindle and normal shaped cells. Black arrows at 
300µg/ml indicate cells with protruded membrane and apoptotic bodies. The scale bar 















         
                                                                                                      
                                                                                                     
(e)Structure of HeLa cells after 24 h treatment with varying concentraions of nevirapine. As 
shown in the diagram, most cells exhibit morphological features of viable cells at all 
concentrations up to 80µg/ml. However, from 120µg/ml to 200µg/ml the cells are increasingly 
becoming spindle-shaped as shown by the arrows. Cells also become less dense with 
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Abstract accepted for the British „Pharmacology 2016‟ annual conference 
TRANSFORMATION OF MONOCYTES TO MACROPHAGES BY 
COMBINATION ANTIRETROVIRAL TREATMENT   
 
Introduction: The increased use of highly active antiretroviral therapy (HAART) has 
resulted in a dramatic increased survival of HIV-infected individuals. A downside of the 
success of antiretroviral therapy (ART) is the premature onset and increased risk of certain 
inflammatory age-related diseases associated with low levels of chronic immune 
activation. Such activation is thought to contribute to what is described as serious non-
AIDS events (SNAEs) [1]. HAART entails combining two nucleoside reverse transcriptase 
inhibitors (NRTIs) with either one or two protease inhibitors (PIs) or non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), in this study usually nevirapine (NVP) [2]. 
 
Method: In an attempt to better understand the impact of HAART on the immune system, 
U937 cells (a histolytic lymphoma monocyte line) were exposed to a range of drugs used 
for HAART therapy and differentiation to macrophage morphology assessed. In 24 well 
plates, cells were treated with single and combination drugs at a final concentration of 
50µg/ml of each drug and incubated at 37
o
C and 5% CO2 for 72hrs (n=3 in all treatments). 
Single drug antiretroviral treatment was with abacavir sulfate (ABC), zidovudine (ZDV), 
lamivudine (3TC), stavudine (dT4) and nevirapine (NVP). The following antiretroviral 
combinations were considered: ABC+3TC, ZDV+3TC, ABC+ZDV+3TC, 
ZDV+3TC+NVP and d4T+3TC+NVP. Following 72 hours treatment with antiretroviral 
drugs, the percentage of adherent cells as a fraction of total live cell count was assessed.  
 
Results: Adherence of single drug treatment was as follows: 3.25% for ABC, 86.03% for 
zidovudine ZDV, 21.05% for 3TC, 47.22% for stavudine dT4 and 12.50% for nevirapine 
NVP. The effect of treatment with combination antiretroviral drugs was as follows: 
13.51% for ABC+3TC, 7.89% for ZDV+3TC, 40.11% for ABC+ZDV+3TC, 42.07% for 
ZDV+3TC+NVP and 39.89% d4T+3TC+NVP. Distinct morphological changes including 
amorphous and granular structure coupled with increased cell size and adherence were  
predominantly observed for ZDV and triple antiretroviral drug combination treated cells. 
 
Conclusion: These initial observations indicate that HAART is capable of stimulating the 
differentiation of monocyte (pre-macrophage) into cells with “macrophages-like” 
morphological characteristics. If replicated in vivo this could go some way to explaining 
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INTRODUCTION 
Combination of nucleoside reverse transcriptase inhibitors (NRTIs) is the predominant method 
for HIV treatment. Highly active antiretroviral treatment (HAART) entailing two or more NRTIs 
and nevirapine (NVP) has been the method of choice in most resource limiting countries. 
Abacavir (ABC), lamivudine (3TC), zidovudine (ZDV) and stavudine (d4T) have been in use in 
these settings. Some double combinations have been of choice in patients presenting with co-
infections or other clinical conditions. We previously evaluated the effect of levonorgestrel (LNG) 
and ethinyl estradiol (EE) [constituents of combined oral contraceptives] on ZDV+3TC+NVP 
induced apoptosis in human cervical epithelial cells. Here, we further evaluate the effect of 
(LNG) and (EE) on ABC+3TC, ZDV+3TC, ABC+ZDV+3TC and d4T+3TC+NVP induced apoptosis. 
METHOD 
HeLa cells (a human cervical epithelial cancer cell line) were treated with combination 
antiretroviral drugs (ARDs) at final concentrations of within the 20-25% inhibitory concentration 
of each drug. The cells were treated with antiretroviral drugs alone for 24hrs and co-treated 
with varying EE and LNG for a further 48hrs. Untreated cells saved as control. MTT cell 
proliferation rate was analysed by one-way ANOVA followed by Dunnett’s multiple comparison 
test (n=3, P<0.05). Further, HeLa cells were treated with ARDs (in the presence or absence of 
EE or LNG) over 48hrs and apoptosis measured by four-way dot plots. Data was analysed by the 
one-way ANOVA followed by Tukey’s test. 
RESULTS 
Overall, combination ARDs increase the rate of apoptosis compared to untreated cells (P<0.05). 
Co-administration with contraceptive hormones further drastically increases the rate of 
combination ARD induced apoptosis compared to cells treated with ARDs only. 
CONCLUSION 
Combination ARD induced apoptosis is suggestive of decreased cervical neoplastic 
transformation as observed in some studies (1,2). Combination ARD co-administration with 
contraceptive hormones is suggestive of increased cell loss and possibly tissue damage as 
depicted by some epidemiological studies suggesting cervical neoplasia progression among 
HAART patients (3). Further prospective and retrospective clinical studies maybe of interest. 
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